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Abstract 
The presence of active telomere maintenance mechanisms in immortal cells allows the 
bypass of senescence by maintaining telomere length. In most immortal cell lines and 
tumours, telomere maintenance is attributable to telomerase reactivation. However, a 
number of immortal cell lines and tumours can achieve telomere maintenance in the 
absence of detectable telomerase activity by the alternative lengthening of telomere (ALT) 
mechanism. Some stem cell populations also have telomerase activity and in telomerase 
biology and a key issue is how the complex pattern of telomerase gene expression is 
maintained in the adult stem cell. Epigenetic mechanisms have been implicated in the 
regulation of telomerase gene expression and here we show that specific modifications 
within the chromatin environment of the hTR and hTERT promoters correlate with 
expression of hTR and hTERT in ALT, normal and telomerase-positive tumour cell lines. 
Lack of expression of hTR and hTERT is associated with repressive histone modifications, 
while, hTR and hTERT expression is associated permissive histone modifications. 
Methylation of lysine 20 H4 was not linked to gene expression but instead was specific to 
the hTR and hTERT promoters of ALT cells providing an insight into the differences 
between ALT and telomerase-positive cells as well as a novel marker for the ALT 
phenotype. Basal transcription machinery dynamics were also shown to be different 
between normal and cancer cells at the telomerase gene promoters. Modulation of the 
chromatin environment was also shown to cause re-expression or increased expression of 
hTR and hTERT further supporting the role of the chromatin environment in controlling 
telomerase gene expression. 
Epigenetic mechanisms are also shown to be involved in the repression of hTERT 
transcription in human mesenchymal stem cell (hMSCs) and modulation of the chromatin 
environment is shown to allow re-expression of hTERT expression, while the disruption of 
telomerase gene expression in human haematopoietic stem cells (hHSCs) in chronic 
myeloid leukemia (CML) and the role of the chromatin environment was also studied. 
These data establishes how epigenetic mechanisms can contribute to transcriptional 
regulation of telomerase and also highlights the potential importance of epigenetics in 
senescence and tumourigenicity. 
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I Introduction 
1 
The term epigenetics is defined as mechanisms through which changes in gene function 
can occur without a change in the DNA sequence. Such mechanisms include covalent 
modifications of histones, DNA methylation, ATP-dependent chromatin remodelling, 
incorporation of variant histones, looping and changes in local conformation of DNA and 
alterations of higher-order chromatin structure. Telomerase gene (hTR and hTERT) 
regulation has been intensely studied but the regulation of the telomerase gene promoters 
by covalent changes to histone proteins has not been fully resolved. Given the importance 
of telomerase in tumourigenesis and senescence, fully resolving different modes of gene 
regulation may be of importance. 
1.1 Regulation of Senescence 
1.1.1 Senescence 
Mammalian cells have a finite replicative potential in vitro and in vivo as upon reaching 
this limit, cells enter a state referred to as cellular senescence and cease to divide. This 
was first observed in normal human fibroblasts (Hayflick, 1965). Senescent cells do 
however remain viable and metabolically active although they cannot re-initiate DNA 
replication in response to mitogenic stimuli and become resistance to apoptosis. As these 
cells do not proliferate, it has been proposed that cellular senescence is a major barrier to 
cancerous transformation. Senescence is also associated with altered cellular morphology, 
size and, importantly, alterations in the expression of numerous genes involved in many 
aspects of cell physiology (Shelton et al., 1999; Hardy et al., 2005; Grillari et al., 2000; 
Untergasser et al., 2002; Yoon et al., 2004; Guo et al., 2004; Mason et al., 2004). 
Therefore the regulation of multiple genes is involved in the senescence phenotype and the 
complexity of the phenotype suggests that epigenetic mechanisms may be involved 
through regulating gene expression. Indeed, it is now apparent that in addition to multiple 
genetic pathways, epigenetics plays an important role in senescence (Bandyopadhyay and 
Medrano, 2003; Young and Smith, 2000) and also in the bypass of senescence leading to 
tumourigenicity (Esteller, 2006; Santos-Rosa and Caldas, 2005; Baylin and Ohm, 2006). 
Therefore, the study of epigenetics, alongside genetics may allow further understanding of 
senescence and tumourigenesis. 
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1.1.2 The Role of Telomeres and Telomerase in Senescence 
1.1.2.1 Telomeres and Telomerase 
2 
Telomeres are DNA-protein complexes forming capping structures that stabilise 
chromosomal ends and prevent them from recognition as DNA double strand breaks and 
from loss of coding sequence at the chromosome end during DNA replication. In humans, 
telomeric DNA is composed in the 5' to 3' direction of a hexameric oligonucleotide 
sequence (TTAGGG) repeated approximately 1000 to 2000 times (Moyzis et al., 1988; 
Blackburn, 1991). Telomeres are usually maintained by the enzyme telomerase which 
catalyses the addition of the telomeric repeats on to the ends of chromosomes, thus 
maintaining their length despite continued cell division (Morin, 1989). Telomerase is 
minimally composed of two components and functions by utilising an RNA template 
subunit and a reverse transcriptase subunit to catalyse the addition of the telomeric repeats 
onto the 3' ends of eukaryotic chromosomes (Greider and Blackburn, 1987). In humans 
the subunits are known as hTR (Telomerase RNA template component) and hTERT 
(Telomerase Reverse Transcriptase component) and have been described as the minimal 
functional requirements for telomerase activity (Autexier et al., 1996; Weinrich et al., 
1997). 
1.1.2.2 Telomeres, Senescence and Immortality 
In adult humans, most normal cells have low or no detectable telomerase activity whereas 
telomerase activity is observed in an estimated 85% of malignant tumours (Shay and 
Bacchetti, 1997). Telomerase activity in cancer cells allows for the unchecked growth of 
cancer cells (See Figure 1.1). However, certain normal cells do exhibit telomerase 
activity, including germ line cells (Wright et al., 1996; Kim et al., 1994), activated 
lymphocytes (Bodnar et al., 1996), some stem cell populations (Hiyama et al., 1995; 
Broccoli et al., 1995; Chiu et al., 1996), basal keratinocytes (Harle-Bachor and Boukamp, 
1996) and endothelial cells (Hsiao et al., 1997). The lack of telomerase activity and 
therefore telomere elongation or maintenance in normal cells, coupled with the fact that the 
machinery which replicates the bulk of chromosomal DNA is intrinsically incapable of 
fully replicating the chromosome termini (the end replication problem) (Olovnikov, 1973), 
leads to the loss of approximately 50-100bp of telomeric sequence at each cell division 
(Harley et al., 1990; Hastie et al., 1990). The loss of telomeric tract during cell division 
also presents a limit to the maximum number of divisions a cell can undertake and 
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Figure 1.1 Telomeres and Telomerase in Normal Somatic Cells and Cancer 
a, In normal human somatic cells, which do not express telomerase, telomeres will shorten 
with age until they reach a critical short length where they will signal for the cell to enter 
senescence. b, In cancer cell, telomerase can become reactivated leading to the 
maintenance of telomere length and therefore telomeres will not reach the critical short 
length where the cell enters to enter senescence. [Picture from Keith et al (Keith et al., 
2002)]. 
a Normal somatic cells 
Telornere 
repeat sequences 
.. ý.. OC 
ý 
®ý 
,ý®® 
ýanescence 
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therefore provides a limit to its lifespan (Allsopp et al., 1992). This is the Hayflick limit 
(or Mortality Stage 1 [Ml]) (Hayflick, 1965) and when cells reach this limit they enter 
senescence, or initiate programmed cell death. This response to telomere shortening is 
thought to have evolved as a tumour suppressive barrier against excessive clonal 
expansion. Senescence can also be triggered by several other mechanisms, including 
cellular stresses, such as activated oncogenes, DNA damage, oxidative stress and sub- 
optimal cell culture condition and has also been observed by a change in the protected 
status of shortened telomeres, rather than by the complete loss of telomeric DNA 
(Karlseder et al., 2002). 
Telomere attrition and dysfunction and cellular stresses lead to the activation of cell cycle 
checkpoint control pathways which can block cell division resulting in a permanent and 
irreversible cell-cycle blockade. Dysregulation of such checkpoint pathways can result in 
continued cell division until the cells enter crisis (M2), a state characterized by massive 
cell death and karyotypic changes associated with end-to-end fusion of chromosomes. 
This can be attributed to telomere dysfunction, as telomeres of cells which bypass MI 
continue to shorten until the cells enter crisis. Very rarely, a cell emerges from crisis 
which has the ability to maintain its telomere length and gains the ability to multiply 
without limits (Wright et al., 1989), a trait termed immortalisation which is considered to 
be one of the prerequisites for tumour formation (Hanahan and Weinberg, 2000). So 
importantly, both tumour suppressor mechanisms and telomere maintenance mechanism 
mediate senescence, immortalisation and tumourigenicity (Figure 1.2). 
Consistent with the proposed roles of telomerase in senescence, inhibition of telomerase 
activity in telomerase positive cells leads to the shortening of telomeres, senescence and, in 
some cases, cell death (Hahn et al., 1999b; Zhang et al., 1999; Herbert et al., 1999) while 
reintroduction of hTERT into telomerase negative normal cells can reactivate telomerase 
activity and increase replicative lifespan (Bodnar et al., 1998; Rufer et al., 2001; Yang et 
al., 1999; Vaziri and Benchimol, 1998). Detectable telomerase activity in an estimated 
85% of malignant tumours (Shay and Bacchetti, 1997) and strong links between 
telomerase activity and malignant cells (Kim et al., 1994) demonstrates the importance of 
telomerase activity in tumourigenesis and also suggests that telomerase activation is the 
most common mechanism for telomere maintenance in cancer cells. 
However, a number of immortal cell lines and tumours lack telomerase activity yet have 
the ability to elongate their telomeres, which suggests the existence of nontelomerase- 
dependent routes to immortalisation (Reddel, 2003). 
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Figure 1.2 Senescence Mediated by Telomere Length and Cell Cycle Checkpoint Genes 
5 
Telomere length after development continually decreases in length with each population 
doublings in normal human somatic cells until telomeres become short and dysfunctional 
and signal for senescence and the cell will stop dividing. If cell cycle checkpoints are lost, 
cells can continue to divide beyond senescence, with continued attrition of telomere length, 
until they reach crisis in which most cells die. A rare cell will arise from crisis with the 
ability to maintain and/or elongate their telomeres and become immortal. 
- -- ,a 
Somatic Cell - 
Telomerase Negative 
Ectopic Telomerase Expression 
ý 
H 
.4 
elomere dependent 
senescence 
Tumour Suppressor 
Pathways 
Loss of Function o Gain Of Telomere 
Maintenance 
Mechanism 
Cell Divisions 
Stuart P. Atkinson, 2006 Chapter 1 
1.1.2.3 Alternative Lengthening of Telomeres 
6 
It is known that the alternative lengthening of telomeres (ALT) mechanism can be used to 
maintain telomere length in the absence of telomerase activity (Bryan et al., 1997). In 
cells where ALT has been activated, telomere length is maintained by a recombination- 
based DNA replication mechanism rather than the catalytic addition of short repeats 
utilised by telomerase (Dunham et al., 2000). ALT cells exhibit elevated levels of post- 
replicative inter-telomeric exchange (Londono-Vallejo et al., 2004) and this may be 
responsible for the heterogeneity in telomere lengths observed in ALT cell lines (Bryan et 
al., 1997) which is a characteristic now taken as a marker for the use of the ALT 
mechanism. Also associated with the use of the ALT mechanism is the presence of ALT 
associated PML bodies (APBs) (Yeager et al., 1999) which contain the protein PML, 
telomeric DNA, the telomeric binding proteins TRF 1 and TRF2 and proteins involved in 
DNA recombination and replication. It has also been proposed that APBs may be actively 
involved in the ALT mechanism (Grobelny et al., 2000). 
Recent studies endeavouring to understand the molecular mechanisms behind ALT and 
have identified that the MREl l/RAD50/NBS1 (MRN) complex is required for telomere 
maintenance in ALT (Jiang et al., 2005) and this complex has been previously proposed to 
play a major role in homologous recombination in mammalian cells. Interestingly, 
although telomerase activation and ALT are thought of as the main telomere maintenance 
mechanisms in immortal cells and tumours, proposed telomere maintenance mechanisms 
other then telomerase activation or ALT have also been reported (Cerone et al., 2005; 
Fasching et al., 2005; Marciniak et al., 2005). 
It has been noted that activation of ALT in tumours cells is a much rarer event that 
activation of telomerase (Bryan et al., 1997) and it has been hypothesised that ALT may 
normally occur under selective pressure when expression of telomerase is prevented. ALT 
is commonly activated in tumours of mesenchymal origin, including osteosarcomas, soft 
tissue sarcomas and glioblastoma multiforme (Henson et a!., 2005; Ulaner et a!., 2003; 
Hakin-Smith et a!., 2003; Johnson et al., 2005), and it is understood that in normal 
mesenchymal tissues telomerase activity is more tightly repressed that in epithelial cells. 
This would lead to the selective pressure for ALT activation over telomerase activity in 
these cell types. 
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It is widely accepted that cancer is the result of multiple alterations in gene expression 
caused by genetic and epigenetic mechanisms. This suggests that the bypass of 
senescence, gain of immortality and transformation would require alterations in many 
genes for such processes to occur. Consistent with this is the finding that although 
expression of telomerase is sufficient to immortalise most normal cells (Bodnar et al., 
1998; Rufer et al., 2001; Yang et al., 1999; Vaziri and Benchimol, 1998) it has been shown 
that alone, telomerase expression does not lead to neoplastic transformation (Jiang et al., 
1999; Morales et al., 1999; Wootton et al., 2003; Klinger et al., 2006). However, multiple 
studies have shown that telomerase activity in combination with inactivation of tumour 
suppressor checkpoint pathway proteins can contribute to transformation. 
In normal human fibroblasts it was observed that only a combination of hTERT, SV40 
Large T antigen, which inactivates p53 and pRB, and H-RAS expression allowed 
establishment of a malignant phenotype (Hahn et al., 1999a). Also, combinations of 
hTERT and H-RAS or c-MYC can transform Leiden human diploid fibroblasts, which 
have an INK4a/ARF mutation resulting in p16INK4a deficiency (Drayton et al., 2003), while 
abrogation of p161NK4a and p53 combined with the expression of SV40 small t antigen, 
hTERT and H-RAS also leads to the transformation of normal human fibroblasts. 
(Voorhoeve and Agami, 2003). These studies suggest that multiple events are required to 
transform normal human cells. 
However, some groups have shown that expression of telomerase activity is sufficient for 
neoplastic transformation. hTERT transduced fibroblasts have been shown acquire 
malignant changes during extended lifespan (Milyavsky et al., 2003; Zongaro et al., 2005) 
as have hTERT transduced human mesenchymal stem cells (hMSCs) (Serakinci et al., 
2004). Amongst other neoplastic changes, the hTERT transduced fibroblasts and hMSCs 
both showed inactivation of the tumour suppressor genes p16 n'1K4a and p 14` RF after 
extended population doublings. 
It has also been shown that transformation by the expression of combinations of oncogenes 
can occur without the need for expression of hTERT in normal human fibroblasts (Lazarov 
et al., 2002; Seger et al., 2002) but tumours derived from these cells had gained telomerase 
activity suggesting that immortalisation did not require telomerase activity but long term 
growth of cancer cells requires it. In an interesting study, the ALT mechanism has also 
been shown to be the equivalent to telomerase activity in neoplastic transformation of 
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human cells by oncogenic Ras (Sun et al., 2005a) thus indicating that telomerase activity is 
not always needed for neoplastic transformation. 
However the fact that telomerase activity is detected in an estimated 85% of malignant 
tumours (Shay and Bacchetti, 1997) and the strong links between telomerase activity and 
malignant cells (Kim et al., 1994) suggests the importance of telomerase activity in 
tumourigenesis. So, immortalisation may not be sufficient for tumourigenesis but may 
provide the necessary prerequisite for accumulating the total number of genetic events 
required for malignancy by allowing an extended lifespan in which neoplastic changes can 
accrue. 
1.1.3 The Role of Tumour Suppressor Genes in Senescence 
Multiple genetic pathways are known to mediate senescence and dysregulation of parts of 
these pathways can lead to bypass of senescence and contribute towards tumourigenesis. 
Two main tumour suppressor pathways in human cells are the p53-p21WAFI-p14ARF 
pathway and the p161rrx4a-pRB pathway (See Figure 1.3). 
1.1.3.1 p53-p21w^"-p14MRF Pathway 
p53 is a sequence specific DNA binding tumour suppressor protein that is frequently 
inactivated in human cancers (Hollstein et al., 1991). Loss of p53 function is sufficient 
for cells to escape senescence and to acquire up to 20-30 extra population doublings (Shay 
et al., 1991; Hara et al., 1991; Bond et al., 1994). Studies have also shown that expression 
of wild type p53 in human cancer cell lines that lack wild type p53 can cause senescence or 
apoptosis (Shaw et al., 1992; Sugrue et al., 1997) while p53 activity was shown to be 
increased upon senescence and its transcriptional activity and DNA binding-activities were 
elevated (Atadja et al., 1995; Bond et al., 1996). Short or dysfunctional telomeres can be 
recognised as DNA double strand breaks (DSBs) (Karlseder et al., 2002) and the 
occurrence of telomere dysfunction in serially cultivated normal human somatic cells 
correlated to an increase in p53 and senescence (d'Adda di Fagagna et al., 2003; Vaziri and 
Benchimol, 1996). Cells react to DSBs by triggering the DNA damage checkpoint 
response, which arrest cell-cycle progression, and this response relies on the upstream 
protein kinases ATM and ATR and downstream transducer kinases CHK1 and CHK2 
which can sense short or dysfunctional telomeres and transduce this as a DNA damage 
response (d'Adda di Fagagna et al., 2003; Karlseder et al., 1999). This leads to the 
phosphorylation of p53 which increases p53 stability and accumulation of p53 leading to 
Stuart P. Atkinson, 2006 Chapter 1 
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senescence (Siliciano et al., 1997; Tibbetts et al., 1999; Canman et al., 1998; Banin et al., 
1998). p53 phosphorylation also inhibits MDM2s ability to promote p53 degradation 
(Shieh et al., 1997) and MDM2 itself a direct transcriptional target of p53 thereby forming 
an negative feedback loop with p53 (Momand et al., 2000). Correspondingly loss of 
phosphorylation of p53 by loss of ATM or CHK2 activity leads to the bypass of DNA 
damage-induced senescence (Gire et al., 2004; Herbig et al., 2004; d'Adda di Fagagna et 
al., 2003). 
p53 can also be positively regulated by p14ARF which is transcribed from the INK4a locus 
from which the p161Nx4a tumour suppressor is also transcribed. p14 'RF expression is 
induced in response to oncogene expression and can contribute to p53 stability by 
antagonising MDM2 (Zhang et al., 1998). Also P14ARF mRNA is expressed at a low level 
in young human fibroblasts but rises when normal human fibroblasts undergo replicative 
senescence (Dimri et al., 2000) and overexpression promotes senescence in human cells 
(Dimri et al., 2000; Wei et al., 2001). Interestingly, the INK4a locus is repressed by the 
Polycomb Group (PcG) protein BMII which becomes downregulated at senescence 
(Itahana et al., 2003). 
p53-dependent senescence is mediated partly by its downstream regulator p21 WAF2 (el- 
Deiry et al., 1994). p53 stabilisation at senescence allows p53 mediated transcription of 
multiple genes, including p2lWAFR, which becomes elevated at senescence in several 
cellular systems (Alcorta et al., 1996; Tahara et al., 1995). p21 WAFI is a cyclin-dependent 
kinase inhibitor (CDKi) which binds to and inactivates cyclin E-CDK2/3 complexes and 
cyclin D1-CDK4 and cyclin D1-CDK6 complexes to promote senescence by preventing 
phosphorylation of pRB tumour suppressor (Xiong et al., 1993; Harper et al., 1993). 
Exogenous expression of p21 WAFT induces senescence in early passage human diploid 
fibroblasts (McConnell et al., 1998), while p21 WAFt inactivation leads to the abrogation of 
senescence and the induction of crisis (Brown et al., 1997). 
1.1.3.2 p16i"K4-pRB Pathway 
The Retinoblastoma (pRB) gene product is a tumour suppressor that regulates multiple 
cellular processes such as growth, differentiation and apoptosis, and is mutated or 
inactivated in many type of human cancers (Weinberg, 1995). The tumour suppressive 
activity of pRB derives from its ability to inhibit cell cycle transit by repressing the 
transcription of genes required for the G1-S-phase transition (Narita et al., 2003; 
Weintraub et al., 1995; Bremner et al., 1995). Loss or inactivation of pRB in normal 
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human fibroblasts leads to the bypass of senescence and entrance into crisis, similar to that 
which happens with the abrogation of the p53-p21wAF1 pathway (Wei et al., 2003; Sage et 
al., 2003; Shay et al., 1991). Correspondingly, it was found that re-introducing pRB into 
pRB-'- cells leads to the induction of senescence (Xu et al., 1997). 
pRB activity is regulated by phosphorylation and dephosphorylation events and these 
events are mediated by Cyclin/CDK complexes (Hinds et al., 1992). At senescence pRB 
is hypophosphorylated and is able to bind to E2F leading to the repression of gene targets 
(Stein et al., 1990; Futreal and Barrett, 1991; Narita et al., 2003). Conversely, pRB is 
phosphorylated by Cyclin D/CDK4 or 6 in G1 and Cyclin E/CDK2 at the G1-S boundary 
and allows the transcription of genes essential to cell cycle progression by E2F (Bremner et 
al., 1995; Hinds et al., 1992; Buchkovich et al., 1989; Chen et al., 1989; Sherr and 
Roberts, 1995). Another CDK inhibitor, p27 KIP' also plays in important role in senescence 
by the inhibition of the phosphorylation of pRB by Cyclin E/CDK2 and increased 
formation of the p27Kip'-Cyclin E-CDK2 ternary complex and decreased associated kinase 
activity are associated with pRB-mediated senescence (Alexander and Hinds, 2001). 
The CDKi p16INK4a acts as an upstream regulator of pRB and keeps pRB in an 
unphosphorylated form in senescent human cells by the inhibition of Cyclin D/CDK4 or 6 
complexes and is a potent mediator of cell cycle arrest (Lukas et al., 1995; Serrano et al., 
1993). p16INK4a is induced by the accumulation of cell population doublings and the 
action of oncogenes (Serrano et al., 1997; Zhu et al., 1998; Alcorta et al., 1996), oncogenic 
signalling (Lin et al., 1998) or DNA damage or stress signals (Robles and Adami, 1998; 
Shapiro et al., 1998). p16INK4a is inactivated in a broad range of tumours (Kamb et al., 
1994; Nobori et al., 1994) and this provides compelling evidence for the role of p16INK4a in 
senescence. Interestingly, epigenetic silencing of p16fNK4a is a common mechanism for 
loss of expression in tumours suggesting the importance of epigenetic mechanisms in 
senescence (Merlo et al., 1995; Huschtscha et al., 1998). It is also noted that the pRB 
expression is also epigenetically silenced in some retinoblastoma tumours (Greger et al., 
1989). 
Cellular lifespan is extended upon the inactivation of the p16'NK4a/pRB pathway 
(Huschtscha et al., 1998; Narita et al., 2003; Bond et al., 2004) or by the overexpression of 
CDK4, the principle target of p16INK4a (Morris et al., 2002). Upstream regulators of 
p16' 40 such as the Polycomb Group (PcG) proteins BMII and CBX7 are also capable of 
mediating senescence by repressing the INK4a locus leading to decreased levels of 
p16'NK4a (Itahana et al., 2003; Gil et al., 2004). The ETSI and ETS2 transcription factors 
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can bind and activate the INK4a locus increasing levels of p16 INK4a, while ID1 represses 
p16INK4a expression (Ohtani et al., 2001). 
1.2 The Role of the Histone Modifications in the 
Regulation of Transcription 
Studies have shown that expression of genes differs greatly in presenescent, senescent and 
transformed cell lines (Shelton et al., 1999; Hardy et al., 2005; Grillari et al., 2000; 
Untergasser et al., 2002; Yoon et al., 2004; Guo et al., 2004; Mason et al., 2004), but how 
this is controlled is still relatively unknown. It is known that epigenetic processes such as 
DNA methylation and post-translational modification of histones are sufficient to alter 
gene expression and can therefore play a role in many cellular processes. Therefore it is 
plausible to suggest that changes in the chromatin environment can play a role in the huge 
changes in gene expression involved in senescence and also in the bypass of senescence 
towards transformation and malignancy. 
The term epigenetics is defined as mechanisms through which changes in gene function 
can occur without a change in the DNA sequence. Such mechanisms include covalent 
modifications of histones, DNA methylation, ATP-dependent chromatin remodelling, 
incorporation of variant histones, looping and changes in local conformation of DNA and 
alterations of higher-order chromatin structure. These processes are required for processes 
involving DNA, due to the nature of the packaging of DNA in the nucleus. DNA is 
packaged as chromatin in the form of approximately 147bp of DNA wound twice around a 
histone octamer consisting of two copies of the H2A, H2B, H3 and H4 histories to form the 
structural subunit of chromatin; the nucleosome. This packaging strategy allows 
approximately 1 metre of DNA to be packaged properly into the I Oµm size of an average 
cell nucleus, but also represents a major obstacle to many processes involving DNA 
including transcription. Epigenetic modifications are necessary to allow such processes to 
proceed by altering chromatin structure to change of accessibility of a region of DNA. 
Sections of the genome can be labelled euchromatin or heterochromatin based on the 
transcriptional permissivity of the chromatin and therefore the accessibility of the DNA. 
Euchromatin is gene rich and is not tightly wrapped around histories meaning that genes 
within the region are frequently transcribed to mRNA in the cell, while heterochromatin is 
darkly staining and tightly packaged or coiled throughout the cell cycle and that is, for the 
most part, genetically inactive. Certain histone modifications are associated with 
Stuart P. Atkinson, 2006 Chapter 1 13 
compacting the binding of DNA to histones, therefore repressing the binding of regulatory 
factors which may mediate expression of the DNA content therein, while certain 
modifications are linked to the relief of this compaction, permitting access of regulatory 
factors to the DNA. Various amino-acid residues mainly on the histone amino-terminal 
tail can be covalently modified by acetylation, methylation, phosphorylation, 
SUMOylation, ubiquitination and ADP-ribosylation (Figure 1.4). Patterns of such 
modifications signify the transcriptional status of the chromatin and therefore the 
transcriptional status of DNA therein. This is known at the "histone code" hypothesis 
(Jenuwein and Allis, 2001; Strahl and Allis, 2000) and entails that combinations of histone 
modifications can be read as a code and translated into an output signal, for example; gene 
transcription on or off. 
1.2.1 Covalent Histone Modifications Linked to the Repression of 
Gene Transcription 
Methylation of specific lysine residues are understood to be linked to gene repression and 
the formation of heterochromatin. Heterochromatin is generally characterised by hypo- 
acetylated histories and methylation of lysines 9 and 27 of histone H3 (K9 H3 and K27 H3) 
and methylation of lysine 20 histone H4 (K20 H4). 
1.2.1.1 Methylation of Lysine 9 Histone H3 
Methylation of K9 H3 has roles in heterochromatin formation and transcriptional silencing 
of euchromatic genes (Boggs et al., 2002; Peters et al., 2002; Nakayama et al., 2001). The 
histone methyltransferases (HMTs) SUV39H1 and SUV39H2 mediate tri-methylation of 
K9 H3 (Rea et al., 2000) and loss of the SUV39H enzymes leads to increased genomic 
instability and increased tumour risk demonstrating that the maintenance of 
heterochromatic domains is essential for cellular stability (Peters et al., 2001). The HP1 
proteins ((x, ß and y) are known to bind methylated K9 H3 to mediate transcriptional 
repression by compacting chromatin through association with other HP I proteins 
(Bannister et al., 2001; Lachner et al., 2001). HP1 has also been shown to recruit 
SUV39H1 (Stewart et al., 2005), DNA-methyltransferases (Fuks et al., 2003) and Histone 
Deacetylases (HDACs) (Vaute et al., 2002) which are all involved in the generation of a 
repressive chromatin environment. 
However, the function and regulation of K9 H3 methylation is different in heterochromatin 
than in euchromatin with the mono- and di-methylated modification restricted to 
Stuart P. Atkinson, 2006 Chapter 1 
Figure 1.4 Histone Modifications of Histones H3 and H4. 
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euchromatin in mammals (Rice et al., 2003; Peters et al., 2003) with the HMTs G9a and 
GLP being the major enzymes which catalyse mono- and di-methylation of K9 H3 in 
euchromatin (Tachibana et al., 2005). However, it is known that pRB can recruit 
SUV39H 1 to the promoters of several S-phase genes in differentiating cells in order to 
methylate K9 H3 and allow binding of HP1 allowing gene repression (Nielsen et al., 2001; 
Vandel et al., 2001). Other co-repressor proteins have also been indicated to recruit 
repressive histone methyltransferase activity, such as KRAB-ZFP, which recruits 
SETDBI/ESET, another K9 H3 specific methyltransferase, to the promoters of specific 
genes and results in transcriptional silencing by methylation of K9 H3 and HP I binding 
(Schultz et al., 2002) and G9a which can be targeted to promoters to promote gene 
silencing (Gyory et al., 2004). Methylation of K9 H3 also inhibits acetylation of K9 H3, a 
modification linked to gene expression, as both these modifications cannot co-exist on the 
same lysine residue, while SUV39H1 recruitment can be inhibited by methylation of lysine 
4 H3 (K4 H3), a modification also linked to gene expression (Nishioka et al., 2002a). 
Demethylation of K9 H3 has also recently been observed with the discovery of the 
demethylase LSD1 (Metzger et al., 2005) which has been shown to be able to demethylate 
a di-methylated K9 H3. 
Recently, a new role for methylation of K9 H3 has been uncovered with the discovery of 
dynamic K9 H3 di- and tri-methylation occurring in the transcribed region of active genes 
in mammalian chromatin (Vakoc et al., 2005). This study links the presence of 
methylated K9 H3 and HP1y to active transcription as their presence is associated with 
elongation by RNA polymerase II and are rapidly removed from repressed genes. 
Methylation of K4 H3 was also observed to be present at the coding sequence of 
transcribed genes, to a level similar to that of methylation of K9 H3, showing that these 
markers can actually be found on the same chromatin fragment in cis. G9a has also 
recently been described as functioning as a transcriptional coactivator for nuclear 
receptors, cooperating synergistically with GRIPI, CARM1 and p300 (Lee et al., 2006) 
further suggesting a role for methylation of K9 H3 in transcriptional activation rather than 
repression. 
1.2.1.2 Methylation of Lysine 27 Histone H3 
Methylation of K27 H3 is also a modification linked to transcriptional repression and 
maintenance of stable epigenetic silencing (Cao et al., 2002; Dellino et al., 2004; Kirmizis 
et al., 2004). Methylation of K27 H3 is mediated by G9a (Tachibana et al., 2001), which 
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can also methylate K9 H3, and the polycomb group proteins EZH2 (Cao et al., 2002) and 
SUZ12 (Cao and Zhang, 2004b). Methylation of K27 H3 allows the binding of Pc, a 
member of the Polycomb Group (PcG) proteins, similar to the binding of HP I to 
methylated K9 H3. The roles of methylation of K27 H3 include the silencing of homeotic 
genes during development (Cao et al., 2002), X-inactivation (Plath et al., 2003), genomic 
imprinting (Czermin et al., 2002; Muller et al., 2002) and heterochromatin formation 
(Peters et al., 2003). 
1.2.1.3 Methylation of Lysine 20 Histone H4 
Methylation of K20 H4 is also linked to gene silencing and is considered to be a marker of 
mammalian heterochromatin (Schotta et al., 2004; Kourmouli et al., 2004). The HMT 
NSD1 mediates K20 H4 methylation as well as K36 H3 methylation (discussed below) 
(Rayasam et al., 2003) while the enzyme PR-SET7/SET8 has also been shown to 
methylate K20 H4 and mediate gene silencing (Nishioka et at, 2002b; Fang et al., 2002). 
The HMTs SUV4-20H1 and SUV4-20H2 can also catalyse tri-methylation of K20 H4 
which precludes histone H4 hyperacetylation, a euchromatic modification, aiding the 
formation of silent chromatin (Sarg et al., 2004). 
Interestingly, tri-methylation of K20 H4 has been observed to accumulate in older tissues 
and also accumulates in cells in the stationary phase of growth (Sarg et al., 2002) while 
another study demonstrated that heterochromatin in cancer cells is less trimethylated at 
K20 H4, further reinforcing the critical role this modification has in the silencing and 
compaction of chromatin (Fraga et al., 2005). This model suggests that the loss of 
methylation of K20 H4 could account for genomic instability observed in cancers, 
although mechanisms of how methylation of K20 H4 is lost are unknown, It is known 
however that the SUV4-20H enzymes directly interact with the RB proteins (Gonzalo et 
al., 2005) and a lack of pRB could the lead to the loss of this modification and the 
silencing properties it entails. Studies have also indicated a link between methylation of 
K9 H3 and K20 H4 and transcriptional repression as the SUV4-20H enzymes have been 
shown to bind to HP 1 and methylation of K20 H4 is abolished at pericentric regions in the 
absence of SUV39H1 and SUV39H2 (Schotta et al., 2004; Kourmouli et al., 2005). 
Although this modification has been linked to silent chromatin, the role of this 
modification has been complicated by the finding of the presence of mono-methylated K20 
H4 at euchromatic regions of the genome, such as promoter sequences and coding regions 
of active genes (Talasz et al., 2005). Mono-methylation of K20 H4 was also linked to 
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hyperacetylation and seems to parallel data from studies of the finding of methylation of 
K9 H3 in the coding regions of actively transcribed genes. 
Methylation of K20 H4 has also been linked to DNA repair in Drosophila. The loss of the 
SET9 gene, which mediates K20 H4 methylation in Drosophila, leads to hypersensitivity to 
DNA double strand breaks rather than disruption of heterochromatin formation (Sanders et 
al., 2004b). This seems to be due to the inability of Crb2 to be recruited to DSBs due to 
the lack of methylated K20 H4. The actions of Crb2 are shown to need constitutive 
methylation of K20 H4 for its role in DNA damage response, so the loss of methylation of 
K20 H4, as previously observed tumour cells, could lead to the abrogation of the DNA 
damage response increasing the likelihood of cells accumulating neoplastic changes. 
Interestingly 53BP1, the human Crb2 homologue, binds to methylated K79 H3 (Huyen et 
al., 2004), a modification linked to gene expression and transcriptional activity. 
Demethylation of K20 H4 has yet to be shown but recent findings that LSD 1 can function 
as a K9 H3 and, as will be discussed later, a K4 H3 demethylase dependent on the complex 
in that it exists, suggests that this enzyme may function as non-specific histone 
demethylase which could therefore play a role in demethylation of K20 H4 (Metzger et al., 
2005; Shi et al., 2004). 
1.2.2 Covalent Histone Modifications Linked to Permissiveness of 
Gene Transcription 
Methylation of specific lysine residues are also understood to be linked to gene activation 
and the formation of euchromatin. Euchromatin is characterised by hyper-acetylated 
histones and methylation of lysines 4,36 and 79 of histone H3 (K4 H3, K36 H3 and K79 
H3). 
1.2.2.1 Methylation of Lysine 4 Histone H3 
Elevated levels of methylation of K4 H3 have been observed at active genes, gene 
promoters and transcriptional start sites (Santos-Rosa et al., 2002; Schneider et al., 2004a; 
Bernstein et al., 2005; Liang et al., 2004; Schubeler et al., 2004). While di-methylation 
of K4 H3 can be found at active and inactive chromatin domains, tri-methylation of K4 H4 
marks exclusively for active transcription (Santos-Rosa et al., 2002). A number of human 
enzymes are known to be able to methylate K4 H3 including SMYD3 (Hamamoto et al.. 
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2004), SET7/9 (Wilson et al., 2002), hSETI (Wysocka et al., 2003) and MLL (Milne et 
al., 2002). 
It is proposed that methylation of K4 H3 can influence gene expression through a number 
of mechanisms. Methylation of K4 H3 can act as a docking site for protein modules as di- 
methylated K4 H3 can be bound by WDR5, a component of an MLL complex required for 
global tri-methylation (Wysocka et al., 2005). MLL also associates with the K16 H4 
acetyltransferase MOF (Dou et al., 2005) thereby promoting the formation of a more 
permissive chromatin environment. Methylation of K4 H3 can also mediate the binding 
of the ATP-dependent chromatin remodeller CHD1, which is linked to the regulation of 
transcription of certain genes (Sims et al., 2005). As well as promoting the binding of 
some proteins, methylation of K4 H3 has been shown to preclude repressive complexes 
including deacetylase complexes (Zegerman et al., 2002) and can inhibit K9 methylation 
by SUV39H enzymes (Wang et al., 2001). So, in general methylation of K4 H3 inhibits 
repressive histone modifications and promotes permissive histone modifications, therefore 
leading to a chromatin environment more likely to allow gene expression. 
The reversibility of this modification has recently been illustrated with the discovery of the 
enzyme LSD 1 which, as well as being able to demethylate K9 H3, has been shown to be 
able to demethylate K4 H3 (Shi et al., 2004). 
Interestingly, methylation of K4 H3 is also proposed to play a role in a type of cellular 
memory by marking for recently transcribed genes. This occurs due to the interaction of 
the RNA polymerase II molecule with a K4 H3 methyltransferase (Ng et al., 2003). This 
was established in yeast, and demonstrated that the yeast K4 H3 HMT Setl, is recruited by 
RNA polymerase II to the 5' portion of active mRNA coding regions. This led to K4 H3 
hypermethylation within the coding region which was observed to persist for considerable 
time after transcriptional inactivation indicating that this modification could provide a 
molecular memory of recent transcriptional activity. 
1.2.2.2 Methylation of Lysine 36 Histone H3 
Methylation of K36 H3 is linked to transcriptional activation and is postulated to have a 
role in transcriptional elongation (Morris et al., 2005; Bannister et al., 2005). Methylated 
K36 H3 has been found to be concentrated at active genes, peaking at the 3' end of the 
gene (Bannister et al., 2005) while other studies in yeast have provided a mechanism by 
which this could occur by showing the interaction of a K36 H3 specific methyltransferase 
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with an elongating RNA polymerase II molecule (Kizer et al., 2005). In humans, two 
proteins have been identified which are able to catalyse the methylation of K36 H3; NSDI 
(Rayasam et al., 2003) and the Huntingtin interacting protein B (HYPB) (Sun et al., 
2005b). 
Interestingly, recent studies in yeast have shown that methylated K36 H3 can be bound by 
a chromodomain containing factor which recruits deacetylase activity (Keogh et al., 2005; 
Joshi and Struhi, 2005), further complicating the role of methylation of K36 H3 in 
transcriptional control. A proposed model indicates that after the RNA polymerase II 
molecule has passed through an "open" coding region of chromatin, it must be "shut" 
again and methylation of K36 H3, while associated with transcription, may mediate the 
condensation of chromatin after transcription has occurred by mediating the binding of a 
chromatin silencing protein to a modification previously mediating the permissivity of the 
chromatin environment. 
The reversibility of this modification has also recently been described with the 
identification of a JmjC domain-containing protein, called JHDM1 (JmjC domain- 
containing histone demethylase 1) which specifically demethylates K36 H3 (Tsukada et 
al., 2005). 
1.2.2.3 Methylation of Lysine 79 histone H3 
Methylation of K79 H3 is catalysed by hDOTL (Feng et al., 2002) which unusually does 
not contain a SET domain unlike all other lysine methyltransferases. It has been shown to 
be a marker for euchromatin in yeast and mammalian cells (Im et al., 2003; Schubeler et 
al., 2004) and recent studies have shown that the fusion of hDOTL to a Mixed Lineage 
Leukaemia (MLL) fusion partner results in the upregulation of a number of genes involved 
in leukaemia, concomitant with methylation of K79 H3 (Okada et al., 2005). Methylation 
of K79 H3 has also been linked to the sensing of double stranded breaks through the 
binding of 53BP 1 (Huyen et al., 2004). Higher order structural changes that occur upon 
the formation of double stranded breaks are thought to reveal methylated K79 H3 which 
are then sensed and bound by 53BP1 which then activates the DNA DSB checkpoint 
pathway by signalling through ATM. 
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In general, histone hyperacetylation occurs in euchromatic regions and correlates to gene 
expression (Schubeler et al., 2004; Bernstein et al., 2005). Acetylation of promoter 
proximal histones is associated with gene expression (Liang et al., 2004; Forsberg et al., 
2000; Roh et al., 2005) with K9 and K14 H3 acetylation highly localised to active 
transcriptional start sites (Liang et al., 2004). These modifications also strongly correlate 
with methylation of K4 H3 (Bernstein et al., 2005). While histone hyperacetylation 
correlates with gene expression, histone hypoacetylation is linked to heterochromatin and 
gene repression (Su et al., 2004). Acetylation is very low in condensed chromatic regions 
and inactive genes show similar levels (Litt et al., 2001; Gilbert and Sharp, 1999). 
Reversible histone acetylation is mediated by the actions of histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). 
Histone lysine acetylation is thought to play several roles in gene regulation. Initial 
studies provided evidence that acetylation of histones allowed flexibility and accessibility 
of chromatin (Krajewski and Becker, 1998) and enhanced binding of transcription factors 
to DNA (Vettese-Dadey et al., 1996). Further studies have shown that acetylation of H3 
and H4 can counteract nucleosome fibre compaction (Bertin et al., 2004) and recent 
studies have definitively shown that acetylation of histones increases chromatin 
accessibility as measured by studying the nuclear distribution of microinjected flourescein- 
labelled dextrans (Gorisch et al., 2005). 
Acetylation can also preclude repressive modifications or repressive complexes in order to 
promote a more permissive chromatin environment. Acetylation of K16 H4, mediated by 
MOF, is observed to be enriched in transcriptionally active gene sequences (Taipale et al., 
2005) and precludes tri-methylation of K20 H4 (Sarg et al., 2004) and histone H3 
acetylation can preclude the binding of INHAT, a repressive chromatin modifying complex 
known to mediate transcriptional repression (Schneider et al., 2004b). Acetylation of 
K 14 H3 and phosphorylation of serine 10 H3 (S 10 H3) can cause dissociation of HP 1 from 
methylated K9 H3 (Mateescu et al., 2004) and acetylation of K9 H3 precludes methylation 
of K9 H3, as these two modifications cannot exist on the same lysine moiety. 
Acetylated lysines can also be bound by bromodomain containing proteins or complexes 
which can affect transcription, such as TFIID, part of the basal transcription machinery, 
which can bind to promoter sequences by recognizing acetylated K9 and K14 (Agalioti et 
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al., 2002). Studies in yeast have also shown that acetylated K14 H3 can be bound by a 
chromatin remodelling enzyme in order to mediate gene expression (Kasten et al., 2004). 
As described, transcriptional activation frequently correlates with additional acetylation of 
histones at promoter nucleosomes and targeting HAT activity to promoters can enhance 
protein expression levels in mammalian cells (Kwaks et al., 2005). Transcription factors 
can recruit co-activators with HAT activity to regulatory DNA sites (Utley et al., 1998). 
MYC binding is concomitant with H4 acetylation by the recruitment of the TIP60 histone 
acetyltransferase complex to chromatin (Frank et al., 2003). Acetylation may also allow 
the passage of RNA polymerase II through nucleosomes (Protacio et al., 2000) and the 
HAT CBP/p300 has been shown to co-localise with RNA polymerase II at transcriptionally 
active domains (von Mikecz et al., 2000). Conversely, transcriptional repressors can 
recruit corepressors with HDAC activity, such as the Mad/Max heterodimer which can 
recruit HDAC activity (Sommer et al., 1997). pRB can also recruit HDACs to promoters 
to repress gene expression (Ferreira et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 
1998; Brehm et al., 1998) and has also been shown to recruit other enzymes such as 
SUV39HI leading to the repression of gene transcription (Gonzalo et at, 2005; Nielsen et 
a!., 2001; Vandel et al., 2001). 
1.2.3 Epigenetics and Cancer 
It is now understood that epigenetics can impact on gene expression and this area has been 
one of the most researched fields over recent times and the importance of epigenetic 
mechanisms in the initiation and progression of cancer has now become apparent. 
Enzymes which control histone modifications through modifying histone tails, and also 
other epigenetic mechanisms represent an additional level of transcriptional control which 
can become dysregulated in tumourigenesis. In many cancers, histone modifying enzymes 
are mutated, fused to other activators/repressors, deleted, duplicated, amplified, 
overexpressed or aberrantly expressed (Santos-Rosa and Caldas, 2005). This can lead to 
the dysregulation of multiple genes mediating many cellular processes due to the important 
role that the chromatin environment has to play in global gene regulation. Many excellent 
reviews have illustrated this point well and suggest an epigenetic model of cancer to 
complement the genetic model (Santos-Rosa and Caldas, 2005; Jones and Baylin, 2002; 
Hake et al., 2004; Esteller, 2006; Feinberg, 2004). 
The epigenetic model of cancer hypothesises that epigenetic modifications can play roles 
in tumour initiation and progression (Feinberg, 2004). Epigenetics is hypothesised to 
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impact on tumour initiation by interacting with the genetic alterations, in that epigenetic 
alterations may determine the effect of subsequent genetic insults by altering the frequency 
of neoplasia after a genetic insult. Another excellent review, discussed in more detail in 
Chapter 5, suggests that epigenetics is at the very root of tumourigenicity, by disruption of 
gene expression at the stem cell level (Feinberg et al., 2006), impacting on both the fields 
of epigenetics and cancer stem cell biology. 
Overall, this further suggests a role for epigenetic disruption in the key early events in 
tumourigenesis, such as the bypass of senescence leading towards transformation and 
further suggests that the regulation of genes involved in senescence and tumourigenicity 
may become altered by epigenetic mechanisms. 
1.3 Epigenetic Mechanisms of Senescence 
Although a great deal is already known about how chromatin regulates cell proliferation 
through its effects on transcription, less is known about how chromatin regulates 
senescence. However, recent studies have begun to shown how modulation of the 
chromatin environment can play an important role in the senescence phenotype. 
1.3.1 Histone Methylation and Senescence 
Initial studies have previously established that chromatin becomes reorganised with 
increased population doublings with large scale affects evident upon senescence (Macieira- 
Coelho, 1991) and recent papers have now shown that the formation of heterochromatin 
can play an important role in the senescence phenotype. Studies have shown that 
treatment with oncogenic RAS can induce the accumulation of p16'NK1a and 
hypophosphorylated pRB with a senescence-like arrest in the IMR90 normal human 
fibroblast cell line (Narita et al., 2003). Intriguingly, electron microscopy then found that 
the senescence-like arrest was associated with the formation of distinct heterochromatic 
structures which were named Senescence Associated Heterochromatin Foci or SAHF 
(Narita et al., 2003). 
Importantly, these heterochromatic foci were formed by newly deposited heterochromatin 
rather than from redistributed heterochromatin and were concentrated for repressive 
histone modifications such as methylation of K9 H3 and HP 1 while methylated K4 H3 and 
acetylated K9 H3 were excluded. It was also established that active transcription was not 
occurring at the sites of these foci and chromatin features indicative of these foci formed 
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on E2F-responsive promoters of genes known to be downregulated at senescence. This 
indicates that these chromatin modifications are vitally important for the stable senescence- 
like arrest attained. The genes that gained heterochromatic features and became 
downregulated included the Cyclin A gene and the PCNA gene and their promoters were 
observed to be bound by pRB, thereby linking pRB binding to the formation of the SAHF. 
pRB has been shown to interact with factors involved in the formation of heterochromatin 
(Ferreira et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998; Brehm et al., 1998; 
Vandel et al., 2001; Nielsen et al., 2001) and so pRB binding to regulatory sequences 
could be sufficient to form these heterochromatic foci to silence gene expression. 
Importantly, the authors showed in the same study that promoters of genes known to be 
upregulated at senescence gained euchromatic patterns at their promoters and lost the 
heterochromatic features at senescence at the same time as the SAHF were being formed 
suggesting that the formation of the SAHFs may be directed towards certain genes and not 
an indiscriminate global effect. Further studies into the formation of SAHF have also 
indicated roles for the chromatin regulators HIRA and ASF 1 and were shown to be rate 
limiting for the formation of SAHF and required for senescence (Zhang et al., 2005). 
These studies suggest a model in which the formation of distinct promoter specific 
heterochromatin structures accompanies the senescence process and indicates a role for 
pRB-mediated heterochromatin formation at growth regulatory genes during senescence, 
leading to the stable repression of these genes. Upregulation of p161Nxaa during 
senescence can inhibit the phosphorylation of pRB leading it to bind to E2F and cause a 
permanent growth arrest by silencing growth regulatory genes by altering the chromatin 
state of the promoter sequences. From this it was proposed that failure of certain 
processes in these cells (INK4a or pRB mutations) may lead to bypass of senescence and 
progression to cancer due to the inhibition of repression of the chromatin environment of 
the growth regulatory genes (Narita et al., 2003). 
These studies have also shown that chromatin changes that occur during senescence can 
affect the "gene expression profile" of the cell as increased repressive modifications on 
proliferation-promoting genes and decreases in repressive modifications at senescence 
associated genes were observed. In addition, it has also been observed that many genes 
upregulated in senescence are actually physically clustered (Zhang et al., 2003a), further 
suggesting that re-organisation of chromatin domains may be responsible for the 
upregulation of these genes by the formation of a more euchromatic chromatin 
environment. 
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Several other papers have recently provided more evidence of the link between chromatin 
remodelling and senescence. Utilising a mouse model, Braig et al have demonstrated that 
oncogenic RAS could halt proliferation of primary lymphocytes by a SUV39HI-dependent 
and K9 H3 methylation-related senescent growth arrest (Braig et al., 2005). In the same 
study, the deletion of SUV39H1 in primary lymphocytes led to the improper methylation 
of K9 H3 ultimately leading to the promotion of RAS-driven lymphanogenesis, indicating 
a necessity for proper regulation of the chromatin environment at senescence and also a 
role for senescence in tumour suppression in RAS driven oncogenesis. 
This study also correlates with other work which demonstrated that loss of methylation of 
K9 H3 and K20 H4 resulted in genomic instability in a variety of normal cells and was 
associated with increased tumour risk (Peters et al., 2001). Decreased expression of 
SUV39H1 has also been observed in the early premalignant stage of tumour development 
in the context of hepatocarcinogenesis induced by methyl deficiency in rats (Pogribny et 
al., 2006), although beyond this point in cancer development, SUV39H1 expression 
increased. The loss of trimethylation of K20 H4 was also observed at both preneoplastic 
and tumour stages of liver cancer in the same study and corresponded to a decrease in the 
K20 H4 HMT SUV4-20H2. These studies provide evidence that improper 
heterochromatin maintenance can lead to genomic instability and tumourigenicity. 
In another study, Michaloglou et al demonstrated that BRAF E600 -mediated oncogenic 
signalling in melanocytes has been shown to induce a senescence like phenotype including 
the formation of SAHF (Michaloglou et al., 2005). BRAF is a protein kinase and 
downstream regulator of RAS and the V600E mutation is an oncogenic mutation observed 
frequently in human naevi (moles). A further study focusing on RAS utilised a mouse 
model with a conditional oncogenic K-RASV12 allele activated by the Cre recombinase 
(Collado et al., 2005). Upon activation of the oncogenic RAS allele, the mice developed 
multiple lung adenomas (pre-malignant) and a few lung adenocarcinomas (malignant) and 
markers for senescence were evident in the adenomas but not in the carcinomas. 
Interestingly HP 1-y was strongly positive in the adenomas, whereas the carcinomas were 
negative. As the HP I proteins can bind methylated K9 H3 to mediate gene silencing, this 
study further reinforcing the role of the chromatin environment in senescence growth 
arrest. 
Although the gain of heterochromatin by increased levels of repressive histone 
modifications in senescence is apparent, the gain of repressive histone modifying activity 
and gene silencing has also been observed to allow extension of lifespan and is involved in 
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cancer while the loss of heterochromatin has been linked to the onset of senescence 
(Howard, 1996). The Polycomb Group (PcG) proteins act by forming multiprotein 
complexes that can repress target gene expression by catalysing the addition of repressive 
modifications of histones. Loss of function of the PcG protein BMI1 was shown to impair 
the progression of normal lymphocytes into S-phase and these cells underwent premature 
senescence, connecting transcriptional repression by PcG proteins with cell-cycle control 
and senescence (Jacobs et al., 1999). BMI1 has also been shown to be downregulated in 
senescing human fibroblasts (Itahana et al., 2003) while BMII over-expression has also 
been observed in tumours and tumour cell lines (Bea et al., 2001; Vonlanthen et al., 2001; 
Itahana et al., 2003; Mori et al., 2005) and has been shown to be required for the short term 
survival of cancer cells (Liu et al., 2006). Further studies have also shown that 
overexpression of BMII is able to transform and immortalise some human cells (Leung et 
al., 2004; Jacobs et al., 1999; Dimri et al., 2002). Importantly the INK4a locus from 
where p16mmx4a and p1 4A' are transcribed from is a critical downstream targets for BMII 
with regard to its effects on cell proliferation and senescence (Itahana et al., 2003). It is 
proposed that by inhibiting the expression of p16J 4a and p14ARF BMII can lead to the 
promotion of cell cycle progression. 
EZH2 is another PcG protein, and has been shown to be able to methylate K27 H3 (Cao 
and Zhang, 2004a). EZH2 is overexpressed in some cancers, again linking the formation 
of heterochromatin to the extension of lifespan (Varambally et al., 2002; Kleer et al., 2003; 
Bracken et al., 2003). EZH2 expression is also known to be repressed by pRB suggesting 
a possible mechanism for EZH2 overexpression in cancers (Bracken et al., 2003). 
Interestingly, the EZH2 expression is also suppressed by activated p53 is seen to be 
specifically downregulated in senescent cells (Tang et al., 2004). The corresponding loss 
of K27 H3 HMT activity may correspond to loss of heterochromatin and activation of 
genes such as p166NK4a and p14ARF leading to senescence (Villeponteau, 1997) while 
overexpression of EZH2 may lead to the proper maintenance of heterochromatin allowing 
the elongation of lifespan in cancer cells by bypassing senescence. These studies establish 
a link between the loss of PcG-mediated silencing and the senescence phenotype and PcG 
mediated silencing and tumourigenesis. 
Overall, that the gain of heterochromatic features can lead to senescence by the repression 
of proliferation-promoting genes, although the repression of some genes by chromatin 
based gene silencing can contribute to tumourigenesis. 
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Other epigenetic mechanisms such as DNA methylation have also been shown to be 
involved in the senescence phenotype. DNA methylation has been shown to decrease 
with age (Wilson and Jones, 1983) and this loss was hypothesised to function as a 
"counting mechanism" for senescence so the senescence phenotype would be signalled 
when a cell lost a certain degree of DNA methylation (Hoal-van Helden and van Helden, 
1989; Wilson and Jones, 1983) similar to the model in which errors in the maintenance of 
heterochromatic domains could lead to senescence (Howard, 1996). Treatment with 5- 
azadeoxycitidine (5-azadC), a DNA demethylating agent, has been shown to reduce the 
replicative lifespan of normal human fibroblasts supporting the "counting mechanism" 
hypothesis (Holliday, 1986; Fairweather et al., 1987). 
Also in agreement with this hypothesis are the findings that DNA methyltransferase 
activity is elevated in cancer cells in vitro, in tumours in vivo (Belinsky et al., 1996) and in 
cells transformed by oncogenic RAS or SV40 large T antigen (Slack et al., 1999; Rouleau 
et al., 1995), while DNA methyltransferase activity decreases in serially passaged normal 
human fibroblasts (Issa et al., 1994). Therefore the loss of DNA methylation with age 
may eventually have deleterious consequences such as dysregulation of gene expression. 
Consistent with this view, it has been hypothesised that DNA methylation may repress a 
set of growth inhibitory genes (Young and Smith, 2001; Jones and Baylin, 2002). As the 
number of cell population doublings increases and DNA methylation decreases, the 
repression of such growth inhibitory genes may become less stringent leading to their 
eventual expression, contributing to senescence. 
However, it has also been shown that a striking feature of some tumours (both benign and 
malignant) is that global DNA methylation is reduced (Feinberg and Vogelstein, 1983; 
Goelz et al., 1985). This loss of gene silencing is also linked to chromosomal instability 
which will contribute to tumourigenesis (Eden et al., 2003; Gaudet et al., 2003). So, 
paradoxically, it has been shown that the loss of DNA methylation can contribute to 
senescence and tumourigenicity. However, it is acknowledged that gene specific 
methylation is variable and that many tumour suppressor genes show promoter specific 
DNA methylation leading to gene silencing, including RB) (Sakai et al., 1991) and 
p16'NK4a (Gonzalez-Zulueta et al., 1995). It is likely that global loss of DNA methylation 
which leads to chromosomal instability will trigger the senescence phenotype as a tumour- 
suppressor mechanism but the promoter specific alterations in key tumour-suppressor 
genes may allow the bypass of senescence and tumourigenicity. 
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Overall, the data suggests that genome wide loss of heterochromatin may lead to genetic 
instability which is detected and the cell will signal for senescence to occur. However, 
gene specific gain of heterochromatic features can also lead to senescence by the 
repression of proliferation-promoting genes. 
1.3.3 Histone Acetylation and Senescence 
The acetylation status of promoter proximal histones has also been linked to senescence. 
Promotion of histone acetylation by HDAC inhibitors can induce senescent-like phenotype 
in human fibroblasts several population doublings after treatment (Ogryzko et al., 1996; 
Munro et al., 2004; Place et al., 2005). It was also demonstrated that in senescing normal 
human fibroblasts, HDAC 1 became downregulated (Place et al., 2005) indicating that 
overall the promotion of acetylation can lead to senescence. 
However histone deacetylation has also been shown to have a role in the extension of 
cellular lifespan. The yeast protein Sir2, identified as an NAD+-dependent HDAC 
involved in rDNA silencing, has been shown to be able to contribute to the replicate 
lifespan of yeast (Kaeberlein et al., 1999; Imai et al., 2000). Enhanced activity of the sir2 
gene was also found to be associated with increased longevity in worm (Hekimi and 
Guarente, 2003), flies (Rogina and Helfand, 2004) and rodents (Cohen et al., 2004). 
Drosophila Sir2 has further been shown to be involved in epigenetic gene silencing by the 
PcG proteins and is physically associated with a complex containing the Drosophila 
homolog of EZH2 further implicating Sir2 in the control of senescence (Furuyama et al., 
2004). SIRTI, the human homologue of Sir2, was also described to be associated with 
longevity and is believed to act primarily by inhibiting cellular senescence (Yeung et al., 
2004; Brunet et al., 2004; Vaziri et al., 2001). Although it is likely that SIRTI and other 
Sir2 homologues main actions are through the deacetylation of transcription factors and not 
on histones, SIRTI has been shown to have K16 H4 deacetylase activity (Michishita et al., 
2005). Recently a SIRTI inhibitor, Sirtinol, was shown to induce a senescence-like 
growth arrest in human cancer cells (Ota et al., 2005) in agreement with the above data, 
showing that HDAC inhibitors could lead to senescence. 
Histone acetyltransferases have also been demonstrated to have a role in senescence. The 
HATs p300 and CBP were studied in senescing human melanocytes and interestingly, 
levels of both proteins were observed to decrease as these cells underwent replicative 
senescence and that this decrease was senescence specific (Bandyopadhyay et al., 2002). 
p300 deficient fibroblasts were also shown to rapidly senesce in another similar study (Yao 
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et al., 1998). This decrease in the levels of the HAT expression led to dramatic decreases 
in total histone H4 acetylation levels while total histone H4 protein levels remained at a 
similar level to proliferating cells. Specifically, the Cyclin E gene promoter was shown to 
lose promoter histone H4 acetylation and become repressed at senescence while in 
proliferating cells Cyclin E is highly expressed and promoter histone H4 is highly 
acetylated. Cyclin E is a critical regulator of senescence and so heterochromatin 
formation at the promoter sequences in senescence may play an important role in stably 
downregulating this gene and the acquisition of the senescent phenotype. Other studies of 
the Cyclin E promoter during senescence showed that pRB and HDACs also bound to the 
promoter to repress transcription, similar to previous studies linking the senescent 
phenotype to the pRB/p16I 4a pathway and the formation of SAHF (Narita et al., 2003). 
A recent review of p53's role in global regulation of chromatin acetylation indicates roles 
for p53 in the control of gene expression by acetylation (Allison and Milner, 2004) and 
p53's intimate relationship with senescence further suggests a role of the regulation of the 
chromatin environment in senescence. 
These studies suggest that the increases in global histone acetylation can lead to 
senescence; perhaps mediated by the re-expression of previously heterochromatically 
silenced genes which when activated, promote senescence, while de-acetylation may serve 
to repress genes which contribute to the senescence phenotype. 
1.4 Aims of this Project 
Modulation of the chromatin environment is now understood to play a major role in the 
transcriptional control of gene expression and this suggests that the chromatin based 
regulatory mechanisms will be important for multiple cellular processes. Modulation of 
the chromatin environment has also been observed in senescence, suggesting that the 
control of the chromatin environment could also have important roles in the bypass of 
senescence and tumourigenesis. Telomerase has long been indicated to play important 
roles in senescence and tumourigenesis, but knowledge about their transcriptional control 
is lacking. Transcriptional control of hTR and hTERT is deemed to be an important level 
of control of hTR and hTERT gene expression and previous studies on the role of 
epigenetics in telomerase gene regulation have been limited. The aims of this project are to 
better understand how alterations of the chromatin environment can affect the expression 
hTR and hTERT by utilising two different model systems; normal, telomerase positive 
tumour cells and ALT cells and also in stem cell populations. 
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The aims of this project in detail are: 
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" To investigate how epigenetic regulation of the gene promoters impacts on hTR and 
hTERT gene expression in three different model systems; normal, ALT and tumour 
cell lines. 
" To investigate how epigenetic regulation of the gene promoters impacts on hTR and 
hTERT gene expression in other model systems; stem cells and cancer stem cells. 
" To investigate how modulation of the chromatin environment can affect the 
dynamics of the basal transcription machinery and hence transcription in all our 
model systems. 
" To investigate any common features in chromatin based regulatory mechanisms 
between hTR and hTERT gene regulation. 
" To investigate whether chromatin based regulatory mechanisms are conserved 
between cell types or whether there are cell type differences. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Tissue Culture Reagents and Plasticware 
RPMI 1640 growth medium 
Minimum Essential Medium (MEM) 
Dulbecco's modified Eagles (DMEM) 
L-glutamine (200mM) 
Trypsin (2.5%) 
Foetal calf serum 
75cm2 flasks 
25cm2 flasks 
2.1.2 Cell Lines 
A2780 ovarian carcinoma 
C33a cervical carcinoma 
5637 bladder carcinoma 
W138 Normal Human Lung Fibroblasts 
W138-SV40 (ALT) 
KMST6 (ALT) 
Invitrogen 
Invitrogen 
Invitrogen 
Invitrogen 
Invitrogen 
Autogen Bioclear 
Iwaki 
Iwaki 
ATCC 
ATCC 
DSMZ 
ECACC 
ECACC 
ECACC 
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SKLU (ALT) ECACC 
SUSMI(ALT) ECACC 
GM847 (ALT) ECACC 
Human Mesenchymal Stem Cells (hMSC) 
Normal and CML CD34+ Haematopoietic Stem Cells (hHSCs) 
2.1.3 Antibodies 
Antibody (and Residues Detected) 
Permissive/ 
Repressive 
Modification Company 
Order 
Number 
Acetylated H3 (Lysines 9 and 14) Permissive Upstate 06-599 
Acetylated H4 (Lysines 5,8,12 and 16) Permissive Upstate 06-866 
Acetylated K9 H3 Permissive Upstate 07-352 
Di-Methylated Lysine 4 H3 Permissive Upstate 07-030 
Tri-Methylated Lysine 4 H3 Permissive Abeam ab8580 
Di-Methylated Lysine 9 H3 Repressive Abeam ab7312 
Tri-Methylated Lysine 9 H3 Repressive Abeam ab8898 
Di-Methylated Lysine 20 H4 Repressive Upstate 07-357 
Tri-Methylated Lysine 20 H4 Repressive Upstate 07-463 
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Antibody Company Order Number 
RNA Polymerase II Abcam ab5408 
Pol II (N-20) rabbit polyclonal IgG Santa-Cruz Biotechnology sc-899 
TFIIB (C- 18) rabbit polyclonal IgG Santa-Cruz Biotechnology sc-225 
c-Myc Upstate 06-340 
2.1.4 Kits, Reagents and Enzymes 
Kit/Reagent 
Nucleospin II RNA extraction kit 
GeneAmp RNA PCR core kit 
Taq PCR core kit 
HotStar Taq DNA polymerase 
DyNAmo SYBR Green qPCR kit 
Chromatin Immunoprecipitation assay kit 
QlAquick PCR purification kit 
Glycogen 
Pepstatin 
Aprotinin 
Supplier 
Abgene 
Roche 
Qiagen 
Qiagen 
Finnzymes 
Upstate Biotechnology 
Qiagen 
Roche 
Roche 
Roche 
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Phenylmethanesulfonyl fluoride (PMSF) Fluka 
DNA molecular markers Invitrogen 
10% SDS solution (sodium dodecyl sulphate) Invitrogen 
RNAseZap Ambion 
DNA 1000 reagents & supplies Agilent Technologies 
DNA Chips Agilent Technologies 
2.1.5 Chemicals 
Chemicals were acquired from Sigma or Fisher Scientific, UK. 
TRIS-hydrochloride 
EDTA (Ethylenediamine tetra-acetic acid) 
Absolute ethanol 
Propan-2-ol 
Sodium hydroxide 
Sodium chloride 
NP40 (IGEPAL) 
Triton-X 100 
Sodium Deoxycholate 
Lithium Chloride 
Agarose 
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Bromophenol blue 
Xylene cyanole 
DMSO (Dimethyl sulfoxide) 
Ethidium bromide 
ß-mercaptoethanol 
Phenol: chloroform: iso-amyl alcohol 
N-Lauroylsarcosine sodium salt 
DEPC (diethylpyrocarbonate) 
2.1.6 General Laboratory Supplies and Reagents 
Provided by Beatson Institute Central Services: 
Sterile distilled water 
Sterile phosphate buffered saline (PBS) 
Sterile PBS + EDTA (PE) 
IOx TBE electrophoresis buffer (Tris Borate/EDTA) 
Sterile glassware and measuring pipettes 
General Supplier 
Falcon tubes 50m1 and 15m1 Becton Dickinson 
Universal containers 5m1,20m1 and 100ml Bibby Sterilin 
Micro-centrifuge tubes 1.5m1 and 0.5m1 Eppendorf/Abgene 
Stuart P. Atkinson, 2006 Chapter 2 
General Supplier 
Cell scrapers (rubber policeman) Corning 
Pipette tips Gilson/Greiner bio-one 
Plastic pipettes lml, 5m1, lOml and 25m1 Corning 
Polyprep Columns BioRad 
2.1.7 Oligonucleotides for PCR 
Primer Name Sequence 5' to 3' 
hTR Expression TRC3F 
CTA ACC CTA ACT GAG AAG GGC 
GTA 
TRC3R 
GGC GAA CGG GCC AGC AGC TGA 
CAT T 
hTERT Splice Variant HT2026F GCC TGA GCT GTA CTT TGT CAA 
HT2482R 
CGC AAA CAG CTT GTT CTC CAT 
GTC 
hTR ChIP HTR29SF CCC GCC CGA GAG AGT GAC 
HTR5ALTR AAG TCA GCG AGA AAA ACA GC 
hTERT ChIP TERTFS TCC CCT TCA CGT CCG GCA TT 
TERTRS AGC GGA GAG AGG TCG AAT CG 
hTERT Exon 12 ChIP Ex12 FA 
CAG GAC AAG GAA GCG GGA GGA 
A 
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Ex12 RAB CAG CCG CAA GAC CCC AAA GA 
GAPDH Expression GAPDH F ACC ACA GTC CAT GCC ATC AC 
GAPDH R CCA CCA CCC TGT TGC TGT A 
S 15 Expression S15 F TTC CGC AAG TTC ACC TAC C 
S15 R CGG GCC GGC CAT GCT TTA CG 
2.1.8 Equipment 
Medical Air Technologies Bio-MAT class 11 microbiological safety cabinet 
Scharfe Systems Casy-1 cell counter 
Forma Scientific CO2 H2O jacketed incubator 
Sigma 4K15/ Beckman GS-6R bench top centrifuges 
Bio-Rad sub-cell GT electrophoresis gel tank/model 200 power supply 
Pharmacia Biotech GeneQuant DNA/RNA calculator 
MJ Research PTC-200 Peltier thermal cycler 
MJ Research DNA Engine Opticon 2 Real Time PCR Detection System 
Beckman J6-MC centrifuge 
Beckman Microfuge-R refrigerated micro-centrifuge 
Bio-Rad Gel Doc 1000 UV transilluminator 
Syngene Gene Genius Bio Imaging system / GeneSnap version 6.03 
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Agilent 2100 Bioanalyzer, Agilent Technologies 
2.2 DNA Techniques 
2.2.1 UV Gel Documentation 
37 
Analysis and photography of ethidium bromide agarose gels was accomplished using the 
Bio-Rad gel doc 1000 UV transilluminator with Molecular Analyst software. This system 
was later replaced by the Syngene Gene Genius Bio Imaging System with GeneSnap 
version 6.03 software. 
2.3 Analysis of Gene Expression 
2.3.1 RNA Extraction 
Before extraction surfaces and pipettes were wiped with RNaseZap (Ambion) to remove 
traces of RNases. RNase free pipette tips were used and microcentrifuge tubes were pre- 
treated with DEPC water (Add 0.1% DEPC to dH2O, bring the DEPC into solution and 
incubate at 37°C for 12 hours. Finally, autoclave the solution for 15 mins to remove 
DEPC). Total RNA was isolated from cultured cells using the NucleoSpin RNA II kit as 
per the manufacturers' instructions. Approximately 1x 106 cells were lysed by addition of 
350µ1 of buffer RAI and vigorous vortexing. The lysate was homogenised by passing 
through a 20 gauge needle and was then applied to a NucleoSpin filter which contains the 
silica membrane. Contaminating DNA, which is also bound to the silica membrane, was 
removed by treatment with DNase-1 solution for 15 minutes at room temperature. Salts, 
metabolites and macromolecular cellular components were removed in washing steps and 
the pure RNA was eluted under low ionic strength conditions with RNase-free water. 
2.3.2 cDNA Synthesis 
cDNA was prepared using the GeneAmp RNA PCR core kit (Roche). RNA was 
quantitated by spectrophotometry using the Pharmacia Biotech GeneQuant 
spectrophotometer and adjusted to 1 gg in RNase-free dH2O. Reactions were prepared in a 
PCR workstation (Labcaire) using RNase-free tubes and tips which were UV crosslinked 
prior to use. A reaction mix was made up with 4µ1 of lOx Buffer, 8.8µl MgC129 8 µl 
dNTPs, 2 µl random hexamers, O. 841 of RNAse inhibitor, 1 gl of reverse transcriptase (RT) 
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and lug of RNA per sample, made up to 40µl with dH2O. For each sample a no RT control 
mix was also prepared. Samples were then incubated at 25°C for 10 minutes, 48°C for 30 
minutes and 95°C for 5 minutes. I µl of cDNA was used in subsequent PCR reactions. 
GAPDH specific Q-PCR was performed for RT-PCR reaction products and no RT controls 
to determine the quality of cDNA produced and to check for DNA contamination of the 
RNA. 
2.3.3 Quantitative Polymerase Chain Reaction (Q-PCR) 
Q-PCR master mixes were made using the Finnzymes DyNAmo SYBR green Q-PCR kit. 
The 2x reaction mix provided contained SYBR green dsDNA binding dye, buffer, Taq 
polymerase and dNTPs in a pre-mixed form, therefore typical reactions consisted of Ix 
SYBR green reaction mix, 0.5µM each primer and Iµd DNA made up to a 20µl volume 
with dH2O. Reaction mixes were prepared in a PCR workstation (Labcaire) and all 
equipment was UV crosslinked before use. Each reaction is completed in triplicate and 
standard curve of a known concentration range of human genomic DNA is used to quantify 
the PCR product levels. Reactions were run on an Opticon 2 DNA Engine from MJ 
Research according to the cycling conditions detailed below. The average value of the 
triplicate reactions was taken as the concentration of PCR product. This also allows errors 
to be generated. 
2.3.4 PCR Primers 
hTR and hTERT splice variant expression primers were previously established in the 
laboratory (Anderson et al., 2006). hTR and hTERT ChIP primers were raised against the 
core promoter sequences of the respective genes. Exon 12 of hTERT primers were raised 
against the coding sequence of Exon 12 of hTERT coding sequence. Gene products for 
Q-PCR were designed to be between 100bp and 200bp in length to allow for efficient Q- 
PCR reactions and promoter specific localisation of the histone modifications detected in 
each ChIP. Each set of primers gave a single specific product, as visualised by melting 
curve analysis within the Q-PCR reaction and also by gel electrophoresis. GAPDH 
primers were also designed, to give a product of approximately 450bp, for Q-PCR 
reactions for use in normalising hTR and hTERT expression levels. The product of these 
primers also gave a single specific product as visualised by melting curve analysis within 
the Q-PCR reaction and also by gel electrophoresis. 
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2.3.4.1 Cycling Conditions 
GAPDH Expression Step 1: 94 °C for 10 mins; Step 2: 95 °C for 30 secs; 
Step 3: 60°C for 45 secs; Step 4: 72°C for 1 min; 
Step 5: 81 °C for 10 secs; Step 6: Plate read; 
Step 7: Goto Step 2,29 times; 
Step 8: Melting curve 70-90°C. 
hTR Expression: Step 1: 94°C for 10 mins; Step 2: 95°C for 30 secs; 
Step 3: 59.5°C for 45 secs; 
Step 4: 72°C for 30 secs; 
Step 5: 81 °C for 10 secs; Step 6: Plate read; 
Step 7: Goto Step 2,31 times; 
Step 8: Melting curve 70-90°C 
hTR and hTERT Promoter ChIP: Step 1: 94°C for 10 mins; Step 2: 95°C for 30 secs; 
Step 3: 64°C for 45 secs; Step 4: 72°C for 30 secs; 
Step 5: 82°C for 10 secs; Step 6: Plate read; 
Step 7: Goto Step 2,39 times; 
Step 8: Melting curve 70-90°C 
hTERT Exon 12 ChIP Step 1: 94°C for 15 mins; Step 2: 95°C for 30 secs; 
Step 3: 66°C for 45 secs; Step 4: 72°C for 30 secs; 
Step 5: 82°C for 10 secs; Step 6: Plate read; 
39 
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S 15 Expression 
Step 7: Goto Step 2,39 times; 
Step 8: Melting curve 70-90°C 
Step 1: 94°C for 10 mins; Step 2: 95°C for 30 secs; 
Step 3: 55°C for 30 secs; Step 4: 72°C for 30 secs; 
Step 5: 82°C for 10 secs; Step 6: Plate read; 
Step 7: Goto Step 2,34 times; 
Step 8: Melting curve 70-90°C 
2.3.5 Polymerase Chain Reaction (PCR) 
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Polymerase Chain Reaction (PCR) master mixes were made using reagents from the 
Qiagen Taq-core kit. HotStar Taq DNA polymerase was used in place of Taq polymerase 
for all TERT PCR reactions. Reaction mixes were prepared in a PCR workstation 
(Labcaire) and all equipment was UV crosslinked before use. Reactions typically 
contained 1 µl template DNA along with final concentrations of master-mix components as 
follows: lx PCR buffer; 0.5µM each primer; 0.2mM each of dATP, dTTP, dCTP, dGTP; I 
unit Taq polymerase. Reaction volumes were made up to 25µL with sterile distilled H2O 
and run according to the cycling conditions detailed below. PCR products were analysed 
by agarose gel electrophoresis. Typically 5-l0µ1 was loaded onto a 0.8% agarose gel 
containing ethidium bromide for UV visualisation of DNA. 
2.3.5.1 Cycling conditions 
hTERT Splice Variants: Step 1: 94°C for 15 mins; Step 2: 95°C for 30 secs; 
Step3: 64°C for 45 secs; Step 4: 72°C for 45 secs; 
Step 5: Goto Step 2,39 times; 
Step 6: 72°C for 5 mins 
Stuart P. Atkinson, 2006 Chapter 2 
2.3.6 Quantitation of DNA using the Agilent Bioanalyser 
41 
The Agilent 2100 Bioanalyzer LabChip system was also used to visualise and quantify 
PCR products and was used for the hTERT splice variant PCR. This system utilises 
LabChips with multiple channels etched into glass. The micro-channels of the chip are 
filled with a sieving polymer with fluorescent dye and a molecular weight marker is added. 
PCR products are separated electrophoretically using strategically located electrodes. 
Sample components are detected by their fluorescence and translated into virtual gel 
images, sized and quantified in relation to internal standards. The samples and chips were 
prepared and loaded according to manufacturers' instructions. 
2.3.7 Calculation of Expression Levels 
hTR levels were established using the specific expression primers and were normalised to 
the expression of GAPDH levels. GAPDH levels were established using the same amount 
of cDNA as for hTR expression level analysis and hTR levels were normalised by dividing 
the hTR figure by the figure for GAPDH expression, and so levels of hTR are expressed as 
a percentage of GAPDH expression (see formula below). 
[Level of hTR expression by Q-PCR for x µl cDNA/Level of GAPDH Expression by Q- 
PCR for x µl cDNA] * 100 = hTR expression levels as percentage of GAPDH. 
Expression levels were found to be similar between three different experiments for each 
cell line and levels shown are from a representative experiment. Means and errors are 
established from triplication within the Q-PCR experiment of the representative 
experiment. 
hTERT expression levels were established, first by analysing GAPDH levels from cDNA 
made from I µg RNA. cDNA amounts used as input in each separate reaction for each cell 
line were then adjusted to the GAPDH level for the hTERT splice variant PCR reaction so 
similar concentrations of cDNA were used in each PCR. hTERT expression levels are 
shown as the sum of all the expressed variants (WT, a, ß and aß). Therefore the hTERT 
levels are expressed as being normalised to GAPDH expression. Expression levels were 
found to be similar between three different experiments for each cell lines. Means and 
errors are established from the average of these Q-PCR experiments. 
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S15 gene expression was utilised in a similar manner to GAPDH to adjust for hTR and 
hTERT expression levels in the CD34+ hHSC samples. S15 expression was used as it 
gave a more robust expression level that for GAPDH for these samples. 
Statistical analysis showing any statistical significance levels was established using the 
ANOVA statistical software program from within the data analysis module of Microsoft 
Excel. 
2.4 Cell Culture 
2.4.1 Maintenance and Storage of Mammalian Cell Lines 
All cell lines were routinely cultured in 75cm2 flasks in 20ml of medium supplemented 
with 10% foetal calf serum (FCS) and 2mM L-Glutamine. A2780 and 5637 cells were 
grown in RPMI 1640, C33a, SKLU, SUSMI and GM847 were grown in DMEM and 
W138, W138-SV40 and KMST6 were all grown in MEM. Cells were trypsinised for sub- 
culturing with Iml of 0.25% trypsin diluted in PE (PBS + EDTA). All cell lines were 
regularly tested for mycoplasma contamination. 
For long term storage, 1 ml aliquots of 1x 106 cells/ml in growth medium supplemented 
with 10% FCS and 10% DMSO were cooled to -70°C overnight and then transferred to 
liquid nitrogen. To recover cells from liquid nitrogen, cryovials were warmed to 37°C. 
The contents were transferred to 19mL of warm growth medium in a 25cm2 flask and 
incubated overnight. The next day, the medium containing DMSO cryopreservant was 
removed and replaced by normal, complete medium. 
2.4.2 Isolation of hMSCs and Cell culture 
Isolation of hMSCs, cell culture and treatment was provided by the laboratory of Dr 
Nedime Serakinci (University of Southern Denmark, Institute of Medical Biology, 
Department of Anatomy and Neurobiology, DK-5000 Odense C, Denmark). Primary 
hMSC isolated from bone marrow aspirates by centrifugation (700g for 15 minutes at 4°C) 
over a Ficoll Hypaque gradient as previously described by Pittenger, et al (Pittenger et al., 
1999). The resulting cells were cultivated in high glucose (4.5 g/1) Dulbecco's modified 
Eagles medium supplemented with 10% fetal bovine serum, 100 U/ml of penicillin and 
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streptomycin and 2 mM of L-glutamine. Cells were plated out with a confluency of 75% 
and next day added TSA at final concentration of 350 µM for 17hrs. 
2.4.3 hHSC Isolation 
hHSCs were provided from the laboratory of Dr Tessa Holyoake (Section of Experimental 
Haematology and Haematopoietic Stem Cells, Division of Cancer Sciences and Molecular 
Pathology, University of Glasgow, Glasgow, Scotland, United Kingdom). Fresh 
leukapheresis products from patients with chronic phase CML or from normal allogeneic 
donors were enriched for CD34+ cells by either StemSep (Stemcell Technologies, Inc., 
Vancouver, BC) or Isolex (NEXELL International, Brussels, Belgium) systems. The cells 
were then cryopreserved in 10% dimethylsulphoxide (DMSO, Sigma Aldrich, UK) in 
ALBA (4.5% Human Albumin Solution, Scottish National Blood Transfusion Service) and 
stored in the vapour phase of liquid nitrogen until required. All human cell samples were 
obtained with informed consent. 
2.4.4 Drug Treatment of Cells 
ALT and Normal cells were treated with TSA or 5-azadC under the following conditions. 
Cells utilised were treated twice for 24 hours with 5-azadC to a final concentration of 
2.5µM, and then treated for 16 hours with Trichostatin A (TSA) at a final concentration of 
35OnM. Control cells were treated over the same time course but with 100% ethanol 
instead of TSA and 50% acetic acid instead of 5-azadC. 
2.5 Chromatin Immunoprecipitation Assay (ChIP) 
During the course of this study 2 ChIP protocols were used. Most of the antibodies used 
worked well with the Upstate ChIP kit protocol (ChIP Assay I), RNA polymerase II 
(Santa-Cruz) and TFIIB a modified protocol was found to be more effective (ChIP Assay 
II). 
2.5.1 Chromatin Immunoprecipitation Assay I 
Cells were grown in 75 cm2 flasks and harvested before reaching confluence with around I 
x 106 cells used per IP. Neutral buffered formalin (NBF) was added to 1% in the media 
within each flask in a fume hood to crosslink proteins and DNA. Flasks were sealed and 
incubated for 10 minutes at 37°C. NBF was removed and cells rinsed twice in cold PBS 
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(4°C). 3ml cold PBS containing protease inhibitors (1mM phenylmethlysulfonyl (PMSF), 
1µg/ml aprotinin and lug/ml pepstatin A) were added to each flask. Cells were scraped 
and transferred to 15m1 falcon tubes then centrifuged at 4000rpm for 10 minutes at 4°C and 
the supernatant removed. The cell pellets were re-suspended in 200 µl of SDS lysis 
buffer (1% SDS, 10mM EDTA, 50mM Tris-HCI, pH 8.1) with protease inhibitors and 
incubated on ice for 10 minutes. Samples were sonicated on ice for 6x 10 second pulses 
using an MSE Soniprep 150, sonicator at amplitude 5 microns, optimised to give 
chromatin fragments of around 500bp. 
The sonicated samples were centrifuged at 13000 rpm for 10 minutes at 4°C to remove 
debris and supernatant transferred to Eppendorf tubes. Chromatin was collected and 
diluted 10 fold with ChIP dilution buffer (0.01 % SDS, 1.1 % Triton X-100,1.2mM EDTA, 
16.7mM Tris-HCL, pH 8.1,167mM NaCI) containing protease inhibitors (1mM PMSF, 
1 gg/ml aprotinin and 1. tg/ml pepstatin A). A 200gl sample was removed and stored at - 
20°C as the Input sample. 40µl of salmon sperm/agarose A protein slurry per ml of diluted 
chromatin was added to each tube of the remaining chromatin and rotated at 4°C for 30 
minutes. Samples were spun at 1000 rpm for 2 minutes at 4°C and the supernatant from 
each was split into -lml aliquots. Antibodies were added to each aliquot, leaving one 
without antibody as a negative control and the samples were left to rotate overnight at 4°C. 
80gl of salmon sperm/agarose A protein slurry was added to each sample and samples 
rotated at 4°C for 1 hour. The samples were spun at 1000 rpm at 4°C for 2 minutes to 
pellet the agarose beads and the supernatant removed, taking care not to remove any beads. 
i ml low salt immune complex wash (0.1% SDS, 1% Triton X-100,2mM EDTA, 20mM 
Tris-HCI, pH 8.1,150mM NaCl) was added to the beads, mixed by rotation at room 
temperature for 4 minutes and centrifuged at 1000 rpm for 2 minutes at 4°C. The 
supernatant was removed and the above step repeated with 1 ml high salt immune complex 
(0.1% SDS, 1% Triton X-100,2mM EDTA, 20mM Tris-HC1, pH 8.1,500mM NaCI), lml 
LiCI immune complex (0.25M LiCI, 1% NP40,1% deoxycholate, 1mM EDTA, IOmM 
Tris-HC1, pH 8.1), and twice with iml TE buffer (10mM Tris-HC1,1mM EDTA, pH 8.0). 
The immune precipitate was then eluted by adding 25011 of elution buffer (0.1M NaHCO3, 
1% SDS), mixing for 15 minutes by rotation at room temperature and centrifugation at 
1000 rpm for 2 minutes at room temperature. This was repeated and supernatants pooled 
to give 500µl. The Input sample (200gl) was diluted with 300µl H2O to give 500gl. 20µl 
of 5M NaCl was added to each sample and these were incubated for 4 hours at 65°C to 
reverse the cross-linking. 
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Proteins were degraded by adding 10µ1 of 0.5 M EDTA, 20µl IM Tris-HC1 and 2µl 
proteinase K to each sample and incubating for 1 hour at 45°C, followed by 
phenol/chloroform/isoamylalcohol extraction. The DNA was precipitated by addition of 
1 ml 100% ethanol and 1 µl of glycogen and incubated at -20 °C overnight. The samples 
were spun at 13000 rpm for 10 minutes and the supernatant removed carefully. The DNA 
pellet was washed in 500µ1 70% ethanol, spun at 13000 rpm for 5 minutes and supernatant 
removed. The pellet was air dried for 15 minutes and then resuspended in 50µl sterile 
water. DNA was further purified using the Qiagen PCR purification kit following 
manufacturers' instructions and DNA was eluted in 50µ1 sterile water. 
2.5.2 Chromatin Immunoprecipitation Assay 11 
Chromatin immunoprecipitation for RNA polymerase II (Santa-Cruz) and TFIIB were 
carried out using a protocol from Prof. R. J. White's laboratory at the University of 
Glasgow (Gomez-Roman et al., 2003) for the hMSC study. Cells were grown in 75 cm2 
flasks and harvested before reaching confluence. Cells were cross-linked for 10 minutes at 
37°C with 1% neutral buffered formaldehyde (NBF) (final concentration) added directly 
into the growth medium. Cross-linked cells were washed in PBS then scraped in 3m1 
PBS/NP40 (0.5%) and transferred to falcon tubes on ice. Cells were centrifuged at 
1500rpm for 5 minutes at 4°C and the supernatant discarded. 
Pellets were subjected to hypertonic lysis by incubation in 40m1 high salt buffer (0.5% 
NP40, PBS, 1M NaCl) for 30 minutes on ice. After centrifugation at 1500rpm for 5 
minutes at 4°C, pellets were washed with PBS/NP40 (0.5%) and subjected to hypotonic 
lysis by incubation in 40m1 low salt buffer (0.5% NP40,10mM Tris-HCI, pH 8.0,1mM 
EDTA, 0.1 M NaCl) for 30 minutes on ice. After centrifugation at 1500rpm for 5 minutes 
at 4°C, pellets were again washed with PBS/NP40 (0.5%) and resuspended in Iml low salt 
buffer. Nuclei were extracted by homogenising the pellet by passing through a 26-gauge 
needle, and a further 1.7m1 low salt buffer was added, to a final volume of 2.7ml. 300µl 
20% sarcosyl was added and each 3ml sample was transferred slowly in I ml fractions to a 
sucrose gradient (100mM sucrose in 40ml low salt buffer) in 50ml falcon tubes. Samples 
were centrifuged at 4000rpm for 10 minutes at 4°C and the supernatant discarded. After 
resuspension of the pellet in 3ml TE buffer (10mM Tris-HC1, pH 8.0,1mM EDTA) the 
lysate was transferred to a second sucrose gradient and again centrifuged at 4000rpm for 
10 minutes at 4°C. Pellets were resuspended in a suitable volume of TE (typically around 
200ul per 5x 106 cells and sonicated on ice for 12 x 10 second pulses using an MSE 
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Soniprep 150, sonicator at amplitude 7 microns, to give chromatin fragments of around 
500bp. 
After sonication samples were centrifuged at 13000rpm for 5 minutes at 4°C to remove 
cellular debris. Supernatants were adjusted with 1/10`h volume l lx NET buffer (1.65 M 
NaCl, 5.5mM EDTA, 5.5% NP40,550mM Tris HCI, pH 7.4) and diluted to a total volume 
of 1 ml/sample in TE buffer. 2001il was removed as the input fraction then the remaining 
sample was immunoprecipitated with the appropriate antibody at 4°C on a rotator 
overnight. 
100µl protein G agarose beads in 1x NET buffer were added to each sample and incubated 
at 4°C for 2 hours on a rotator and then transferred to polyprep columns. Beads were 
washed twice with lOml RIPA buffer (150mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% 
NP40,50mM Tris-HCI, ph 8.0), twice with 10m1 LiCI buffer (250mM LiCl, 0.5% NP40, 
0.5% deoxycholate, 1 mM EDTA, 10mM Tris-HCI, pH 8.0) and twice with l Oml TE all at 
4°C. After washing, beads were resuspended in Iml TE, transferred to 1.5m1 tubes and 
centrifuged at 8000rpm for 1 minute at 4°C. Immunoprecipitated chromatin was eluted 
from the beads twice in 200µl TE/1% SDS and pooled to 400µl final volume. Input 
fractions were also made up to 400µl in TE/1% SDS. Protein was degraded by incubation 
with 5µl Proteinase K at 56°C for 4 hours or 42°C overnight. DNA was extracted twice 
with 400µl phenol/chloroform/isoamylalcohol and once with 400g1 chloroform and then 
precipitated with I ml 100% ethanol and 40µ1 3M sodium acetate at '20°C overnight. The 
samples were spun at 13000 rpm for 20 minutes and the supernatant removed carefully. 
The glassy DNA pellet was washed in 500µ1 70% ethanol, spun at 13000 rpm for 5 
minutes and supernatant removed. The pellet was air dried for 15 minutes and then 
resuspended in 501il sterile water. 
2.5.3 Calculation of ChIP Results 
In each ChIP experiment an Input sample (200u1) is taken before the antibody-IP 
incubation and is a 20% fraction of the chromatin used in each antibody-IP. After Q-PCR, 
the results for each antibody-IP are then related back to the Input sample in order to 
normalise the data between experiments. Therefore the results for each antibody-IP are 
expressed as being a percentage of the Input fraction. 
As a negative control, an IP to which no antibody is added is included (IP-) is used. This 
method of normalisation has been previously used and shown to be reproducible in 
Stuart P. Atkinson, 2006 Chapter 2 47 
independent experiments from our laboratory (Anderson et al., 2006). Throughout the 
ChIP experiments within these studies the IP- is zero or negligible and this lack of 
background was reproducible between multiple experiments of each different set of 
experiments and between the different primers sets. The use of this control will establish 
any background signal present and can be subtracted from the results to control for 
background in each experiment. 
Each ChIP experiment was repeated in triplicate and was found to be similar between 
experiments. Results shown are for a representative experiment and means and standard 
errors are generated from Q-PCR reactions by reading each sample in triplicate. 
Statistical analysis showing any statistical significance levels was established using the 
ANOVA statistical software program from within the data analysis module of Microsoft 
Excel. 
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3 Epigenetic Regulation of hTR Expression in 
Normal, Tumour and ALT Cell Lines 
3.1 Introduction 
48 
Reactivation of telomerase activity in cancer cells is often attributed to the re-expression or 
an increase in the levels of hTERT. However, telomerase activity is minimally 
reconstituted by hTERT and hTR (Autexier et al., 1996; Weinrich et al., 1997) and so the 
expression of hTR may also be important in the regulation of telomerase activity. hTR is 
the RNA template component of the telomerase holoenzyme and was first cloned in the 
ciliate Tetrahymena and was found to contain a sequence complimentary to that of 
telomeric repeats and is the template for telomere elongation (Greider and Blackburn, 
1989; Shippen-Lentz and Blackburn, 1990). 
Although expression of hTR is evident in some normal tissues (Feng et al., 1995) levels of 
expression of hTR are increased relative to the levels observed in normal tissues in human 
tumours (Downey et al., 2001; Soder et al., 1998; Avilion et al., 1996; Guilleret et al., 
2002b). Upregulation of hTR expression in tumour cell lines derived from multiple 
cancer tissues relative to primary mortal cell lines has also been observed (Feng et al., 
1995). Studies in mice have also shown that mTR is essential for telomere length 
maintenance (Blasco et al., 1997; Hathcock et al., 2002; Chiang et al., 2004) while 
increases in mTR expression have also been observed in the early pre-neoplastic stages and 
further increased during the progression of certain carcinomas (Blasco et al., 1996). 
Overall, these studies indicate an underlying mechanism for transcriptional upregulation of 
hTR during tumourigenesis. Interestingly, hTERT activation has also been shown to 
occur concomitant with elevation of hTR transcription suggesting partially overlapping 
regulatory mechanisms (Yi et al., 1999; Stanta et al., 1999). 
Some interesting studies have also indicated a new role for hTR. Depletion of hTR has 
been shown to lead to rapid growth inhibition of human cancer cells independently of p53 
or telomere length (Li et at, 2004). This was due to changes in the global gene expression 
profile of the cells and a response pathway to hTR depletion was proposed which was 
distinct from the response to uncapping of telomeres (Li et al., 2005). All telomerase 
positive tumour cell lines tested showed a similar response to hTR depletion but this was 
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not observed in the W138-SV40 cell line which maintains its telomeres by utilising the 
ALT mechanism. 
Cloning and characterisation of the hTR promoter sequence aided investigations into how 
hTR expression is regulated at the transcriptional level (Zhao et al., 1998) which has been 
identified as an important level of control in the regulation of hTR expression (Yi et al., 
1999). The hTR gene was found to lie within a CpG island 733bp in length (Zhao et al., 
1998) suggesting that DNA methylation could be a possible regulatory mechanism for hTR 
expression. However, initial studies found no correlation between hTR expression and 
DNA methylation of the promoter sequence (Guilleret et al., 2002b; Nakamura et al., 
2004) but further studies showed that the lack of hTR expression in some ALT cell lines 
was found to be tightly correlated to DNA methylation of the hTR promoter (Hoare et at., 
2001). 
Analysis of the hTR promoter uncovered binding sites for many transcription factors 
including Spl sites, a CCAAT box, a binding site for the hetero-trimeric NF-Y complex 
and a Hypoxia Response Element (HRE) (Anderson et al., 2006). Studies showed that 
Spl and NF-Y binding could activate the hTR promoter, while Sp3 and MDM2 could 
mediate repression (Zhao et al., 2003; Zhao et al., 2000; Zhao et al., 2005). Upregulation 
of hTR gene expression under hypoxic conditions was also shown to occur, mediated 
through the binding of Hypoxia Inducible Factor 1a (HIF 1 (x) to an HRE (Anderson et al., 
2006). Unexpectedly pRB was also found to activate the hTR promoter through an E2F- 
independent mechanism (Zhao et al., 2000) while the adenoviral E1A protein was also 
found to activate the hTR promoter by sequestering the co-repressor CtBP which is found 
in histone modifying complexes which mediate gene repression (Shi et al., 2003; 
Glasspool et al., 2005). 
These studies showing the role of DNA methylation and transcriptional regulation suggest 
that the chromatin environment could have a role to play in the regulation of hTR 
expression. To this end, the chromatin environment surrounding the hTR promoter was 
studied in telomerase positive tumour, telomerase negative ALT and normal cell lines to 
establish any links between hTR expression and the endogenous chromatin environment. 
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3.2 Results 
3.2.1 Expression of hTR in Tumour, Normal and ALT Cell Lines 
50 
To understand the relationship between expression levels of hTR and chromatin 
remodelling at the promoter, we first examined hTR gene expression levels from each cell 
line. Three tumour cell lines (A2780; ovarian carcinoma, 5637; bladder carcinoma and 
C33a; cervical carcinoma), one normal (W138; normal human foetal lung fibroblast) and 
five ALT cell lines (SUSM-l, KMST-6, GM847, W138-SV40 and SKLU) were utilised. 
Firstly, total RNA was extracted and cDNA synthesised in order to quantitate hTR 
expression. Semi-quantitative PCR was used to analyse GAPDH expression as a loading 
control for subsequent PCR reactions and semi-quantitative PCR for hTR was then used to 
evaluate the levels of hTR in each cell line. 
Figure 3.1 demonstrates that hTR is expressed in the tumour cell lines, the normal cell line 
and two of the ALT cell lines. The ALT cell line GM847 expresses the highest levels of 
hTR with 5637, A2780, SKLU, C33a and W138 also expressing hTR, although W138 
expresses very low levels. hTR expression levels were negligible in SUSM-1, KMST-6 
and W138-SV40. This range of cell lines with differing hTR expression levels allows the 
study of the chromatin environments in relation to various levels of expression. 
3.2.2 Profile of Repressive Histone Lysine Methylation 
Modifications at the hTR Promoter 
In order to examine the relationship between hTR expression and histone modifications 
present at the promoter sequences, ChIP assays using antibodies against specific histone 
modifications were used to generate a profile of the chromatin environment surrounding 
the hTR promoter in each cell line. Using the ChIP assay, a high definition in vivo 
snapshot of the chromatin environment of the endogenous hTR promoter can be 
constructed (Eberhardy et al., 2000; Orlando, 2000; Kuo and Allis, 1999). 
The cells lines are ranked in respect to their hTR expression levels in order to aid 
establishment of any trends. Modifications linked to repression of gene transcription were 
studied first and so methylation of K9 H3 and methylation of K20 H4 were studied. 
Antibodies recognising the di- and tri-methylated forms of K9 H3 and K20 H4 were used 
and the respective totals for the two antibodies compared between cell lines. Figure 3.2A 
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Figure 3.1 hTR Expression in Normal, Tumour ALT and Normal Cells 
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Cell lines from which hTR levels are established are ALT (A), telomerase positive tumour 
(T) or normal (N) cell lines, as noted after each cell line name. RNA was extracted from 
each cell line and cDNA synthesised using 1µg RNA. hTR levels were detected using 
specific primers by Quantitative PCR (Q-PCR) using specific primers to the hTR coding 
sequence. hTR levels were normalised to the expression of GAPDH levels established 
using the same amount of cDNA as for hTR. Therefore, levels of hTR are expressed as a 
percentage of GAPDH expression. Similar expression levels were established from at 
least 3 different experiments for each cell line and levels shown are from a representative 
experiment. Means and errors are established from triplication within the Q-PCR 
experiment. 
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Figure 3.2 Modifications Linked to Repression of hTR Transcription 
Levels of A Di- and tri-methylated K9 H3 and B di- and tri-methylated K20 H4 present at 
the hTR promoter in ALT (A), telomerase positive tumour (T) or normal (N) cell lines, 
detected by Q-PCR using primers which detect the hTR core promoter sequence, from 
products of chromatin immunoprecipitation assays. Results are expressed as the total IP 
amount for both the antibodies and are expressed as a percentage of an Input sample, 
which is a 20% fraction of chromatin utilised for each IP experiment, and so normalises the 
data. Each IP is also corrected for a control IP experiment, established in parallel with 
other IP's, in which no antibody was added to control for any background. Each IP value 
was established in at least three separate experiments and found to be similar and the IP 
figure shown is of a representative experiment. Means and standard errors are from 
triplication within the Q-PCR reactions. 
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shows that total methylated K9 H3 is elevated in cells with low or no hTR expression 
(W138, SUSM-1, KMST-6 and W138-SV40) when compared to cells expressing relatively 
high levels of hTR (GM847,5637, A2780, SKLU and C33a), which were nearly devoid of 
methylated K9 H3. Levels of both di- and tri-methylated K9 H3 were elevated in W138, 
SUSM1 and W138-SV40, while in the KMST6 cell line only tri-methylated K9 H3 is 
elevated. This demonstrates that increased levels of methylated K9 H3 at the hTR 
promoter are linked to lower hTR gene expression. 
Figure 3.2B indicates that there is no clear link between methylation of K20 H4 and hTR 
expression in any of the cell lines. Indeed, methylation of K20 H4 seems only to be 
elevated in the ALT cell lines (GM847, SKLU, SUSM-1, KMST-6 and W138-SV40) 
which could indicate a novel role for this modification. Interestingly the total levels of 
methylated K20 H4 are similar between these cell lines at approximately 4-8%. In these 
cell lines both di- and tri-methylated K20 H4 were elevated except in the SKLU cell line in 
which only tri-methylated K20 H4 is elevated. Therefore the data may demonstrate a new 
role for methylation of K20 H4 outwith regulation of expression, perhaps as a novel 
marker for the ALT phenotype. 
3.2.3 Profile of Transcriptionally Permissive Histone Lysine 
Modifications at the hTR Promoter 
Modifications linked to gene expression such as acetylation of K9 H3, acetylation of H3 
and H4 and methylation of K4 H3, were studied next. The respective totals for the ChIP 
assay for acetylated H3 and H4 were compared between cell lines, as was the total of the 
di- and tri-methylated forms of K4 H3. 
Figure 3.3A shows that high levels of acetylated H3 and H4 are linked to elevated levels of 
hTR gene expression with GM847,5637, A2780, SKLU, C33a and W138 exhibiting higher 
levels of acetylated H3 and H4 than SUSM-1, KMST-6 and W138-SV40. Acetylation of 
H3 seemed to be more prevalent in these cell lines, although both acetylated H3 and H4 are 
at higher levels than in SUSM1, KMST6 or W138-SV40. 
Levels of acetylated K9 H3 (Figure 3.3B) are also elevated in cell lines with higher hTR 
expression although this is only evident in GM847,5637, A2780 and SKLU. Although 
C33a and W138 express hTR, the levels of acetylated K9 H3 found at the promoter were 
similar to that found for SUSM1, KMST6 and W138-SV40. The antibody used to detect 
acetylated H3 recognises acetylated K9 H3 and K 14 H3 so may also reflect the importance 
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Figure 3.3 Modifications Linked to Permissiveness of hTR Transcription 
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of K14 H3 acetylation in transcriptional regulation of hTR expression. These data 
demonstrates a clear link between the presence of acetylated H3 and H4 and acetylated K9 
H3 at the hTR promoter and hTR gene expression. 
Figure 3.3C indicates that high levels of methylated K4 H3 are linked to elevated hTR 
gene expression with GM847,5637, A2780, SKLU, C33a and W138 exhibiting higher 
levels of methylated K4 H3 than SUSM-1, KMST-6 and W138-SV40. Both di- and tri- 
methylation are elevated in the hTR expressing cell lines as compared to SUSM1, KMST6 
and W138-SV40. Di-methylation appears at a similar level in each of the expressing cell 
lines, while tri-methylation differs, with GM847 and SKLU showing higher levels of tri- 
methylated K4 H3 than 5637, A2780, C33a and W138. This data demonstrates a clear link 
between the presence of methylation of K4 H3 at the hTR promoter and hTR gene 
expression. 
3.2.4 Can Promotion of Permissive Histone Modifications at the 
hTR Promoter Lead to Changes in hTR Gene Transcription? 
Patterns of permissive chromatin modification at the hTR promoter are linked to hTR 
expression so it was next asked whether the promotion of such modifications in cells 
without or having very low hTR expression could lead to increased levels of hTR 
expression. Treatments of cell lines with drugs which can enhance permissive epigenetic 
modifications have been shown to cause the re-expression of previously silent genes. 
TSA is a potent, but broad spectrum, histone deacetylase inhibitor, whose use can lead to 
the promotion of histone acetylation (Bartova et al., 2005). 5-azadC is a DNA 
methylation inhibitor, which has been shown to have some effect on K9 H3 methylation 
(Nguyen et al., 2002) and whose use can also lead to the re-expression of silenced genes. 
Synergism between these two drugs in activation of genes silenced in cancer has also been 
reported (Cameron et al., 1999) and so these drugs were used in tandem in order to 
investigate whether modulation of the chromatin environment could lead to re-expression 
of hTR. 
Cells were treated twice for 24 hours with 5-azadC and then treated for 16 hours with TSA. 
KMST6, W138 and W138-SV40 cell lines were used for these studies. KMST6 and WI38- 
SV40 were studied as they do not express hTR (or hTERT) and W138, a normal cell line, 
was also studied, although it does express hTR. Treatment of KMST-6, W138 and WI38- 
SV40 with TSA and 5-azadC in combination resulted in significantly increased hTR gene 
expression (Figure 3.4). 
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Figure 3.4 hTR Expression Following Treatment with TSA and 5-azadC 
Cell lines from which hTR levels are established are ALT (A) or normal (N) cell lines, as 
noted after each cell line name. Cells were treated twice for 24 hours with 5-azadC to a 
final concentration of 2.5mM, and then treated for 16 hours with Trichostatin A (TSA) at a 
final concentration of 350nM (+). Control cells were treated over the same time course 
but with 50% acetic acid instead of 5-azadC and 100% ethanol instead of TSA (-). RNA 
was extracted from each cell line and cDNA synthesised using 1µg RNA. hTR levels 
were detected using specific primers by Quantitative PCR (Q-PCR). hTR levels were 
normalised to the expression of GAPDH levels established using the same amount of 
cDNA as for hTR. Therefore, levels of hTR are expressed as a percentage of GAPDH 
expression. Similar expression levels were established from at least 3 different 
experiments for each cell line and levels shown are from a representative experiment. 
Means and errors are established from triplication within the Q-PCR experiment. Statistics 
were analysed using ANOVA software from the Microsoft Excel data analysis tool pack. 
Asterisks denote a statistically significant difference between untreated and treated; *p < 
0.05; * *p < 0.01. 
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Histone modifications known to allow for a transcriptionally permissive chromatin 
environment were studied to allow us to link increases in expression with increases in such 
modifications. Acetylation of H3 and H4 were studied (Figure 3.5A), and in the KMST6 
and W138-SV40 cell line, overall acetylation increased after treatment. Acetylated H4 
levels increased dramatically, while increases in acetylated H3 were less obvious. In the 
W138 cell line, total acetylation increased after treatment, but while acetylated H3 
increased, there was a noticeable decrease in acetylated H4. Acetylated K9 H3 was also 
studied, and Figure 3.5B shows that significant increases in acetylation at this residue were 
observed for each cell line tested. 
Levels of methylated K4 H3 were studied next (Figure 3.5C) and increases in total 
methylated K4 H3 were observed in KMST6 and W138 but unexpectedly, overall levels 
decreased slightly in W138-SV40. Further analysis shows that di-methylation of K4 H3 is 
absent in both the KMST6 and W138-SV40 cell lines and only tri-methylation of K4 H3 
shows any changes. In the W138 cell line, both di- and tri-methylation of K4 H3 showed 
significant increases upon treatment. Again, some synergism is observed between H3 and 
H4 acetylation and methylated K4 H3, with higher levels of acetylation generally linking 
to higher levels of methylated K4 H3 in the KMST6 and W138 cell lines. Overall, this 
data shows clearly that the formation of a more permissive chromatin environment, can 
lead to re-expression or increase expression levels of hTR. 
3.2.5 Involvement of Basal Transcriptional Machinery in h TR 
Expression 
Alterations in the composition and dynamics of the basal transcriptional machinery can 
also have effects on transcription. Transcription of the hTR gene is under the control of 
the RNA polymerase 11 machinery (Zhao et al., 2003) unlike in lower eukaryotes where the 
RNA polymerase III machinery is utilised (Hargrove et al., 1999) and therefore RNA 
polymerase II occupancy at the hTR promoter was analysed by ChIP to investigate basal 
transcriptional machinery binding at the promoter. The three tumour cell lines (A2780, 
C33a and 5637) and a normal cell line (W138) were used in this experiment. 
Analysis of RNA polymerase II occupancy at the hTR promoter shows a link between 
expression and promoter occupancy as Figure 3.6A shows that RNA polymerase II 
occupancy at the promoter is higher in cells with higher expression. 5637 and A2780 
show higher expression and have higher amounts of RNA polymerase II at the promoter 
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Figure 3.5 Changes in Histone Modifications at the hTR Promoter Following Treatment with 
TSA and 5-azadC 
Q-PCR results of the ChIP using antibodies against A Acetylated H3 and H4, B Acetylated 
K9 H3 and C Di- and Tri-methylated K4 H3 detected by Q-PCR using primers which 
detect the hTR core promoter sequence. Cell lines used are ALT (A) or normal (N) cell 
lines, as noted after each cell line name. Cells were treated twice for 24 hours with 5-azadC 
to a final concentration of 2.5mM, and then treated for 16 hours with Trichostatin A (TSA) 
at a final concentration of 350nM (+). Control cells were treated over the same time 
course but with 50% acetic acid instead of 5-azadC and 100% ethanol instead of TSA (-). 
Results are expressed as the total IP amount for both the antibodies (apart from acetylated 
K9 H3) and are expressed as a percentage of an Input sample, which is a 20% fraction of 
chromatin utilised for each IP experiment, and so normalises the data. Each IP is also 
corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background. Each IP value was established in at 
least three separate experiments and the IP figure shown is of a representative experiment. 
Means and standard errors are from triplication within the Q-PCR reactions. Statistics 
were analysed using ANOVA software from the Microsoft Excel data analysis tool pack. 
Asterisks denote a statistically significant difference between untreated and treated; *p < 
0.05; * *p < 0.01. 
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Figure 3.6 RNA Polymerase II Binding at the hTR Promoter 
Q-PCR results of the ChIP for A RNA Pol II in tumour (T) and normal (N) cells and B 
RNA Pol II following treatment of the normal (N) cell line W138 with 5-azadC and TSA 
detected by Q-PCR using primers which detect the hTR core promoter sequence. W138 
cells were treated twice for 24 hours with 5-azadC to a final concentration of 2.5mM, and 
then treated for 16 hours with Trichostatin A (TSA) at a final concentration of 350nM (+). 
Control cells were treated over the same time course but with 50% acetic acid instead of 5- 
azadC and 100% ethanol instead of TSA (-). Results are expressed as a percentage of 10% 
of the Input sample, with the Input fraction being a 20% fraction of chromatin utilised for 
each IP experiment, and so normalises the data. Each IP is also corrected for a control IP 
experiment, done in parallel with other IP's, in which no antibody was added to control for 
any background. Each IP value was established in at least three separate experiments and 
the IP figure shown is of a representative experiment. Means and standard errors are from 
triplication within the Q-PCR reactions. 
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relative to C33a and W138, which have lower levels of hTR expression and show less RNA 
polymerase II at the promoter. RNA polymerase II occupancy of the hTR promoter was 
also studied in W138 upon treatment with TSA and 5-azadC. As this treatment has been 
shown to increase hTR expression, this study therefore leads us to believe that RNA 
polymerase II occupancy should be increased in W138 treated with TSA and 5-azadC. 
Figure 3.6B shows that RNA polymerase II occupancy is indeed increased at the hTR 
promoter in W138 upon treatment with TSA and 5-azadC. 
This data shows a positive link between RNA polymerase II binding at the hTR promoter 
and hTR expression and between RNA polymerase 11 binding and general permissiveness 
of the chromatin environment. 
3.2.6 Transcription Factor Binding at the hTR Promoter 
Occupancy of MYC of the hTR promoter was also analysed by ChIP, although no role for 
MYC has been described for regulating hTR expression and no known consensus site for 
MYC exists in the hTR proximal promoter sequences. Figure 3.7 shows that occupancy 
of the hTR promoter by MYC was observed in all cells tested; 5637, A2780, C33a and 
W138. Higher levels were observed in the cell lines with the greatest hTR expression and 
which have the most permissive chromatin environment, which were 5637 and A2780. 
C33a and W138, which have lower hTR expression and a less permissive chromatin 
environment surrounding the promoter has less MYC occupancy at the promoter. 
3.3 Discussion 
Classically, cancer is viewed as a set of diseases that are driven by progressive genetic 
abnormalities that include mutations in tumour-suppressor genes and oncogenes, and 
chromosomal abnormalities. However, it is now becoming apparent that cancer is also a 
disease that is driven by "epigenetic changes" - patterns of altered gene expression that 
are mediated by mechanisms that do not affect the primary DNA sequence. Extensive 
alterations to chromatin in cancer cells in comparison with the normal cells from which 
they are derived are observed. These involve both losses and gains of DNA methylation 
as well as altered patterns of histone modifications (Jones and Baylin, 2002; Fraga et al., 
2005; Seligson et al., 2005; Herman and Baylin, 2003). However, how these changes 
affect senescence and tumourigenesis is relatively unknown. 
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Figure 3.7 MYC Occupancy of the hTR promoter 
Q-PCR results of the ChIP for Myc in tumour (T) and normal (N) cells detected by Q-PCR 
using primers which detect the hTR core promoter sequence. Results are expressed as a 
percentage of 10% of the Input sample, which is a 20% fraction of chromatin utilised for 
each IP experiment, and so normalises the data. Each IP is also corrected for a control IP 
experiment, done in parallel with other IP's, in which no antibody was added to control for 
any background. Each IP value was established in at least three separate experiments and 
the IP figure shown is of a representative experiment. Means and standard errors are from 
triplication within the Q-PCR reactions. 
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hTR overexpression has been observed in tumourigenesis (Avilion et al., 1996; Soder et 
al., 1998; Downey et al., 2001; Wisman et al., 2000; Feng et al., 1995) and consistent with 
this was the increased expression of hTR in the three telomerase positive tumour cell lines 
(Figure 3.1), and in two ALT cell lines (GM847 and SKLU) relative to the normal W138 
cell line. The data shows that hTR is expressed in a range of cells and the range of 
expression in these is useful in studying the regulation of hTR expression. Further it is 
observed that the tumour cells lines and some of the ALT cell lines show increased levels 
of hTR expression linking increased hTR expression with tumourigenesis. Overall, the 
data shows that a repressive pattern of modifications present at the hTR promoter 
sequences is associated with the repression of transcription in the ALT cell lines. 
Further, a permissive pattern of modifications present at the hTR promoter is linked to hTR 
expression in telomerase positive tumour, normal and ALT cell lines. hTR gene 
expression in normal tumour and ALT cells is shown to be linked to histone 
hyperacetylation, methylation of K4 H3 and lack of methylation of K9 H3, while 
conversely hTR gene repression in ALT cells is shown to be linked to histone 
hypoacetylation, methylation of K9 H3 and lack of methylation of K4 H3. 
It is also noted that the patterns for H3 and H4 acetylation and methylation of K4 H3 are 
very similar. This may be evidence of synergism between these two modifications in 
positive regulation of hTR expression as has been previously described (Bernstein et al., 
2005; Liang et al., 2004). However, overall, the chromatin environments of the hTR 
promoter in some of the tumour cell lines and the hTR expressing ALT lines was actually 
very similar to the W138 cell line, suggesting that an integrative view of multiple 
regulatory mechanisms is needed in order to fully comprehend the transcriptional 
regulation of hTR and also other genes. The chromatin environment however is very 
important in expression as shown by the repressive chromatin environment of the hTR 
promoter associated with the ALT cell lines which lacked hTR expression. 
As well as uncovering a link between hTR transcription and the chromatin environment of 
the promoter, understanding promoter specific chromatin changes upon the bypass of 
senescence is also permitted. As has been discussed previously, changes in chromatin 
structure are observed upon senescence or senescence-like arrest leading to the repression 
and activation of genes important in controlling proliferation and growth (Narita et al., 
2003). It is possible that dysregulation of pathways controlling histone modifications 
could lead to the reactivation of genes needed for cell proliferation and growth permitting 
the bypass of senescence and may also allow the gain of a tumourigenic phenotype. 
Stuart P. Atkinson, 2006 Chapter 3 66 
The data presented allows a comparison to be drawn between a normal presenescent cell 
and a transformed cell of the same cell type and can allow us to ascertain whether or not 
chromatin changes occur upon the bypass of senescence and the gain of an immortal 
phenotype, at least for the two genes studied here; hTR and as will be studied in the next 
chapter, hTERT. Compared to W138, expression of hTR is further repressed in the WI38- 
SV40 cell line, which exhibits increased methylation of K9 H3 and K20 H4 at the hTR 
promoter compared to the W138 cell line. Acetylation of H3 and H4 and methylation of 
K4 H3 at the promoter is also decreased in the W138-SV40 cell line when compared to the 
W138 cell line. So, the bypass of senescence in the normal W138 cell line leads to a 
decrease in hTR expression with an increase in repressive chromatin modifications and a 
decrease in permissive modifications at the promoter, which may be why the W138-SV40 
cell line uses the ALT mechanism to mediate telomere maintenance. The formation of 
heterochromatin at the hTR promoter will lead to the heavy repression of hTR expression 
and therefore repression of telomerase activity in these cells and in turn could lead to 
selective pressure to activate the ALT mechanisms in this cell line. 
Also, the W138 cell line is a fibroblastic cell line and therefore mesenchymal in origin and 
it is understood that telomerase expression is tightly repressed in such tissues and so the 
repression of hTR in this cell line and the utilisation of ALT are understandable. The 
relatively low hTR expression in the W138 cell line may be part of the repressive nature of 
the cell type utilised. This study indicates that the bypass of senescence can lead to 
changes in the chromatin environment at the promoter sequences and will possibly have 
global effects as modulation of the chromatin environment can have genome wide effects. 
So, overall the transformation process in W138 which has lead to the use of the ALT 
telomere maintenance mechanism is linked to the downregulation of hTR expression by 
the formation of a repressive chromatin environment at the hTR promoter. 
The treatment of hTR negative ALT cell lines and a normal cell line with low hTR 
expression with drugs capable of modulating the chromatin environment have shown that 
the promotion of permissive histone modifications at the promoter sequence can allow re- 
expression or increased levels of expression. Lack of acetylated H3 and H4 and 
methylated K4 H3 has been previously linked to gene silencing and indeed loss of these 
modifications has been proposed to be the primary event in gene silencing (Mutskov and 
Felsenfeld, 2004) and so the promotion of these modifications could lead to re-expression 
of previously silenced genes. On treatment with the DNA-methylation inhibitor 5-azadC 
and the HDAC-inhibitor TSA, higher levels of acetylated H3 and H4 were present and 
some increases in methylated K4 H3 were apparent at the hTR promoter, linked to the 
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observed increase in hTR expression. This data is in agreement with previous studies on 
the synergistic effect of TSA and 5-azadC treatment showing increases in acetylated K9 
H3 and methylated K4 H3 at previously silenced gene promoters (Kondo et al., 2003). 
This data further shows that the role of the chromatin environment is key to the regulation 
of hTR expression. Whether this increase is enough to allow telomerase activity (also 
allowing for hTERT expression) in the cells in question is unknown but the low levels of 
expression obtained suggest that if telomerase activity is present, it would be at very low 
levels. The increased levels of hTR in the hTR negative cell lines were much less than 
that of even the levels of expression in any of the tumour cell lines, indicating that 
although the chromatin environment has an important role to play, other mechanisms must 
also act to allow high hTR expression. A recent study also showed that treatment of ALT 
cell lines with 5-azadC and TSA leads to the enhancement of hTR expression although the 
chromatin environment of the hTR promoter was not studied (Kumakura et al., 2005). 
This study is in agreement with this previous data and strengthens the point by studying 
changes in chromatin modifications. 
Although general patterns of histone modifications have now been linked to hTR 
expression and repression, the data attained for methylation of K20 H4 did not show any 
correlations to activation or repression. As mentioned, methylation of K20 H4 has been 
previously linked to gene repression but the data suggests that methylation of K20 H4 may 
have another interesting role as of the cell lines examined only the ALT cell lines had high 
levels of methylated K20 H4 which suggests that this modification may mark for the ALT 
phenotype rather than having a role in silencing of hTR expression. Regardless of hTR 
expression levels, methylation of K20 H4 is present in each ALT cell line at similar levels 
(approximately 4-8%). 
Other than being linked to transcriptional repression, methylation of K20 H4 has also been 
previously linked with the sensing of DNA double stranded breaks in yeast by the binding 
of Crb2 to this modified lysine residue (Sanders et al., 2004b). Constitutively high levels 
of methylated K20 H4 are needed for the Crb2 mediated DNA damage response so the 
highly methylated K20 H4 observed in the ALT cell lines might be explained as a DNA 
damage or stress response (Figure 3.8A) perhaps as a response to telomere dysfunction due 
to the heterogeneous telomere length observed in ALT cell lines. However, the human 
homologue of Crb2,53BP1, is known to bind methylated K79 H3 in double-stranded break 
response instead (Huyen et al., 2004). Further studies into the role of methylated K79 H3 
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Figure 3.8 Possible Roles of K20 Methylation in Telomerase Gene Expression and ALT 
68 
A Methylation of K20 H4 as a DNA damage response could lead to the activation of ALT 
over telomerase activity. B Tight repression of telomerase activity due to the formation of 
heterochromatin at the telomerase gene promoters in mesenchymal tissues could lead to the 
preferential activation of ALT. C Active Rb could lead to the maintenance of methylation 
of K20 H4 favouring ALT activation. D Lack of telomerase gene activity due to activation 
of ALT could lead to the formation of heterochromatin at the telomerase gene promoters. 
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could be of interest and could aid in the elucidation of the role for methylation of K20 H4. 
Investigating factors which are able to bind methylated K20 H4 in ALT cells and cells 
undergoing various forms of cellular stresses could further uncover the role of methylation 
of K20 H4 in mammals. 
Interestingly, the phosphorylated form of TRF2, which is present after DNA damage and is 
known to be found in ALT-associated PML bodies (Yeager et al., 1999), is present at 
telomeres in ALT cells (Tanaka et al., 2005). The authors report that the phosphorylated 
form of TRF2 is present only at telomeres in cell types undergoing telomere-based crisis 
and cells using the ALT pathway, likely as a consequence of a telomere-based DNA 
damage response. Also, long time cellular stress has been hypothesised to lead to 
epigenetic re-programming leading to senescent cells overcoming cell cycle arrest leading 
to tumourigenesis (Karpinets and Foy, 2005). Although the authors studied cellular stress 
with relation to DNA methylation, it is plausible that certain repressive histone 
modifications could become altered in a similar way leading to the bypass of senescence 
and tumourigenesis. 
DNA damage response mediated signalling of the onset of cellular senescence and the 
methylation of K20 H4 observed in ALT cells could be linked. The concentration of 
heterochromatic chromatin modification has been observed at cellular senescence (Narita 
et al., 2003), and methylation of K20 H4 has been linked to heterochromatin formation. 
The accumulation of heterochromatin at senescence has been shown to be mediated by 
pRB (Narita et al., 2003), which can recruit K20 H4 specific methyltransferases (Gonzalo 
et al., 2005) perhaps in a similar promoter specific mode observed with SAHF formation 
with enzymes with K9 H3 methyltransferase activity (Narita et al., 2003). Therefore the 
gain of heterochromatic modifications at the promoters could be part of a senescence 
induced phenomenon in the ALT cells. 
It is also known that ALT is commonly activated in tumours of mesenchymal origin, 
including osteosarcomas and soft tissue sarcomas and it is known that in mesenchymal 
tissues telomerase activity is tightly repressed (Henson et al., 2005; Ulaner et al., 2003; 
Hakin-Smith et al., 2003; Johnson et al., 2005). Mesenchymal tissues have a slower 
turnover and less telomere shortening than in many epithelial type cells and this is possibly 
why they may repress telomerase more tightly. Three of the ALT cell lines investigated 
within this study tend to show a more heterochromatic environment at the hTR promoter 
(as well as hTERT as will be discussed in the next chapter), with hTERT and in some cases 
hTR, being transcriptionally silenced. Therefore, methylation of K20 H4 may be a 
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specific cellular response of the mesenchymal type cells to repress telomerase activity 
(Figure 3.8B) and further ALT may be utilised over telomerase activity due to this 
repression of telomerase gene expression. However, the fact that two of the ALT cells 
express hTR and the W138 cell line has little K20 H4 methylation seems to argue against 
this point. Cells undergoing a transforming event which would require telomerase activity 
could perhaps be "forced" to utilise the ALT pathway as hTR expression, needed for 
telomerase activity, would be tightly repressed due to the heterochromatic nature of the 
hTR promoter sequence. This may also occur for hTERT, in the context of telomerase 
activity, as will be discussed in the next chapter. 
A recent study has shown that globally, chromatin in cancer cells is less trimethylated at 
K20 H4 (Fraga et al., 2005), and in agreement with this, the telomerase positive tumour 
cell lines (C33a, A2780 and 5637) show a distinct lack of any methylated K20 H4. The 
normal cell line, W138, also shows minimal K20 H4 methylation, but the ALT cells all 
show comparatively high levels of methylated K20 H4. The loss of trimethylation of K20 
H4 has also been observed at both preneoplastic and tumour stages of liver cancer in the 
context of hepatocarcinogenesis induced by methyl deficiency in rats (Pogribny et al., 
2006) and corresponded to a decrease in the K20 H4 HMT SUV4-20142. Loss of 
methylation of K20 H4 and therefore loss of heterochromatin formation could account for 
genomic instability observed in cancers, although mechanisms on how methylation of K20 
H4 is lost are unknown. The SUV4-20H enzymes directly interact with pRB (Gonzalo et 
al., 2005), and the loss of pRB could the lead to the loss of this modification and the 
silencing properties it entails (Figure 3.8C). This could lead to a permissive chromatin 
environment at the telomerase gene promoters perhaps leading to telomerase activity being 
more likely to be activated over ALT. 
If methylation of K20 H4 is a global effect in ALT cells, it could counter genomic 
instability encountered by the loss of heterochromatin in telomerase positive tumour cells 
and could lead to ALT tumours being less aggressive and having less neoplastic potential 
than telomerase positive tumours. Indeed ALT tumours have these characteristics as 
indicated by laboratory studies (Stewart et al., 2002; Chang et al., 2003). In one study of 
osteosarcoma, progression free and overall survival was observed to be much better in the 
hTERT negative ALT primary tumour samples than the hTERT positive primary tumour 
samples, linking ALT to better overall survival (Sanders et al., 2004a). Another study 
studying the prevalence of telomerase activity in osteosarcoma and Ewing's sarcoma 
primary tumour and metastasis samples showed that telomerase activity was far more 
prevalent than ALT in the metastasis when compared to the primary tumour samples in 
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which few samples showed telomerase activity (Sotillo-Pineiro et al., 2004). The 
presence of the ALT telomere maintenance mechanism is also linked to a better prognosis 
in glioblastoma multiforme (Hakin-Smith et al., 2003). 
However several studies have found different outcomes. A study of osteosarcoma tumour 
samples found that the absence of telomere maintenance mechanisms was linked to better 
survival (90%) (Ulaner et al., 2003) and another study also showed no correlation between 
telomere maintenance mechanism and patient outcome or tumour aggressiveness in soft 
tissue sarcomas and osteosarcoma (Henson et al., 2005). Correlating with these studies, 
were the findings that the ALT phenotype was associated with complex karyotypes in 
sarcomas (Montgomery et al., 2004) and the presence of ALT associated with 
chromosomal instability in osteosarcomas (Scheel et al., 2001). A recent study in mouse 
embryonic fibroblasts has also shown that chromosomal instability upon loss of hTERT 
and the WRN helicase leads to the activation of ALT (Laud et al., 2005). 
It may also be possible that the telomerase gene promoters become heterochromatinised 
because they are not active. In this model, the lack of activating transcription factors 
binding at the telomerase gene promoters will lead to the accumulation of repressive 
histone modifications. So the repressive chromatin environment could be due to 
telomerase gene repression and not telomerase gene repression due to the accumulation of 
repressive histone modifications (Figure 3.8D). All of the above hypotheses are 
summarised in Figure 3.8. Overall, this and other studies suggest an interesting role for 
methylation of K20 H4 in regulation of telomerase gene control and a possible marker for 
the ALT mechanism. Further work studying the effects of methylated K20 H4 globally 
and in the context of ALT could uncover some very interesting molecular pathways 
towards controlling telomere maintenance mechanisms. 
Overall, this data provides evidence that the expression of hTR is linked to the state of the 
chromatin environment. To better understand expression of hTR, transcriptional 
dynamics were investigated by studying RNA polymerase II occupancy of the promoter, to 
investigate how the chromatin environment may be directly linked to gene 
repression/expression. The data shows that the more permissive the chromatin 
environment is, as in 5637 and A2780, higher binding of RNA polymerase II at the 
promoter sequence is observed and the less permissive the chromatin environment is, as 
with C33a and W138, lower binding of RNA polymerase II at the hTR promoter sequence 
is observed. Also by modulating the chromatin environment to promote the formation of a 
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more permissive chromatin environment in the normal cell W138, we observe an increase 
in RNA polymerase II binding at the hTR promoter. 
RNA polymerase II has been shown to associate with various proteins which mediate K4 
H3 methylation (Ng et al., 2003), K36 H3 methylation (Kizer et al., 2005) and histone 
acetylation (von Mikecz et al., 2000). K4 H3 and K36 H3 methylation has been 
associated with transcriptional elongation (Kizer et al., 2005; Ng et al., 2003) and it is 
shown in this study that a more permissive chromatin landscape at promoter sequences is 
associated with higher RNA polymerase II binding and increased transcription. 
A recent study has also highlighted the role of a RNA polymerase II associated protein in 
tumourigenesis (Moniaux et al., 2006). The protein in question, hPAF 1 is the human 
homologue of yeast pafl which is proposed to promote gene transcription by allowing the 
formation of a permissive chromatin environment through tri-methylation of K4 H3 
(Adelman et al., 2006). Therefore the overexpression of hPAF1 in human cancer could 
allow increased transcription of genes involved in tumourigenesis by facilitating RNA 
polymerase II mediated gene transcription. Each of the cell lines studied shows a degree 
of RNA polymerase II binding to the promoter and correspondingly, each cell line does 
show some trimethylation of K4 H3. Increased permissivity of the chromatin environment 
may make the DNA more accessible to RNA polymerase II binding or certain histone 
modifications, such as acetylation, may promote the binding of members of the basal 
transcriptional machinery (such as TAF(II)250 binding through bromodomains). 
However, basal transcriptional machinery has also been shown to bind silenced chromatin 
(Sekinger and Gross, 2001) suggesting that modulation of the chromatin environment may 
allow promoter clearance and elongation rather than enhancing actual binding. Changes 
in the chromatin environment of promoter sequences may therefore drive changes in the 
dynamics of the basal transcription machinery and complex interactions between 
transcriptional complexes and chromatin may therefore be important in mediating 
transcriptional activity. 
Also studied was the role of MYC in telomerase gene regulation in the context of the 
chromatin environment. MYC genes are key regulators of cell proliferation, and their 
deregulation contributes to the genesis of most human tumours (Adhikary and Eilers, 
2005). The role of MYC in hTERT transcription is well documented (Xu et al., 2001; Oh 
et al., 1999b; Kyo et al., 2000; Wu et al., 1999) but any role for MYC in the regulation of 
hTR expression has not been reported and no consensus binding site for MYC exists in the 
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basal hTR promoter. The data presented here provides some evidence that MYC has a 
positive link with hTR expression, although further studies will need to be undertaken to 
uncover the full influence of MYC on the regulation of hTR expression. MYC binding is 
observed to be increased in cell lines with a more permissive chromatin environment (5637 
and A2780) and MYC binding is decreased in cell lines with a less permissive chromatin 
environment (C33a and W138). 
MYC binding to promoters without consensus binding sites has been observed (Fernandez 
et al., 2003) and MYC has been observed to bind to variants of the consensus sequence in 
vitro and such variants can also be high-affinity binding sites in vivo (Grandori et al., 
2003). Another possibility is that MYC may be recruited to non-consensus binding sites 
through the interaction with other transcription factors to modulate transcription (Mao et 
al., 2003). Further to MYCs role in the modulation of the chromatin environment, MYC 
has been shown to bind to histone acetyltransferases (Liu et al., 2003; Frank et al., 2003; 
Faiola et al., 2005) although one study has shown that the chromatin around the MYC- 
bound loci was highly acetylated, even before MYC binding (Fernandez et al., 2003) 
suggesting that the permissivity of the chromatin environment is needed to allow MYC 
firstly to bind at promoter sequences. 
Evidence for a role for MYC in regulating hTR expression is however lacking and so 
further studies will be needed to ascertain MYCs role on hTR expression. Transient 
transfection studies utilising an hTR promoter driven reporter gene with MYC protein co- 
transfection may shed some light on the roles of MYC on hTR expression by allowing us 
to study if different amounts of transfected MYC can lead to increases in hTR expression. 
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4 Epigenetic Regulation of hTERT Expression in 
Normal, Tumour and ALT Cell Lines 
4.1 Introduction 
74 
hTERT is a specialised reverse transcriptase initially purified from the ciliate Euplotes 
aediculatus as a protein homologous to the yeast protein Est2p (Lingner et al., 1997) and is 
one of the core components required for reconstitution of telomerase activity (Weinrich et 
al., 1997). While being absent or at extremely low levels in normal human cells, 
expression is observed to be reactivated or greatly increased in cancer cell lines and 
tumours (Ramakrishnan et al., 1998; Meyerson et al., 1997) demonstrating that tight 
regulation of hTERT expression in normal cells is of great importance and so the 
elucidation of regulatory mechanisms in normal and cancer cells would be also of great 
importance and interest. 
Cloning and characterisation of the hTERT gene and promoter (Horikawa et al., 1999; 
Takakura et al., 1999; Cong et al., 1999; Wick et al., 1999) has allowed detailed analysis 
of hTERT regulation and has revealed regulation at many levels. Initial analysis of the 
hTERT gene revealed complex splicing patterns in different cell types (Kilian et al., 1997) 
and modulation of telomerase activity by splice variant expression has now been shown to 
be an important regulator of telomerase activity in both development (Ulaner et al., 1998) 
and cancer progression (Ulaner et al., 2000; Drummond et al., 2005; Anderson et al., 
2006). While the full length wild type variant is the only transcript with reverse 
transcriptase activity, three main deletions variants are also usually expressed. These are 
the a, ß and y splice variants and importantly the a-deletion variant has been shown to be a 
dominant negative inhibitor of telomerase activity (Colgin et al., 2000; Yi et al., 2000). 
Evaluation of the promoter sequences established that the hTERT gene promoter contains a 
large CpG island although the correlation between CpG methylation and hTERT 
expression remains unclear. Initial studies found no clear link between methylation and 
expression (Dessain et al., 2000; Devereux et al., 1999), however some studies have shown 
positive (Guilleret and Benhattar, 2003; Guilleret et al., 2002a) and also negative 
correlations (Bechter et al., 2002; Shin et al., 2003). These data suggest that methylation 
may play an important but complex role in the regulation of hTERT expression but that 
other mechanisms are also crucial. 
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Transcriptional regulation of hTERT is generally understood to be greatly important in 
mediating hTERT expression. Characterisation of the promoter sequence revealed 
binding sites for multiple transcription factors (Horikawa et al., 1999; Takakura et al., 
1999; Cong et al., 1999; Wick et al., 1999). The core promoter sequences contain two E- 
box sequences to which MYC/MAX heterodimers are known to bind and transactivate the 
promoter (Wu et al., 1999) while MAD/MAX heterodimers can bind the same sites to 
repress the promoter (Oh et al., 2000). 
Several other factors can compete with MYC for binding to E-boxes including Upstream 
Stimulatory Factor (USF) which can activate the hTERT promoter (Goueli and Janknecht, 
2003) and the HTLV-1 oncoprotein Tax (Gabet et al., 2003) which represses the promoter. 
The tumour suppressor protein BRCA1 (Xiong et al., 2003) also mediates repression by 
binding to and repressing MYCs activating properties. Sp I sites are also evident in the 
promoter and Spl and Sp3 can activate and repress the hTERT promoter respectively 
while Spl can synergise with MYC to activate hTERT transcription (Kyo et al., 2000). 
The human Papillomavirus type 16 E6 protein can also activate hTERT expression 
seemingly through binding to MYC and Spl (Oh et al., 2001), while p53 and p73 
seemingly inhibit hTERT expression by sequestering Spl away from the promoter (Xu et 
al., 2000; Racek et al., 2005). There also exists two sites in the core hTERT promoter 
sequence to which the oestrogen receptor (ER) can bind, one being a half site next to a 
canonical recognition sequence for Spl, allowing synergism between the ER and Spl 
(Krishnan et al., 1994) and oestrogen has been shown to activate the hTERT promoter 
(Kyo et al., 1999). 
HREs have also been discovered in the hTERT promoter and HIF 1a has recently been 
shown to regulate hTERT splice variant expression under hypoxic conditions in human 
cancer cells (Anderson et al., 2006). HIFIa binding correlated to higher expression of the 
full length active form being transcribed, at the expense of the other inactive deletion 
variants. Other factors which can activate the hTERT promoter include the adenoviral 
E1A protein (Glasspool et al., 2005) possibly acting by sequestering the co-repressor CtBP 
away from the promoter sequences. CtBP can be found in histone modifying complexes 
which can mediate heterochromatin formation (Shi et al., 2003) and so the removal of 
CtBP may allow for the formation of a more permissive chromatin environment allowing 
transcription. Two consensus binding sites for the ETS transcription factor are also 
evident in the hTERT promoter sequence, which can directly mediate EGF-induced 
transactivation of hTERT (Maida et al., 2002). 
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Negative regulation of hTERT can be mediated by several factors through binding sites 
within the hTERT promoter. These include MZF2 (Fujimoto et al., 2000), which 
represses hTERT transcription through several sites in the promoter and the Wilms' 
Tumour 1 (WT1) tumour suppressor gene (Oh et al., 1999a). E2F1 can also repress 
transcription of hTERT possibly through the binding of pRB leading to possible 
heterochromatin formation and silencing of the promoters sequence (Crowe et al., 2001). 
There also exists a Vitamin D3 receptor (VDR) binding site, through which VDR and the 
retinoid x receptor (RXR) can bind and inhibit hTERT expression (Ikeda et al., 2003; 
Pendino et al., 2003). 
Interestingly many of the transcription factors discussed above have been shown to interact 
with chromatin modifying enzymes. Differentiation of HL-60 cells leads to decreases in 
histone acetylation at the hTERT promoter. This is concomitant with a change from 
MYC/MAX binding to MAD/MAX binding and decreases in hTERT transcription and 
indicates that the MYC/MAX and MAD/MAX complexes recruit HATs and HDACs 
respectively (Xu et al., 2001). SpI and Sp3 have been shown to be able to recruit HDAC 
activity to the hTERT promoter to repress transcription in normal human somatic cells 
(Won et al., 2002). E2F1 and pRB generally bind and repress promoters and pRB has 
been shown to recruit repressive histone modifying activities which could alter the 
chromatin environment leading to the repression of transcription (Brehm et at., 1998; 
Gonzalo et al., 2005; Nielsen et al., 2001; Nguyen and Crowe, 1999; Won et al., 2004; 
Narita et al., 2003). 
Data showing the presence of DNasel hypersensitivity sites at the hTERT regulatory 
sequences in hTERT expressing cells further strengthens the hypothesis that the chromatin 
environment plays a role in the regulation of hTERT expression (Wang and Zhu, 2003; 
Wang and Zhu, 2004; Szutorisz et al., 2003). Other studies have shown that down- 
regulation of hTERT expression during differentiation is concomitant with histone 
deacetylation and the accumulation of CpG methylation at the hTERT promoter (Liu et al., 
2004; Lopatina et al., 2003) and upon screening for proteins involved in hTERT 
transcriptional regulation, a novel human gene encoding a HAT-like protein was 
discovered by one group (Lv et al., 2003). 
Recently regulation of hTERT transcription by histone phosphorylation has also been 
demonstrated (Ge et al., 2006). A recent study has also shown that phosphorylation of 
SIO H3 is known to enhance histone acetylation (Lo et al., 2000) and so may aid 
transcription of hTERT. The use of drugs which can target histone modifying enzymes, 
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notably Trichostatin A (TSA), have been shown to cause increases in transcription of 
hTERT in normal human cells (Takakura et al., 2001; Mukhopadhyay et al., 2005; Cong 
and Bacchetti, 2000; Hou et al., 2002). This has been shown to be due to the acetylation 
of promoter proximal histones possibly by inhibiting the interactions between negative 
regulatory factors and HDACs or by inhibiting their actions at the hTERT promoter (Hou 
et al., 2002). 
These findings, showing the role of DNA methylation and chromatin modifications suggest 
that the chromatin environment could have a role to play in the regulation of hTERT 
expression. To this end, the chromatin environment surrounding the hTERT promoter 
was studied in tumour, ALT and normal cell lines to establish any links between hTERT 
expression and the endogenous chromatin environment. 
4.2 Results 
4.2.1 Expression of hTERT in Tumour, Normal and ALT Cell Lines 
As for hTR we first established hTERT gene expression levels from each cell line. Semi- 
quantitative PCR was used to analyse GAPDH expression to normalise for subsequent 
PCR reactions. Primers that recognise the main splice variants of hTERT were used and 
total amounts for each splice variant summed and expressed as total hTERT expression. 
As Figure 4.1 shows, of the cell lines studied only the tumour cell lines (C33a, A2780 and 
5637) have appreciable levels of hTERT gene expression. Apart from the GM847 cell 
line which expresses very low amounts of hTERT (only the ß deletion variant, data not 
shown), the ALT and normal cell lines exhibited no hTERT expression. The profile of the 
chromatin environment surrounding the hTERT promoter was then established and any 
relationship to expression was examined. 
4.2.2 Profile of Transcriptionally Repressive Histone 
Modifications at the hTERT Promoter 
In order to examine the relationship between hTERT expression and histone modifications 
present at the promoter sequences, chromatin immunoprecipitation (ChIP) assays using 
antibodies against specific histone modifications were used to generate a profile of the 
chromatin environment surrounding the hTERT promoter in each cell line. 
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Figure 4.1 hTERT Expression in Normal, Telomerase Negative Tumour and ALT Cell Lines 
Cell lines from which hTERT expression levels are established are ALT (A), telomerase 
positive tumour (T) or normal (N) cell lines, as noted after each cell line name. RNA was 
extracted from each cell line and cDNA synthesised using 1 pig RNA. hTERT expression 
levels were established, first by analysing GAPDH levels. cDNA amounts used as input 
in each separate hTERT splice variant PCR reaction for each cell line were then adjusted 
so similar concentrations of cDNA were used in each PCR reaction. hTERT expression 
levels are shown as the sum of all the expressed variants (WT, a, ß and aß). Therefore 
total hTERT levels are expressed as being normalised to GAPDH expression. Expression 
levels were found to be similar between three different experiments for each cell lines. 
Means and errors are established from the average of these Q-PCR experiments 
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Modifications linked to repression of gene transcription were studied first and to this end 
methylation of K9 H3 and methylation of K20 H4 were studied. Figure 4.2A shows that 
overall levels of methylated K9 H3 are negligible at the hTERT promoter in the cell lines 
expressing high levels of hTERT (C33a, A2780 and 5637) but high levels of methylated 
K9 H3 are observed in GM847, W138-SV40 and SUSMI and lower levels of this 
modification are present in other cell lines with no hTERT expression (W138, KMST6 and 
SKLU). Cell lines which exhibited high total levels of methylated K9 H3 tended to have 
more di-methylated than the tri-methylated form (GM847, WI38-SV40 and SUSMI), 
although the dimethylated form was still present at high levels in some cell lines (WI38- 
SV40 and SUSMI). A low level of a repressive modification in a cell line with no hTERT 
expression underlies the principle that multiple modifications need to be studied in order to 
understand fully the interplay between the chromatin environment and gene transcription. 
This data does however demonstrate that in some of the cell lines studied, increased levels 
of methylation of K9 H3 at the hTERT promoter is linked to decreased levels of hTERT 
gene expression. 
Methylation of K20 H4 has also been linked to gene repression and levels of this 
modification at the hTERT promoter were studied. Figure 4.2B shows that cell lines 
which do not express hTERT tend to have higher levels of total methylated K20 H4. In all 
but the SUSMI cell line, di-methylated K20 H4 was prevalent, and tri-methylated K20 H4 
is observed in each of the ALT cell lines. However, further analysis of the data again 
shows, as in the studies of the hTR promoter, methylation of K20 H4 seems to be linked to 
the ALT phenotype rather than to transcriptional status. Although this relationship is not 
as obvious as for hTR, it can be observed that the W138 cell line, which does not express 
hTERT, has levels of methylated K20 H4 similar to that in the tumour cell lines which do 
express hTERT (C33a, A2780 and 5637). This data demonstrates a link between hTERT 
gene repression and methylation of K20 H4 at the hTERT gene promoter although the 
presence of methylated K20 H4 in the 5 ALT cell lines and absence in the normal cell line 
may indicate another role for this modification as we observed for hTR. 
4.2.3 Profile of Transcriptionally Permissive Histone 
Modifications at the hTERT Promoter 
Modifications linked to gene expression were then studied. The modifications studied 
were acetylation of K9 H3, acetylated histones H3 and H4 and methylation of K4 H3. 
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Figure 4.2 Modifications Linked to Repression of hTERT Transcription 
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Levels of A Di- and tri-methylated K9 H3 and B di- and tri-methylated K20 H4 present at 
the hTERT promoter in ALT (A), telomerase positive tumour (T) or normal (N) cell lines, 
detected by Q-PCR using primers which detect the hTERT core promoter sequence, from 
products of chromatin immunoprecipitation assays. Results are expressed as the total IP 
amount for both the antibodies and are expressed as a percentage of an Input sample, 
which is a 20% fraction of chromatin utilised for each IP experiment, and so normalises the 
data. Each IP is also corrected for a control IP experiment, done in parallel with other 
IP's, in which no antibody was added to control for any background. Each IP value was 
established in at least three separate experiments and the IP figure shown is of a 
representative experiment. Means and standard errors are from triplication within the Q- 
PCR reactions. 
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Histone acetylation of promoters is linked to gene expression and so the acetylation status 
of the hTERT promoter was established. Figure 4.3A shows that in the two cell lines 
expressing the highest levels of hTERT (C33a and A2780), total acetylation was also 
highest. Levels of acetylated H3 and H4 were very similar between these two cell lines 
(approximately 20% total and 10% each for acetylation of H3 and H4 for both cell lines) 
and this links well to hTERT expression. Acetylation in those cell lines with little or no 
hTERT expression (GM847, W138, W138-SV40, KMST-6, SKLU and SUSM-1) was 
much lower than in A2780 and C33a. However the 5637 cell line which expresses 
hTERT at a relatively high level does not have levels of total acetylation any higher than 
those cell lines which do not express hTERT. Studies of acetylated K9 H3 at the hTERT 
promoter (Figure 4.3B) shows similar results as those seen for acetylated H3 and H4 with 
only C33a and A2780 showing high levels of acetylation while the other cell lines, 
including the 5637 cell line, show very low or no acetylated K9 H3. In general this data 
shows a positive link between histone acetylation and hTERT expression. 
Methylation of K4 H3 at the hTERT promoter was then studied next. Figure 4.3C shows 
that only the A2780 cell line, which does express hTERT, has high levels of methylated 
K4 H3. However, methylation of K4 H3 is higher in the three hTERT expressing cell 
lines (C33a, A2780 and 5637) than the hTERT non-expressing cell lines except for 
KMST6. It is also obvious that each cell lines does exhibit a certain amount of methylated 
K4 H3. Across the cell lines, tri-methylated K4 H3 seems to be the prevalent state of this 
modification and is present in each cell line. This may be linked to previous hTERT 
expression in these cell lines and the hypothesis of transcriptional memory, or may suggest 
that the hTERT promoter is "primed" in these cell lines, ready for a signal, ready for 
transcription. In general, methylated K4 H3 does not link exclusively to hTERT 
transcription. 
4.2.4 Can Promotion of Permissive Histone Modifications at the 
hTERT Promoter Lead to Changes in hTERT Gene 
Transcription? 
Again it was studied whether modulation of the chromatin environment surrounding the 
gene promoter can affect transcription. As for hTR studies, W138, W138-SV40 and 
KMST-6 cell line were used and were treated with TSA and 5-azadC. 
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Figure 4.3 Modifications Linked to Permissiveness of hTERT Transcription 
Levels of A Acetylated H3 and H4, B Acetylated K9 H3 and C Di- and Tri-methylated K4 
H3. present at the hTERT promoter in ALT (A), telomerase positive tumour (T) or normal 
(N) cell lines, detected by Q-PCR using primers which detect the hTERT core promoter 
sequence, from products of chromatin immunoprecipitation assays. Results are expressed 
as the total IP amount for both the antibodies (apart from acetylated K9 H3) and are 
expressed as a percentage of an Input sample, which is a 20% fraction of chromatin utilised 
for each IP experiment, and so normalises the data. Each IP is also corrected for a control 
IP experiment, done in parallel with other IP's, in which no antibody was added to control 
for any background. Each IP value was established in at least three separate experiments 
and the IP figure shown is of a representative experiment. Means and standard errors are 
from triplication within the Q-PCR reactions. 
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Primers that recognise the main splice variants of hTERT (wild type, a, 0 and aß splice 
variants) were used and total amount of each splice variant summed and expressed as total 
hTERT expression. hTERT expression was re-activated in KMST-6, W138 and WI38- 
SV40 following treatment with TSA and 5-azadC in combination (Figure 4.4) although the 
relative levels of expression do not reach the levels observed in the tumour cell lines 
(A2780, C33a and 5637). 
Histone modifications known to allow for a transcriptionally permissive chromatin 
environment were studied to allow us to link increases in expression with increases in such 
modifications. Figure 4.5A shows that in each cell line reactivation of expression was 
concomitant with significantly elevated levels of acetylated H3 and H4, with levels of 
acetylated H4 generally higher than acetylated H3. Acetylated K9 H3 levels were also 
monitored (Figure 4.5B) and levels were found to be significantly higher after treatment in 
each cell line. Methylation of K4 H3 was then studied and Figure 4.5C shows that overall 
K4 H3 methylation does increase in each cell line upon treatment, but only to a large 
extent in the W138 cell line. Levels of di- and tri-methylated K4 H3 significantly 
increased upon treatment in the W138 cell line, although in KMST6 and W138-SV40 cell 
lines increases in only tri-methylated K4 H3 were evident and only the increase in the 
W138-SV40 cell line was significant. Indeed, no di-methylated K4 H3 was observed in 
the W138-SV40 cell line, before or after treatment. 
So as for hTR, this data shows clearly that the formation of a more permissive chromatin 
environment can lead to the re-expression or increased expression levels of hTERT. 
4.2.5 Involvement of Basal Transcriptional Machinery Involved in 
hTERT Expression 
Analysis of RNA polymerase II occupancy was undertaken as for hTR, although for 
hTERT tracking of RNA polymerase II along the hTERT gene was also studied. This was 
studied by analysing the RNA polymerase II occupancy of a downstream exon of hTERT 
(exon 12) some 31kb downstream of the promoter sequence. Increased occupancy of 
downstream sites for RNA polymerase II indicates that the gene is being transcribed and 
higher occupancy of these downstream sites, as well as at the promoter, indicates increased 
transcription (Sandoval et al., 2004; Anderson et al., 2006). Three tumour cell lines 
(A2780, C33a and 5637) and a normal cell line (W138) were utilised for this assay. 
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Figure 4.4 hTERT Expression Following Treatment with TSA and 5-azadC 
Cell lines from which hTERT levels are established are ALT (A) or normal (N) cell lines, 
as noted after each cell line name. Cells were treated twice for 24 hours with 5-azadC to a 
final concentration of 2.5mM, and then treated for 16 hours with Trichostatin A (TSA) at a 
final concentration of 350nM (+). Control cells were treated over the same time course 
but with 50% acetic acid instead of 5-azadC and 100% ethanol instead of TSA (-). 
hTERT expression levels were established, first by analysing GAPDH levels from cDNA 
made from 1 µg RNA. cDNA amounts used as input in each separate reaction for each cell 
line were then adjusted for the hTERT splice variant PCR reaction so similar 
concentrations of cDNA were used in each PCR. hTERT expression levels are shown as 
the sum of all the expressed variants (WT, a, ß and a(3). Therefore the hTERT levels are 
expressed as being normalised to GAPDH expression. Expression levels were found to be 
similar between three different experiments for each cell lines. Means and errors are 
established from the average of these Q-PCR experiments. 
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Figure 4.5 Changes in Levels of Histone Modifications at the hTERT Promoter Following 
Treatment with TSA and 5-azadC 
86 
Q-PCR results of the ChIP using antibodies against A Acetylated H3 and H4, B Acetylated 
K9 H3 and C Di- and Tri-methylated K4 H3 detected by Q-PCR using primers which 
detect the hTERT core promoter sequence, from products of chromatin 
immunoprecipitation assays. Cell lines used are ALT (A) or normal (N) cell lines, as 
noted after each cell line name. Cells were treated twice for 24 hours with 5-azadC to a 
final concentration of 2.5mM, and then treated for 16 hours with Trichostatin A (TSA) at a 
final concentration of 350nM (+). Control cells were treated over the same time course 
but with 50% acetic acid instead of 5-azadC and 100% ethanol instead of TSA (-). Results 
are expressed as the total IP amount for both the antibodies (apart from acetylated K9 H3) 
and are expressed as a percentage of an Input sample, which is a 20% fraction of chromatin 
utilised for each IP experiment, and so normalises the data. Each IP is also corrected for a 
control IP experiment, done in parallel with other IP's, in which no antibody was added to 
control for any background. Each IP value was established in at least three separate 
experiments and the IP figure shown is of a representative experiment. Means and 
standard errors are from triplication within the Q-PCR reactions. Statistics were analysed 
using ANOVA software from the Microsoft Excel data analysis tool pack. Asterisks 
denote a statistically significant difference between untreated and treated; *p < 0.05; **p < 
0.01. 
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hTERT is expressed in the three tumour cell lines (A2780, C33a and 5637) and we see 
RNA polymerase II binding at the promoter sequence in all 3 cell lines (Figure 4.6A). 
Relative amounts of RNA polymerase II binding seems to be directly linked to hTERT 
expression but surprisingly, a significant amount of RNA polymerase II is also observed at 
the promoter in the normal W138 cell line which does not express hTERT although this is 
much less than that observed in the tumour cell lines. Analysis of RNA polymerase II 
occupancy at Exon 12 shows that the higher the expression of hTERT the higher levels of 
occupancy we observe. Again, a significant amount of RNA polymerase II is observed at 
exon 12 in the W138 cell line. 
Treatment of the W138 cell line with TSA and 5-azadC leads to the re-expression of 
hTERT and so changes in RNA polymerase II tracking where also studied before and after 
treatment. Figure 4.6B shows that upon treatment RNA polymerase II occupancy 
increases at the hTERT promoter and exon 12 indicating that there is an increase in 
transcription of hTERT expression. 
This data shows a positive link between RNA polymerase II binding at the hTERT 
promoter and coding sequence and hTERT expression and between RNA polymerase II 
binding and general permissiveness of the chromatin environment. 
4.2.6 Transcription Factor Binding at the hTERT Promoter 
The transcription factor MYC is known to be involved in hTERT transcription (Greenberg 
et al., 1999; Kyo et al., 2000; Wu et al., 1999; Zou et al., 2005; Xu et al., 2001) and 
binding is associated with the formation of a more permissive chromatin environment (Xu 
et al., 2001). Therefore, MYC occupancy of the hTERT promoter was examined in C33a, 
A2780,5637 and W138. Figure 4.7 shows that MYC binding was high in the A2780 and 
C33a cell lines, relative to 5637 in which MYC binding was lower and W138 in which 
MYC binding was lowest of the cell lines examined. The binding of MYC to the hTERT 
promoter is linked to expression and also the chromatin environment, as the more 
permissive the chromatin environment is, the higher the MYC binding is observed to be. 
4.3 Discussion 
These studies demonstrate that changes in the chromatin environment of the hTERT 
promoter in normal and telomerase positive tumour and telomerase negative ALT cell lines 
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Figure 4.6 RNA Polymerase 11 Binding at the hTERT promoter and Exon 12 of hTERT 
89 
Q-PCR results of the ChIP for A RNA Pol II in tumour (T) and normal (N) cells and B 
RNA Pol II following treatment of the normal (N) cell line W138 with 5-azadC and TSA 
detected by Q-PCR using primers which detect the hTERT core promoter sequence and 
Exon 12 of hTERT. W138 cells were treated twice for 24 hours with 5-azadC to a final 
concentration of 2.5mM, and then treated for 16 hours with Trichostatin A (TSA) at a final 
concentration of 350nM (+). Control cells were treated over the same time course but 
with 100% ethanol instead of TSA and 50% acetic acid instead of 5-azadC (-). Results are 
expressed as a percentage of a 10% Input sample, with the Input fraction being a 20% 
fraction of chromatin utilised for each IP experiment, and so normalises the data. Each IP 
is also corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background. Each IP value was established in at 
least three separate experiments and the IP figure shown is of a representative experiment. 
Means and standard errors are from triplication within the Q-PCR reactions. 
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Figure 4.7 MYC Occupancy of the hTERT promoter 
91 
Q-PCR results of the ChIP for Myc in tumour (T) and normal (N) cells detected by Q-PCR 
using primers which detect the hTERT core promoter sequence. Results are expressed as 
a percentage of a 10% Input sample, which is a 20% fraction of chromatin utilised for each 
IP experiment, and so normalises the data. Each IP is also corrected for a control IP 
experiment, done in parallel with other IP's, in which no antibody was added to control for 
any background. Each IP value was established in at least three separate experiments and 
the IP figure shown is of a representative experiment. Means and standard errors are from 
triplication within the Q-PCR reactions. 
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is different and these changes correlates with expression. hTERT expression is repressed 
in the normal and ALT cell lines and data shows that a repressive pattern of modifications 
present at the hTERT promoter sequences is associated with the repression of hTERT 
transcription in the ALT and normal cell lines. Further, a permissive pattern of 
modifications present at the hTERT promoter is linked to hTERT expression in telomerase 
positive tumour cell lines. hTERT gene expression in tumour cells is linked to histone 
hyperacetylation, methylation of K4 H3 and lack of methylation of K9 H3 while hTERT 
gene repression in normal and ALT cell lines is linked to histone hypoacetylation and 
methylation of K9 H3. 
The distinct patterns of modifications, however, do not always apply. The 5637 cell line 
expresses relatively high amounts of hTERT but the acetylation status of the promoter 
remains at a level similar to those cell lines with no hTERT expression. It is known that 
when used in reporter assays, 5637 cells have very low promoter activity, compared to 
C33a and A2780 (Bilsland et al., 2003; Plumb et al., 2001). Whether or not the 
endogenous chromatin environment becomes reconstituted on However the role of these 
plasmid based reporter assays is not know and therefore effects of the chromatin 
environment on expression could be partly negated. hTERT promoter activity in 5637 is 
in fact very similar to that observed in SUSM1, SKLU and W138 which do not have 
hTERT expression. This suggests that although the chromatin environment is hugely 
important in the regulation of gene expression, other factors must be taken into account 
when studying gene regulation and promoter activity. 
However, it may be that the lack of repressive modifications and the presence of 
methylated K4 H3 may allow the formation of a chromatin environment which will allow 
transcription to occur at a low level, for example in the 5637 cell line. Similarly, W138, 
KMST6 and SKLU cell lines have relatively low levels of methylated K9 H3 at the 
promoter but still do not express hTERT. This may be due to the fact that these cell lines 
have promoters which lack high levels of acetylation of histones H3 and H4. Therefore 
the lack of permissive modifications at the hTERT promoter in these cell lines may be 
enough to repress transcription. 
hTERT plays an important role in senescence and immortalisation and so allows an 
excellent opportunity to study modes of gene regulation in senescence bypass and 
immortalisation. This study also allows a comparison to be drawn between a normal 
presenescent cell and a transformed cell of the same cell type and to ascertain whether or 
not chromatin changes occur upon the bypass of senescence and the gain of an immortal 
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phenotype. When comparing the W138 and its transformed cell line W138-SV40 some 
interesting differences are observed. Upon transformation the W138-SV40 cell line 
utilises the ALT pathway to maintain telomeres instead of the activation of telomerase 
activity. Neither cell line expresses hTERT but distinct differences in the chromatin 
environment are observed when comparing the two cell lines. In the W138 cell line the 
chromatin environment seems to be a "blank canvas" or an environment in that no great 
amounts of permissive or repressive modifications are present at the promoter. In 
comparison, the W138-SV40 cell line has high levels of methylated K9 H3 and K20 H4 
while acetylation levels and methylation of K4 H3 remain similar. The lack of these 
permissive modifications in the W138 cell line but the lack of many repressive 
modifications may represent a "primed" state for hTERT expression while the 
accumulation of methylated K9 H3 and K20 H4 may represent heavy transcriptional 
repression and link to the ALT mechanism, as for hTR. 
This further indicates that the transformation process and therefore the bypass of 
senescence is associated with changes in the chromatin environment. Again, as for hTR, 
the formation of a heavy repressive heterochromatic environment at the hTERT promoter 
may not allow the expression of hTERT, repress telomerase activation and may "force" the 
cell to utilise the ALT mechanism for telomere maintenance. 
Comparisons of the W138 cell line with the telomerase positive cell lines also lead to some 
interesting conclusions. It is shown that hTERT expression is increased in the three 
tumour cells as compared to the normal W138 cell with the upregulation of hTERT activity 
in C33a, A2780 and 5637 is associated with the upregulation of a similar pattern of 
modifications, such as methylation of K4 H3 and acetylation of H3 and H4 while lacking 
repressive modifications. This suggests that the mode of hTERT upregulation may be 
conserved in these tumour cell lines and that a common mechanism may be regulating 
hTERT expression in these different tumour cell lines; namely the modulation of the 
chromatin environment of the gene promoters. 
Similar data for two genes (hTR and hTERT) with direct links to immortalisation and the 
bypass of senescence, showing upregulation of gene expression linked to permissive 
modification patterns at promoter sequences, enhances the claim that the observed changes 
in the chromatin environment on the bypass of senescence are a global effect rather than 
specific for one gene. These data suggest further analysis of the chromatin environment 
and the role it plays in transcriptional control of the telomerase genes and also of the 
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chromatin environment on multiple genes in the control of senescence and in 
immortalisation. 
The role of methylation of K20 H4 in regulation of hTERT shows some similarity to data 
gained for hTR. Methylated K20 H4 again seems to mark strongly for the ALT phenotype 
rather than being linked to gene repression. However, the modification is present at high 
levels in 5 of the 6 cell lines showing no or negligible hTERT expression, which would 
indicate that methylation of K20 H4 does have a role in the repression of transcription of 
hTERT. However, alternate roles, highlighted by the studies of hTR, can not be ignored. 
Similarly to data collected for hTR it is shown that if levels of permissive modifications 
(methylated K4 H3 and acetylation of histones H3 and H4) are enhanced by the use of 
TSA and 5-azadC, hTERT can become re-expressed. However expression does not 
increase to levels similar to that in the three tumour cells, exemplifying that although the 
modulation of the chromatin environment is important, other mechanisms must be 
involved in mediating transcriptional activation. Whether this increase is enough to allow 
telomerase activity in the cells in question (also allowing for hTR expression) is unknown 
but the low levels of expression obtained suggest that if telomerase activity is present, it 
would be at low levels. 
Prior studies have suggested that TSA alone can induce hTERT expression in normal 
human cells but not in telomerase positive tumour cells, except for in a few cell lines 
which have very low levels of telomerase activity (Hou et al., 2002; Cong and Bacchetti, 
2000; Mukhopadhyay et al., 2005; Takakura et al., 2001). This may indicate that the 
formation of a permissive chromatin environment may be an early event in transcriptional 
activation, being the "priming" event allowing other factors further involved in 
transcriptional activation play a role. Transient transfection assays with the proximal 
hTERT promoter sequences (Hou et al., 2002; Cong and Bacchetti, 2000; Takakura et al., 
2001) and the lack of the effect on hTERT transcription of the protein synthesis inhibitor 
cyclohexamide (CHX) upon TSA treatment (Mukhopadhyay et al., 2005) suggest that TSA 
directly affects the hTERT promoter, although TSA is a broad-spectrum HDAC inhibitor 
and indirect effects cannot be ruled out. The latter study also showed that treatment with 
5-azadC had no effect on hTERT expression although various other studies have shown 5- 
azadC has a positive effect on hTERT transcription (Kumakura et al., 2005; Dessain et al., 
2000; Shin et al., 2003). 
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Dual use of TSA and 5-azadC has also been observed to be needed for hTERT re- 
expression (Devereux et al., 1999) agreeing with this study and again this data is also in 
agreement with previous studies on the synergistic effect of TSA and 5-azadC treatment 
showing increases in acetylated K9 H3 and methylated K4 H3 at previously silenced gene 
promoters (Kondo et al., 2003). 
The recent study by Kumakura et al (Kumakura et al., 2005) also studied the chromatin 
environment surrounding the hTERT promoter. Ratio's of methylation of K9 H3 to 
permissive modifications such as methylation of K4 and acetylation of K9 and K14 H3, 
where observed to be higher in telomerase negative ALT cells with no hTERT expression 
as compared to hTERT expressing telomerase positive cells, in which the ratios where 
much higher. TSA or 5-azadC treatment alone was shown to be able to promote the 
presence of permissive chromatin modifications at a previously repressive chromatin 
domain at the hTERT promoter. These changes were shown to lead to hTERT re- 
expression and telomerase activity, with 5-azadC having a greater effect on hTERT re- 
expression than TSA in some cell lines. TSA alone was unable to induce telomerase 
activity, whereas 5-azadC could induce telomerase activity but treatment with both TSA 
and 5-azadC led to more robust levels of activity. This study further indicates that 
epigenetic control of hTERT is important in transcriptional regulation and is in agreement 
with the data in this study showing that hTERT re-expression only occurred with the 
treatment of both TSA and 5-azadC (Kumakura et al., 2005). 
Also studied was the role of the basal transcriptional machinery in promoter clearance and 
elongation in the context of chromatin remodelling. As for hTR, RNA polymerase II 
binding was linked to the chromatin environment of the promoter, with RNA polymerase II 
binding at the promoter being higher in those cell lines with a more permissive chromatin 
environment. Also studied was RNA polymerase II trafficking by investigating RNA 
polymerase II occupancy at hTERT exon 12. Higher binding at hTERT exon 12 has been 
previously linked to higher gene expression (Anderson et al., 2006) and correspondingly 
RNA polymerase II binding at exon 12 was higher in those cell lines with higher hTERT 
expression linking the permissivity of the chromatin environment at the promoter with 
increased transcription. 
Creation of a more permissive chromatin environment by treatment of WI38 with TSA and 
5-azadC, led to increased RNA polymerase II binding and trafficking to hTERT exon 12, 
likely as a result of the permissive chromatin environment allowing a more open chromatin 
structure therefore allowing increased binding and competence for transcriptional 
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machinery complex assembly. As noted for hTR, the RNA polymerase II molecule is 
known to co-localise with chromatin modifying enzymes capable of generating a 
permissive chromatin environment for the passage of the RNA polymerase II molecule. 
This study indicates that increased RNA polymerase II binding at the hTERT promoter is 
linked to a more transcriptionally permissive chromatin environment with increased levels 
of permissive modifications present with higher levels of RNA polymerase II binding. 
However, RNA polymerase II binding was still apparent in the W138 cell line which does 
not exhibit a permissive chromatin environment and does not show any hTERT expression. 
This binding of RNA polymerase II at the promoter and exon 12 in the W138 cell line 
could be explained by the presence of paused RNA polymerase II molecule being present 
at the promoter, perhaps indicating that the hTERT gene may be permissive for 
transcription, only needing changes in the chromatin environment of the promoter to allow 
transcription. 
Basal transcriptional machinery has been shown to bind silenced chromatin (Sekinger and 
Gross, 2001) suggesting that modulation of the chromatin environment may allow 
promoter clearance and elongation rather than enhancing actual binding. Appreciable 
levels of RNA polymerase II occupancy at the hTERT promoter in W138 suggest that RNA 
polymerase II binding does occur at silent chromatin domains and that the permissivity of 
the chromatin environment of the promoter sequences is important in enhanced RNA 
polymerase II binding at the promoter and gene transcription. Changes in the chromatin 
environment of promoter sequences may therefore drive changes in the dynamics of the 
basal transcription machinery and complex interactions between transcriptional complexes 
and chromatin may therefore be important in mediating transcriptional activity. 
MYC has been linked to hTERT transcription in many different studies (Xu et al., 2001; 
Oh et al., 1999b; Kyo et al., 2000; Wu et al., 1999) and so MYC binding was interrogated 
at the hTERT promoter. MYC binding was found to be increased in the tumour cells 
expressing higher levels of hTERT (C33a, A2780 and 5637) when compared to the normal 
W138 cell line which does not express hTERT. Expression of C33a and A2780 is higher 
than in the 5637 cell line and this is reflected in MYC binding. The permissiveness of the 
chromatin environment is therefore linked to MYC binding, although the nature of this link 
is not known, as MYC binding could be causing increased histone acetylation (Frank et al., 
2001; Frank et al., 2003; Xu et al., 2001) or the permissiveness of the chromatin 
environment could allow increased MYC binding although high levels of acetylation have 
been shown to exist at a promoter sequence even before MYC binding (Fernandez et al., 
2003). 
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5 Epigenetic Regulation of the Telomerase Genes 
in Stem Cell Populations 
5.1 Introduction 
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Stem cells are unique in their ability to both self renew and to give rise to differentiated 
tissues. The self-renewal capacity of stem cells has been linked to neoplastic growth 
potential (Reya et al., 2001; Pardal et al., 2003) and studies into stem cells as the originator 
cells for cancer are of great interest (Marx, 2003). Strong links between normal stem cells 
and cancer stem cells in many tissues (AI-Hajj et al., 2003; Perez-Losada and Balmain, 
2003; Collins et aL, 2005; Singh et al., 2004; Kim et al., 2005; Gibbs et al., 2005) suggest 
that stem cells are targets for neoplastic transformation (Keith, 2004). 
Further lending support to the cancer stem cell hypothesis is the recent hypothesis that 
epigenetic disruption of stem cells may be a common unifying theme in cancer aetiology 
(Feinberg et al., 2006). This so called "epigenetic progenitor model" may help to explain 
many different aspects about cancer. In this model, cancer arises in three steps; first is an 
epigenetic alteration of stem/progenitor cells within a given tissue, second is a gatekeeper 
mutation (GKM) and third is genetic and epigenetic instability, which leads to increased 
tumour evolution. Also noted is the correlation between the properties of advanced 
tumours and the inherent properties of the progenitor cells that give rise to the primary 
tumour which include invasion, metastasis and drug resistance, further highlighting the 
importance of epigenetic factors in tumour progression. Therefore, studying the 
epigenetic regulation of gene expression in normal and cancer stem cells is an exciting 
opportunity. 
Human mesenchymal stem cells (hMSCs) are multipotential cells and have the ability both 
in vivo and in vitro to differentiate into a variety of adult mesenchymal tissues, such as 
bone, cartilage, adipose and muscle (Pittenger et al., 1999). Unusually for a stem cell, 
hMSCs lack telomerase activity (Zimmermann et al., 2003) and when passaged in culture, 
hMSCs gradually reduce their proliferative rate and enter replicative senescence (Simonsen 
et al., 2002; Stenderup et al., 2003). Ectopic expression of hTERT in the hMSC leads to 
reactivation of telomerase activity and maintenance of telomere length, abolishes the 
senescence-associated phenotype and can lead to extension of lifespan and maintenance of 
proliferative capacity (Simonsen et al., 2002; Shi et al., 2002). This has consequences for 
the therapeutic potential of the hMSC in tissue engineering as such cells may only have a 
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limited lifespan. However, the re-expression of telomerase by the ectopic expression of 
hTERT in the hMSC has been shown to allow the accumulation of neoplastic changes 
(Serakinci et al., 2004; Burns et al., 2005). Recent studies have also shown that the long 
term passaging of hMSCs without hTERT transduction can also lead to the formation of 
tumourigenic mesenchymal type cells (Wang et al., 2005; Rubio et al., 2005). These 
studies suggest that the adult hMSC can be a target for neoplastic transformation. 
The lack of hTERT expression in the hMSC provides an ideal model to study telomerase 
gene regulation in the normal adult stem cell. A key issue in telomere biology is how the 
complex pattern of telomerase gene expression is maintained in the adult stem cell and the 
hMSC can allow us to study hTR and hTERT transcriptional control. As discussed 
previously, the histone deacetylase inhibitor TSA has previously been shown to cause an 
increase in histone acetylation at the hTERT promoter and cause re-expression of the 
hTERT gene. To this end, hMSCs were studied before and after treatment with TSA to 
investigate possible mechanisms behind the silencing of hTERT expression and possible 
pathways controlling hTR and hTERT expression in the hMSC. This includes all stages 
of promoter function including the key steps of transcription pre-initiation complex 
formation, promoter clearance and elongation in the context of chromatin remodelling. 
hTERT and hTR expression was analysed and ChIP assays were utilised in order to study 
the acetylation status of the hTR and hTERT promoters and RNA polymerase II and TFIIB 
dynamics. 
Also studied were human haematopoietic stem cells (hHSCs), a stem cell population in 
which cancer stem cells were first identified and studied. The haematopoietic system is 
organized in a hierarchical manner, in which rare haematopoietic stem cells (hHSCs) 
initiate the hierarchy. They have the ability to self-renew, proliferate and differentiate into 
different lineages of peripheral blood cells though intermediating haematopoietic 
progenitor cells (HPCs) (Reya, 2003). hHSC self-renewal is driven by both intrinsic and 
extrinsic factors but serial transplantation studies have clearly indicated that self-renewal 
potential of hHSCs is impaired after replicative stress (Kamminga et al., 2005b). hHSC 
activity may be irreversibly lost in a single cell division (Nakauchi et al., 2001; Takano et 
al., 2004) indicating that the epigenetic regulation of gene expression may play an 
important role. Indeed expression of PcG proteins BMI1 and EZH2, which are found in 
complexes and can repress target gene expression by modification of histones, allows the 
counteraction of senescence and allows self-renewal of hHSCs (Kamminga et al., 2005a; 
Park et al., 2003; Lessard and Sauvageau, 2003). Loss of BMI1 has also been noted to 
cause a decrease in hHSC number (Park et al., 2003) and limits proliferative capacity in 
Stuart P. Atkinson, 2006 Chapter 5 99 
normal and leukaemic haematopoietic stem cells (Lessard and Sauvageau, 2003) and 
inhibition of HDACs is also known to promote haematopoietic stem cell self-renewal 
(Young et al., 2004; Bug et al., 2005). 
It is also known that in a number of haematological malignancies that arise in hHSCs, the 
functions of chromatin modifiers can become altered due to chromosomal rearrangements 
and translocations. Many chromosomal translocations associated with acute leukaemias 
disrupt genes either encoding histone modifying factors or express transcription factors 
that recruit histone-modifying complexes. Enzymes implicated include the histone 
methyltransferase MLL, histone acetyltransferases CBP/p300, MOZ, MOF, MORF and 
histone deacetylases (Linggi et al., 2005). Therefore, modulations in the chromatin 
environment may be involved in modulating growth potential in the haematopoietic system 
in a similar way to that the regulation of chromatin environment can affect senescence and 
differentiation in many normal and tumour cell lines. 
With regards to telomerase activity, it is known that hHSCs express telomerase only at a 
low level which is not enough to fully counteract telomere shortening with replication and 
age (Vaziri et al., 1994; Broccoli et al., 1995; Chiu et al., 1996) but is enough to allow 
hHSCs to function properly throughout a normal lifespan (Engelhardt et al., 1997). The 
telomere loss is represented by about 4kb shorter telomeres in the adult bone morrow 
compared to foetal liver hHSCs (Vaziri et al., 1994). However, dysfunction of hHSCs has 
been observed during normal aging (Kamminga et al., 2005b) and ex-vivo cultures of 
hHSCs undergo a replicative stress that causes accelerated senescence due to rapid 
telomere shortening (Piacibello et al., 2005). 
Chronic Myeloid Leukaemia (CML) is a clonal myeloproliferative disorder that arises in 
an hHSC. Leukaemic cells are characterised by the presence of the Philadelphia 
chromosome and the BCR-ABL oncogene (Sawyers, 1999) and the disease typically 
follows three distinct phases: chronic phase (CP) which lasts around 5 years, accelerated 
phase (AP) lasting 6-12 months and an aggressive blast phase (BP) which is invariably 
fatal. Proliferation of CML CD34+ hHSCs is increased compared to normal CD34+ 
hHSCs and this is thought to lead to shortening of telomere length observed in CML 
(Brummendorf et al., 2000), with the rate and degree of telomere shortening offering some 
prognostic information regarding time to disease progression and correlates with the 
Hasford Risk score (Drummond et al., 2004). In peripheral blood leukocytes, the rate of 
telomere loss in CP CML was 10 to 20 times the rate observed in normal granulocytes and 
in BP CML 30-60 additional divisions were observed (Drummond et al., 2005). Telomere 
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shortening is linked to disease evolution in CML (Boultwood et al., 1999) as extended 
amounts of telomere erosion can increase genetic instability leading to additional 
mutations and defects can accumulate. Telomere shortening in CML suggests that the 
telomerase genes expression may become dysregulated and links between accelerated 
telomere loss and dysregulation of the telomerase genes in the CML CD34+ hHSCs have 
recently been uncovered (Drummond et al., 2005; Campbell et al., 2006). 
In the first study, telomerase activity was first observed to be increased when comparing 
CML CD34+ cells to normal CD34+ in the chronic phase of CML, but this was actually 
correlated to increased cell cycling within the CML CD34+ hHSCs. Expression of hTR 
and hTERT were analysed to understand whether dysregulation of either of these genes 
could be contributing to the enhanced telomere loss observed in CML CD34+ hHSCs. 
Although total amounts of hTERT expression did not change, a switch in splicing was 
observed with more full-length transcript being present at the expense of the ß-deletion 
variant. In addition, hTR expression was observed to be decreased 5-fold in the BCR- 
ABL+ CD34+ hHSCs when compared to the normal CD34+ hHSCs. This dysregulation 
in hTR expression in CP CML CD34+ cells, in conjunction with increased cell cycle 
activity, may contribute to the rapid telomere loss seen in early stages of CML and during 
disease progression from CP through AP to BP. The second study also analysed 
expression of hTR and hTERT in CP CML and demonstrated that hTERT expression 
decreased in contradiction with the first study, but splicing still favoured the wild type 
hTERT transcript as was found in the first study (Campbell et al., 2006) and also found 
that hTR levels were increased in CP CML, again in contradiction with the first study. 
This study suggests that reduction of hTERT expression is causally linked to the decrease 
in telomere length in the CP of CML, leading to genomic instability and disease 
progression. 
Overall, studies suggest that dysregulation of telomerase gene expression may lead to 
telomere shortening and disease progression due to genomic instability observed in CML. 
Dysregulation of telomerase gene expression in CML CD34+ hHSCs provides an excellent 
opportunity to dissect regulatory pathways affecting telomerase gene expression between a 
normal stem cell population and a cancer stem cell population within the same cell type. 
To this end we studied hTR and hTERT expression in respect to any changes in the 
chromatin environment of the hTR and hTERT gene promoters in normal CD34+ hHSCs 
and CML CD34+ hHSCs establishing whether modulations in the chromatin environment 
surrounding the telomerase gene promoters can be linked to changes in transcription of 
hTR and hTERT. 
Stuart P. Atkinson, 2006 Chapter 5 
5.2 Results 
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5.2.1 hTERT Gene Expression, Chromatin Remodelling and Basal 
Transcriptional Machinery Dynamics at the hTERT Promoter 
in the hMSC 
Isolation of hMSCs, cell culture and treatment was undertaken by the laboratory of Dr 
Nedime Serakinci (University of Southern Denmark, Institute of Medical Biology, 
Department of Anatomy and Neurobiology, DK-5000 Odense C, Denmark). hTERT 
expression was studied before and after treatment with TSA and histone acetylation at the 
promoter was also analysed by ChIP assays in order to link changes in the chromatin 
environment with any changes in gene expression. 
In control (untreated) hMSCs, there was a lack of expression of any hTERT transcripts 
(Figure 5.1). Acetylation of H3 was not detected and acetylation of H4 was low (Figure 
5.2), linking the lack of expression of hTERT with low levels of promoter proximal histone 
acetylation. However, upon treatment with TSA, hMSCs showed re-expression of full- 
length hTERT transcripts (Figure 5.1) and this was associated with increased levels of 
acetylated H3 and acetylated H4 (Figure 5.2), linking remodelling of the chromatin 
environment of the hTERT promoter with re-expression of hTERT. However, although 
increases are observed for both acetylated H3 and acetylated H4, only the increase in 
acetylated H4 was statistically significant. 
As well as monitoring acetylation, RNA polymerase II and TFIIB occupancy at the hTERT 
promoter and exon 12 of hTERT were studied to investigate the trafficking of the basal 
transcription machinery along the hTERT gene. Exon 12 is located some 31 kb downstream 
from the promoter and therefore can give an insight into the extent of basal transcription 
machinery tracking along the gene coding sequence. RNA polymerase II levels were low 
at the hTERT promoter before treatment with TSA (Figure 5.3A) perhaps signifying that 
any RNA polymerase II that was present at the promoter was not engaged in transcription. 
The decreased levels of RNA polymerase II observed at the hTERT promoter after 
treatment might be explained by increased movement of RNA polymerase II from the 
promoter onto the coding sequence of the gene (Figure 5.3A). Levels of RNA polymerase 
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Figure 5.1 hTERT Splice Variant Expression in hMSC 
102 
hTERT spice variant expression analysis of hMSC before and after treatment with TSA. 
hMSCs were treated with 350 µM TSA for 17hrs, while the control hMSC were treated 
with 100% Ethanol, after which RNA was extracted. hTERT expression levels were 
established, first by analysing GAPDH levels from eDNA made from 1 µg RNA. cDNA 
amounts used as Input in each separate reaction were then adjusted for the hTERT splice 
variant PCR reaction so similar concentrations of cDNA were used in each PCR. Splice 
Variant expression was then visualised using the Agilent Bioanalyser (Agilent 
Technologies). Lane I shows size markers, lane 2, the negative control for the PCR 
reaction, lane 3, hTERT expression for the hMSC, lane 4, hTERT expression for the hMSC 
treated with TSA, and lane 5, hTERT expression in the MCF7 cell line as comparison. 
Splice variants are labelled on the right side of the gel, while the size of these products are 
shown on the left (in bp). The results are shown from a single experiment. 
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Figure 5.2 Acetylation Status of the hTERT Promoter in hMSCs 
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Q-PCR results of the ChIP using antibodies against Acetylated H3 and H4, analysed by Q- 
PCR using primers which detect the hTERT core promoter sequence before and after 
treatment with TSA (350 pM TSA for 17hrs, while the control hMSC were treated with 
100% Ethanol). Results are expressed as a percentage of an Input sample, which is a 20% 
fraction of chromatin utilised for each IP experiment, and so normalises the data. Each IP 
is also corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background (IP-). Means and standard errors are 
from triplication within a Q-PCR reaction from a single experiment. Asterisks denote a 
statistically significant difference between untreated and treated (ANOVA): *p < 0.05. 
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Figure 5.3 RNA polymerase 11 and TFIIB Tracking on hTERT Promoter and Exon 12 in the 
hMSC 
ChIP assays were performed for A, RNA Pol II occupancy and B, TFIIB occupancy of the 
promoter and exon 12 of hTERT before and after treatment of hMSCs with TSA (350 . tM 
TSA for 17hrs, while the control hMSC were treated with 100% Ethanol). Results are 
expressed as a percentage of an Input sample, which is a 20% fraction of chromatin utilised 
for each IP experiment, and so normalises the data. Each IP is also corrected for a control 
IP experiment, done in parallel with other IP's, in which no antibody was added to control 
for any background (IP-). Means and standard errors are from triplication within a Q-PCR 
reaction from a single experiment. Asterisks denote a statistically significant difference 
between untreated and treated (ANOVA): *p < 0.05; **p < 0.01. 
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II at exon 12 were increased after treatment with TSA (Figure 5.3B) indicating that 
increasing amounts of RNA polymerase II trafficking was involved in the process of 
transcription of the hTERT gene. TFIIB levels in hMSCs were increased at the promoter 
upon TSA treatment, perhaps due to the relaxing of the chromatin environment allowing 
the stabilisation of the pre-initiation complex and increased transcription of hTERT by 
RNA polymerase II. Low levels of TFIIB at Exon 12 before and after TSA treatment 
suggests that the role of TFIIB is primarily at the promoter stabilising the pre-initiation 
complex. 
5.2.2 hTR Gene Expression, Chromatin Remodelling and Basal 
Transcriptional Machinery Dynamics at the hTR Promoter in 
the hMSC 
hTR expression was also studied before and after treatment with TSA and histone 
acetylation was analysed at the promoter by ChIP assays in order to link changes in the 
chromatin environment with any changes in gene expression. In control (untreated) 
hMSCs, hTR expression was detected but increased following treatment with TSA (Figure 
5.4). However, no obvious changes in the levels of histones H3 and H4 acetylation at the 
hTR promoter were observed after treatment with TSA (Figure 5.5). 
Although there was no obvious increase in histone acetylation, hMSCs treated with TSA 
did however show an increase in RNA polymerase II and TFIIB levels at the promoter 
sequence (Figure 5.6), although this was not statistically significant. Nominal levels of 
RNA polymerase II and TFIIB were detected before treatment with TSA and upon 
treatment elevated levels of RNA polymerase II and TFIIB at the promoter could indicate 
an increase in stability of the transcriptional complex and therefore an increase in 
transcription levels of hTR that would account for the increase in expression. As the hTR 
gene is relatively short, extended analysis of RNA polymerase II and TFIIB trafficking was 
not possible. 
5.2.3 hTERT Expression, Chromatin Remodelling and Basal 
Transcriptional Machinery Dynamics at the hTERT Promoter 
in CD34+ hHSCs 
All hHSCs were provided from the laboratory of Dr Tessa Holyoake (Section of 
Experimental Haematology and Haematopoietic Stem Cells, Division of Cancer Sciences 
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Figure 5.4 hTR Expression in hMSCs 
hTR expression analysis of hMSC before and after treatment with TSA. hMSCs were 
treated with 350 µM TSA for 17hrs, while the control hMSC were treated with 100% 
Ethanol, after which RNA was extracted. RNA was extracted from each cell line and 
cDNA synthesised using lug RNA. hTR levels were detected using specific primers by 
Quantitative PCR (Q-PCR) using specific primers to the hTR coding sequence. hTR 
levels were normalised to the expression of GAPDH levels established using the same 
amount of cDNA as for hTR. Therefore, levels of hTR are expressed as being relative to 
GAPDH expression. Means and errors are established from triplication within the Q-PCR 
experiment from a single experiment. Asterisks denote a statistically significant 
difference between untreated and treated (ANOVA): *p < 0.05. 
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Figure 5.5 Acetylation Status of the hTR Promoter in hMSCs 
Q-PCR results of the ChIP using antibodies against Acetylated H3 and H4, analysed by Q- 
PCR using primers which detect the hTR core promoter sequence before and after 
treatment with TSA (350 µM TSA for 17hrs, while the control hMSC were treated with 
100% Ethanol). Results are expressed as a percentage of an Input sample, which is a 20% 
fraction of chromatin utilised for each IP experiment, and so normalises the data. Each IP 
is also corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background (IP-). Means and standard errors are 
from triplication within a Q-PCR reaction from a single experiment. 
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Figure 5.6 RNA polymerase II and TFIIB Occupancy of hTR Promoter 
ChIP assays were performed for RNA Pol II occupancy and TFIIB occupancy of the 
promoter hTR before and after treatment of hMSCs with TSA (350 µM TSA for 17hrs, 
while the control hMSC were treated with 100% Ethanol). Results are expressed as a 
percentage of an Input sample, which is a 20% fraction of chromatin utilised for each IP 
experiment, and so normalises the data. Each IP is also corrected for a control IP 
experiment, done in parallel with other IP's, in which no antibody was added to control for 
any background (IP-). Means and standard errors are from triplication within a Q-PCR 
reaction from a single experiment. 
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and Molecular Pathology, University of Glasgow, Glasgow, Scotland, United Kingdom). 
hTERT expression was analysed in relation to the chromatin environment of the promoter 
in normal and CML CD34+ hHSCs. Figure 5.7A shows total hTERT expression, adjusted 
to levels of S15 expression, from five normal and four CML CD34+ hHSCs. hTERT 
expression is decreased in the CML samples as compared to the normal samples, but when 
splice variant expression is studied (non-normalised), it is observed that there tends to be 
more full-length active hTERT transcript in the CML samples as compared to the normal 
samples as a proportion of total expression. Full length hTERT transcript is expressed in 
each CML sample, but hTERT expression is totally absent in one Normal sample (Normal 
5), two Normal samples show no full length hTERT transcript (Normal 1 and 2) and while 
two normal samples do show full length hTERT transcript expression (Normal 3 and 4), 
one sample also expresses the a-deletion variant, known to be a dominant-negative 
inhibitor of telomerase activity. Therefore in the CML samples, wild type hTERT 
transcript makes up a higher proportion of total transcripts expressed relative to the Normal 
samples even though total expression decreases. 
The chromatin environment of the hTERT promoter in the five Normal and four CML 
samples was analysed by ChIP except for di- and tri-methylation of K20 H4 and RNA 
polymerase II in which 4 normal and 4 CML samples were analysed. Figure 5.8A shows 
that overall, methylation of K9 H3 is higher in the CML samples while Figure 5.8B 
indicates that while overall methylation of K20 H4 is similar, dimethylation of K20 H4 is 
decreased in the CML samples. Figure 5.9A shows that levels of methylated K4 H3 are 
similar, while Figure 5.9B indicates that overall, acetylation is increased in the CML 
samples as compared to the normal samples. 
RNA polymerase II occupancy was also studied and Figure 5.10 shows a slight increase in 
RNA polymerase II tracking for hTERT in the CML samples signified by increases in 
levels of RNA polymerase II at the promoter at exon 12. However, this results may be 
distorted by CML sample four having large amounts of RNA polymerase II at the 
promoter, unlike other samples. Overall the data indicates an increase in K9 H3 
methylation, a decrease in dimethylation of K20 H4 and an increase in acetylation of H3 
and H4, coupled to increased RNA polymerase II tracking. 
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Figure 5.7 Expression of hTERT in Normal and CML CD34+ Haematopoietic Stem Cells 
RNA was extracted from each sample and cDNA was synthesised. Q-PCR using specific 
primers for S15 expression was used to normalise the amount of cDNA used for hTERT 
splice variant PCR which was then quantified on the Agilent Bioanalyser. A, Total 
amounts of splice variant expression were totalled and plotted and show expression levels 
of hTERT in 5 normal and 4 CML CD34+ hHSCs samples. Means and errors are 
established from triplication of the Q-PCR reaction within Q-PCR for each sample. B, 
Un-normalised splice variant expression of hTERT showing the main splice variants. For 
each sample, each splice variant (WT, a, ß and aß) is expressed as a percentage of the 
samples total hTERT splice variant expression level. 
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Figure 5.8 Repressive Modifications at the hTERT Promoter in Normal and CML CD34+ 
hHSCs 
Levels of A Di- and tri-methylated K9 H3 from 5 normal and 4 CML CD34+ hHSCs and 
B di- and tri-methylated K20 H4 from 4 normal and 4 CML CD34+ hHSCs present at the 
hTERT promoter detected by Q-PCR using primers which detect the hTERT core promoter 
sequence, from products of chromatin immunoprecipitation assays. Results are expressed 
as the total IP amount for both the antibodies and are expressed as a percentage of an Input 
sample, which is a 20% fraction of chromatin utilised for each IP experiment, and so 
normalises the data. Each IP is also corrected for a control IP experiment, done in parallel 
with other IP's, in which no antibody was added to control for any background. Means 
and standard errors are from triplication within the Q-PCR reactions for each sample. 
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Figure 5.9 Permissive Modifications at the hTERT Promoter in Normal and CIVIL CD34+ 
hHSCs 
113 
Levels of A Di- and Tri-methylated K4 H3 and B Acetylated H3 and H4 for 5 normal and 
4 CML CD34+ hHSCs present at the hTERT promoter detected by Q-PCR using primers 
which detect the hTERT core promoter sequence, from products of chromatin 
immunoprecipitation assays. Results are expressed as the total IP amount for both the 
antibodies and are expressed as a percentage of an Input sample, which is a 20% fraction 
of chromatin utilised for each IP experiment, and so normalises the data. Each IP is also 
corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background. Means and standard errors are from 
triplication within the Q-PCR reactions for each sample. 
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Figure 5.10 RNA Pol II Tracking at hTERT in Normal and CML CD34+ hHSCs 
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Q-PCR results of the ChIP for RNA Pol II detected by Q-PCR using primers which detect 
the hTERT core promoter sequence and Exon 12 of hTERT in 4 normal and 4 CML 
CD34+ hHSCs. Results are expressed as a percentage of a 10% Input sample, with the 
Input fraction being a 20% fraction of chromatin utilised for each IP experiment, and so 
normalises the data. Each IP is also corrected for a control IP experiment, done in parallel 
with other IP's, in which no antibody was added to control for any background. Means and 
standard errors are from triplication within the Q-PCR reactions for each sample. 
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5.2.4 hTR Expression, Chromatin Remodelling and Basal 
Transcriptional Machinery Dynamics at the hTR Promoter in 
CD34+ hHSCs 
As for hTERT, hTR expression, as normalised to S 15 expression, was studied in relation to 
the chromatin environment of the promoter. Figure 5.11 shows the hTR expression values 
for five normal and four CML CD34+ hHSC samples are decreased in the CML samples as 
compared to the normal samples. As for hTERT, the chromatin environment surrounding 
the hTR gene promoter was then investigated by ChIP assays. Methylation of K9 H3 was 
studied (Figure 5.12 A) and showed little change in levels between the normal and CML 
samples, however Figure 5.12 B indicates that overall methylation of K20 H4 is decreased 
in the CML samples. Figure 5.13A indicates that levels of K4 H4 methylation are very 
similar between normal and CML samples while Figure 5.13B shows that overall histone 
acetylation is increased in the CML samples. 
RNA polymerase II occupancy of the hTR promoter was also studied (Figure 5.14) and 
showed that occupancy at the promoter did not differ greatly between the normal and CML 
samples. Overall, a decrease in methylation of K20 H4 and an increase in acetylation of 
H3 and H4 are observed. 
5.3 Discussion 
These findings give essential information about the regulation of the endogenous 
telomerase genes in normal and cancer stem cells. Understanding telomerase gene 
regulation in the context of the chromatin environment of the promoters in the hMSC and 
hHSC, and similar cell types, is of importance as differences in regulation may reflect 
distinct regulatory pathways for telomerase gene expression in these cell types, which need 
not be the same as in normal and cancer cell lines (Anderson et al., 2006) and may also 
highlight differences in telomerase gene regulation between different populations of stem 
cells. 
This study shows that hTERT expression is repressed in the hMSC and that the mode of 
repression is chromatin based. Upon TSA treatment of hMSCs, hTERT becomes re- 
expressed concomitant with an increase in promoter histone acetylation. Beside hTERT 
expression, hTR expression is also increased upon TSA treatment although large changes 
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Figure 5.11 Expression of hTR in Normal and CML CD34+ hHSCs 
RNA was extracted from each sample and cDNA was synthesised from 5 normal and 4 
CML CD34+ hHSCs. Q-PCR using specific primers for S15 expression and used to 
normalise data established for hTR expression, using hTR specific primers in Q-PCR, 
established using the same amount of cDNA. Therefore, levels of hTR are expressed as 
being relative to S15 expression. Means and standard errors are from triplication within 
the Q-PCR reactions for each sample. 
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Figure 5.12 Repressive Modifications at the hTR Promoter in Normal and CIVIL CD34+ 
hHSCs 
117 
Levels of A Di- and tri-methylated K9 H3 from 5 normal and 4 CML CD34+ hHSCs and 
B di- and tri-methylated K20 H4 from 4 normal and 4 CML CD34+ hHSCs present at the 
hTR promoter detected by Q-PCR using primers which detect the hTR core promoter 
sequence, from products of chromatin immunoprecipitation assays. Results are expressed 
as the total IP amount for both the antibodies and are expressed as a percentage of an Input 
sample, which is a 20% fraction of chromatin utilised for each IP experiment, and so 
normalises the data. Each IP is also corrected for a control IP experiment, done in parallel 
with other IP's, in which no antibody was added to control for any background. Means 
and standard errors are from triplication within the Q-PCR reactions for each sample. 
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Figure 5.13 Permissive Modifications at the hTR Promoter in Normal and CIVIL CD34+ 
hHSCs 
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Levels of A Di- and Tri-methylated K4 H3 and B Acetylated H3 and H4 for 5 normal and 
4 CML CD34+ hHSCs present at the hTR promoter detected by Q-PCR using primers 
which detect the hTR core promoter sequence, from products of chromatin 
immunoprecipitation assays. Results are expressed as the total IP amount for both the 
antibodies and are expressed as a percentage of an Input sample, which is a 20% fraction 
of chromatin utilised for each IP experiment, and so normalises the data. Each IP is also 
corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background. Means and standard errors are from 
triplication within the Q-PCR reactions for each sample. 
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Figure 5.14 RNA Pol II occupancy of the hTR Promoter Normal and CML CD34+ hHSCs 
Q-PCR results of the ChIP for RNA Pol II detected by Q-PCR using primers which detect 
the hTR core promoter sequence in 4 normal and 4 CML CD34+ hHSCs. Results are 
expressed as a percentage of a 10% Input sample, with the Input fraction being a 20% 
fraction of chromatin utilised for each IP experiment, and so normalises the data. Each IP 
is also corrected for a control IP experiment, done in parallel with other IP's, in which no 
antibody was added to control for any background. Means and standard errors are from 
triplication within the Q-PCR reactions for each sample. 
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in histone acetylation are not apparent. This suggests that chromatin and epigenetic 
mechanisms are involved in telomerase gene regulation in the hMSC and it has been 
previously suggested that dysregulation of epigenetic mechanisms in this stem cell type 
could alter the cells neoplastic potential (Serakinci et al., 2004). Therefore, dysregulation 
of chromatin modifications in the hMSC could lead to the accumulation of neoplastic 
changes leading to neoplastic transformation. The chromatin based repression of hTERT 
transcription and hence repression of telomerase activity may act as a tumour suppressor 
mechanism, whereby hMSCs would have a limited lifespan and cannot divide long enough 
to accumulate neoplastic changes and become tumourigenic (Serakinci et al., 2004). 
Basal transcription machinery dynamics were also changed upon TSA treatment as when 
studying the hTERT gene we find an increased level of RNA polymerase II at Exon 12 
after treatment with TSA. As previously discussed the association of RNA polymerase II 
with gene coding regions has been shown to coincide with active gene transcription 
(Sandoval et al., 2004; Zhang et al., 2003b). Also apparent is a significant level of RNA 
polymerase II at the promoter sequence before treatment with TSA when hTERT is 
repressed, indicating that RNA polymerase II is bound at the hTERT promoter even when 
the chromatin environment seems to be heterochromatic. 
RNA polymerase II binding to silenced chromatin has been demonstrated before (Sekinger 
and Gross, 2001) and so RNA polymerase II binding to the hTERT promoter in the hMSC 
may indicate that the hTERT gene may be permissive for transcription, only needing 
changes in the chromatin environment of the promoter to allow transcription (Figure 5.15). 
The apparent decrease in RNA polymerase II binding at the promoter and the large 
increase at exon 12 can be accounted for by increased RNA polymerase II tracking along 
the gene, being no longer paused at the promoter. Differences in RNA polymerase II 
dynamics between hTR and hTERT may reflect the different regulation of each of these 
genes. Overall it is proposed that modulation of the chromatin environment of promoter 
sequences may drive changes in the dynamics of the basal transcription machinery and 
further suggests that complex interactions between transcriptional complexes and 
chromatin may be important in mediating transcriptional activity. 
While TSA treatment does lead to an increase in hTERT and hTR expression, when 
compared to the telomerase positive MCF7 breast carcinoma cell line (Figure 5.1), hTERT 
expression in the hMSC treated with TSA is very low and it has been observed that these 
cells display no detectable telomerase activity as measured by TRAP (Data not included). 
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Figure 5.15 Chromatin and Basal Transcriptional Machinery Dynamics in hMSCs 
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As shown in this diagram, changes in the chromatin environment of promoter sequences 
may lead to changes in gene transcription through the relaxation of the chromatin 
environment. 
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This observation indicates that while modulation of the chromatin environment by TSA is 
important in the control of hTERT and hTR expression, this action alone is not enough to 
increase levels of hTERT and hTR expression to a level high enough to reconstitute 
telomerase activity, perhaps due to the lack of other factors which can influence gene 
expression. The gain in permissive modifications at the hTERT promoter could allow the 
binding of transcription factors, basal transcription machinery and further chromatin 
modifying enzymes to the promoter DNA. However, if such factors are not freely 
available within the cell, the relaxation of the chromatin environment alone will not be 
sufficient to mediate high levels of transcription. Analysis of the binding of regulatory 
factors influencing hTERT and hTR expression in the hMSC will therefore be an important 
next step in understanding telomerase gene regulation. 
Further analysis of histone modifications involved in telomerase gene repression in the 
hMSC may also allow the identification of enzymes and co-regulators involved, which can 
then be targeted to allow a more specific method of modulating telomerase gene 
expression other than TSA. Although TSA treatment has been shown to cause chromatin 
changes at the hTERT and hTR promoter, and studies have shown seemingly direct actions 
of TSA on the hTERT promoter (Mukhopadhyay et al., 2005; Hou et al., 2002; Cong and 
Bacchetti, 2000; Takakura et al., 2001), indirect effects cannot be ignored. However, the 
use of TSA does allow us to observe that changes in the chromatin environment, be they 
direct or indirect, can lead to changes in telomerase gene expression. 
Overall, these data provides an impetus for further, more detailed analysis of the interplay 
between the chromatin environment, general transcription machinery and other important 
regulatory factors which may affect telomerase gene expression in the hMSC and has 
implications for tissue regeneration and studies in cancer stem cells. 
Understanding how gene expression changes in the hHSC upon acquisition of the BCR- 
ABL oncogene will lead to greater understanding of the disease and how it can possibly be 
treated. Several studies have been undertaken to understand gene expression changes 
involved in CML (Ohmine et al., 2001; Nowicki et al., 2003; Salesse and Verfaillie, 2003; 
Kronenwett et al., 2005; Kaneta et al., 2003; Hakansson et al., 2004) and it has been 
shown that genes deregulated in CML are important in the regulation of the chromatin 
environment (Nowicki et al., 2003). Therefore, dysregulation of the expression of 
proteins controlling epigenetic mechanisms have a role in controlling gene expression 
profiles in CML vs. normal CD34+ hHSCs. Also important is the expression of the 
telomerase genes in relation to disease progress in CML and how this expression is 
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regulated. Normal and CML CD34+ hHSCs give us an opportunity to study the 
epigenetic regulation of expression of hTR and hTERT and therefore how epigenetic 
dysregulation could impact on disease progression. 
Telomerase gene expression has been shown to become dysregulated in CP CML and so 
gives us an excellent system in which to dissect modes of telomerase gene regulation in a 
stem cell population (Drummond et al., 2005; Campbell et al., 2006). This study 
demonstrated that total hTERT expression decreased in the CML samples compared to the 
Normal samples, contradictory to some previous data (Drummond et al., 2005) but in 
agreement with the another (Campbell et al., 2006) and so the reduction in telomere length 
could be due to the decrease in hTERT expression observed. However changes in splicing 
favouring the full length hTERT transcript are observed in the CML samples agreeing with 
both previous studies (Drummond et al., 2005; Campbell et al., 2006). 
The ChIP data presented here initially suggests the formation of a more repressive 
chromatin environment at the hTERT promoter in the CML samples as there is an increase 
in methylation of K9 H3. However an increase in acetylated H3 and H4 and a decrease in 
dimethylation of K20 H4 were also observed in the CML samples and would generally 
correlate with a more permissive chromatin environment and would correlate with 
enhanced hTERT expression. Changes in hTERT splice variant expression are observed 
in the CML samples and contributions of the chromatin environment to alternate splicing 
have been shown before and therefore may be influencing hTERT splice variant 
expression. Use of TSA, which enhances histone hyperacetylation, has been shown to 
lead to the skipping of alternate exons, and this was suggested to be due to the facilitation 
of the passage of RNA polymerase II across the transcribed region of the gene (Nogues et 
al., 2002). The human STAGA complex contains the histone acetyltransferase GCN5 and 
studies have suggested cellular roles of STAGA in transcription-coupled processes through 
direct interactions transcriptional activators and with components of the splicing and DNA 
repair machineries (Martinez et al., 2001). 
A recent study has also shown that the ATP-dependent chromatin remodeller Brm also has 
a role in regulating splice variant transcription, although its catalytic activity was shown to 
be dispensable for this role (Batsche et al., 2006). The hTERT promoter has also been 
shown to be relatively weak in terms of transcriptional activity (Bilsland et al., 2003; 
Plumb et al., 2001) and therefore the formation of a more permissive chromatin 
environment may allow more efficient splicing perhaps by increased association of the 
transcriptional machinery to the hTERT promoter. RNA polymerase II analysis shows an 
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increase in tracking in the CML samples, suggesting that changes in the chromatin 
environment may be sufficient to alter RNA polymerase II dynamics, which can in turn 
alter splicing events and may also allow the promoter to be more permissive to binding of 
factors which may influence hTERT gene splicing. Therefore, changes in the chromatin 
environment of the coding sequence of the genes may be able to influence splice variant 
expression and therefore further detailed analysis of chromatin modifications covering the 
hTERT coding sequence may uncover any roles that the chromatin environment has to 
play in the regulation of hTERT splice variant expression. 
hTR expression was observed to decrease in the CML samples in agreement with a 
previous study (Drummond et al., 2005). ChIP analysis showed a decrease in methylated 
K20 H4, but also showed an increase in acetylated H3 and H4 in the CML CD34+ hHSCs. 
With a decrease in expression one would perhaps expect a more repressive chromatin 
environment to be present at the hTR promoter, not as it seems a more permissive 
environment, as observed with the increase of histone acetylation and decrease in 
repressive histone methylation at the promoter. In this case, hTR expression may be 
regulated by different means or other important modifications of the chromatin 
environment not encompassed by this study may be linked to transcription. DNA 
methylation has been shown to be important in the regulation of hTR expression in some 
cell types and may have some influence here (Hoare et al., 2001). However, the data 
does suggest that further studies may be fruitful in further uncovering the role of the 
chromatin environment in hTR gene regulation in CML. Therefore the reduction in hTR 
expression observed could lead to the telomere loss observed in CML. 
Interestingly, acetylation of H3 and H4 was upregulated for both hTR and hTERT in the 
CML CD34+ hHSCs. This is consistent with gene expression analysis of BCR-ABL- 
dependent leukaemogenesis in which it was observed that the histone acetyltransferases 
HATI and TRRAP were overexpressed in CML cells (Nowicki et al., 2003). It was noted 
that the profiling studies in which samples from CML patients and normal donors were 
compared, a novel phenotype was uncovered. Many genes upregulated in CML were 
observed to play a role in modification of chromosomes/chromatin/DNA dynamics. 
Transcriptional regulators such as MYC, which are known to be able to interact with 
histone modifying enzymes, are also upregulated. 
Of note, is a study which has shown that inhibition of BCR-ABL signal transduction by 
the use of the tyrosine kinase inhibitor Imatinib mesylate (IM) (Uziel et al., 2005) can 
cause inhibition of telomerase activity and cell proliferation in various malignant cell lines. 
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Inhibition of telomerase activity was observed to be mainly by post-translational 
modifications by the dephosphorylation of AKT but the early downregulation of hTERT 
transcription was also implicated. Changes in histone modification were not studied, but 
investigating the chromatin environment of the hTERT promoter and globally before and 
after treatment of CML BCR-ABL CD34+ hHSCs with IM would be of interest. Also, 
antisense inhibition of BCR-ABL/c-ABL has been shown to lead to the enhancement of 
hTERT levels in human leukaemic cells (Bakalova et al., 2004). 
Interestingly, a recent study has shown an important role for BCR-ABL in H4 acetylation 
(Brusa et al., 2006). BCR/ABL was shown to be associated with H4 hyperacetylation 
which was decreased upon treatment with IM and conversely, trimethylation of K20 H4 
was decreased in the presence of BCR-ABL and increased upon treatment with IM. This 
agrees with data shown here, as for hTR and hTERT, H4 acetylation was increased while a 
decrease in levels of dimethylation of K20 H4, rather than tri-methylation of K20 H4 was 
observed. Loss of methylation of K20 H4 has been observed in cancer (Fraga et al., 2005) 
alongside the loss of acetylated K16 H4 and although we do see increases in H4 
acetylation, it is conceivable that we do lose K16 H4 acetylation, and overall acetylation 
may be increased by increased acetylation at other residues within the histone tail. The 
interaction of pRB with K20 H4 histone methyltransferases has also been noted (Gonzalo 
et al., 2005) which can lead to the formation of heterochromatin observed in senescing 
cells. pRB has been shown to be phosphorylated by BCR-ABL which could lead to the 
loss of interactions with K20 H4 methyltransferases (Nagano et al., 2006) and therefore 
may be a mechanism by which we see the reduction of K20 H4 methylation noted in the 
CML samples. 
Overall, this study of normal and CML CD34+ hHSCs show that a reduction in hTERT 
and hTR expression could lead to reductions in telomerase expression in CP CML in 
CD34+ hHSCs leading to telomere shortening and that the chromatin environment of the 
hTR and hTERT genes may have a role in the differential regulation of the telomerase 
genes in CML. 
Overall, it has been shown that the chromatin environment has an important role on the 
regulation of the telomerase gene promoters in these two stem cell populations. Further 
more detailed studies would be of interest and but these studies do provide an excellent 
platform from which more detailed studies can now be started. 
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6 Summary and Conclusions 
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A common set of features distinguish cancer cells from their normal counterparts and 
includes the loss of cell cycle regulation, loss of control over invasion and metastasis, 
failure of apoptotic mechanisms and bypass of senescence (Keith et al., 2002; Hahn and 
Weinberg, 2002). Cellular models designed to recapitulate the features of multistage 
neoplastic progression have been developed by a number of groups and epitomised by the 
work from the Weinberg lab (Hahn and Weinberg, 2002). A common element of these 
models is to use ectopic expression of the hTERT gene to induce telomerase activity and to 
overcome senescence and thus provide the immortalisation step of cancer progression. 
However, whilst this model for neoplastic transformation may be of considerable use in 
defining a number of the key events in progression, by ectopically expressing hTERT, the 
molecular events required to upregulate hTERT in cancer development are inevitably 
missed. Further, the role of hTR in telomerase activity and senescence and 
tumourigenesis is often overlooked. Therefore, given the critical role that telomerase has 
in tumour progression and with the cancer cell reliant on telomerase for its survival, 
understanding that the mechanisms regulating telomerase gene expression could be of 
great interest (Keith et al., 2002). Further, it has also been proposed that epigenetic 
changes have a role to play in the transition of a cell through senescence and towards 
neoplasia through altering the expression of genes important in overcoming senescence 
and promoting neoplasia. 
For the first time, the chromatin environment of the hTR and hTERT gene promoters in 
multiple cell lines; telomerase positive tumour, ALT, normal, and in stem cell populations, 
both normal and cancer stem cells, was extensively evaluated. The use of multiple models 
allowed commonalities in telomerase gene regulation to be apparent. The wide range of 
histone modifications studied also makes this study unique in its scope, by trying to 
understand fully the contributions that multiple modifications, both acetylation and 
methylation, can have on transcriptional regulation. 
The first part of the study, utilising normal, telomerase positive cancer and telomerase 
negative ALT cells provided an excellent cellular system in which to study the epigenetic 
regulation of telomerase gene expression and also allowed us to understand how 
epigenetics may impact on the mechanisms utilised to maintain/elongate telomeres. A cell 
has two routes it can utilise to gain immortality and move towards neoplasia, reactivation 
Stuart P. Atkinson, 2006 Chapter 6 
Figure 6.1 Telomere Maintenance Mechanisms and the Routes to Neoplasia 
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Cells can utilise two "on-ramps" towards immortality; either telomerase activity or the 
ALT mechanism. These routes lead to telomere elongation/maintenance and lead to the 
bypass of the "exit route" of senescence, and can eventually lead to neoplasia. 
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or upregulation of telomerase activity or ALT (Figure 6.1). However, why some cells 
utilise the ALT pathway while others reactivate telomerase is not fully understood, but this 
study illustrates that the chromatin environment of the telomerase gene promoters may 
influence this choice. This study has shown that telomerase reactivation may occur by 
chromatin remodelling allowing a more permissive state of transcription to occur at the 
hTR and hTERT promoters, therefore enhancing the transcription of the telomerase genes. 
Also this study has also shown that the ALT phenotype may arise due to the tight 
repression of the hTR and/or hTERT promoter caused by chromatin remodelling of the 
promoter sequences, leading to the tight repression of the telomerase genes. Therefore, 
chromatin remodelling events which cause increased levels of repressive modifications to 
concentrate at promoter sequences may "force" a cell to utilise the ALT telomere 
maintenance mechanism other than that of telomerase activity, due to the inability of the 
cell to re-express either hTR or hTERT (Figure 6.2). Further, chromatin remodelling 
events which cause the accumulation of permissive modifications led to reactivation or 
increased levels of telomerase gene expression. Thus, chromatin remodelling is central to 
telomerase gene regulation and may determine the "road" taken to achieve telomere- 
dependent cellular immortality (Figure 6.1). This mode of regulating which telomere 
maintenance mechanism is used has not been previously described. 
This study also has uncovered a novel association of methylated K20 H4 with ALT, and 
may represent a new marker for the ALT phenotype alongside telomere length analysis and 
ALT-associated PML Body (APB) presence. Recent studies have begun to unravel a role 
of methylated K20 H4 in cancer and aging (Fraga et al., 2005; Sarg et al., 2002) and 
further studies aimed at resolving the role of this modification in the ALT phenotype 
would be of great interest. The clarification of the role of methylated K20 H4 in ALT 
may also provide a novel therapeutic target, which could be used along side telomerase- 
targeted therapeutics in cancer treatment. ALT occurs in a small but clinically relevant 
percentage of all tumours overall and can be the prevalent telomere maintenance 
mechanism in some mesenchymal tumours so the ability to somehow target or even to 
better understand the molecular mechanism inherent in these ALT cells would be an 
attractive proposition. 
The next part of the study utilised hMSC and hHSC stem cell populations, allowing 
different models to study epigenetic regulation of the telomerase gene promoters and 
further allowing the study of normal and cancer stem cells. Moving these studies from 
normal and tumour cell lines into stem cells was an important step in order to fully 
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Figure 6.2 How Chromatin Modifications May Influence Telomere Maintenance Mechanisms 
Telomerase gene expression is linked to the accumulation of permissive histone 
modifications, which could lead to telomerase expression and the elongation/maintenance 
of telomere length. However, heavy repression of the telomerase gene promoters by the 
accumulation of repressive histone modifications could lead to the utilisation of the ALT 
phenotype for telomere elongation/maintenance due to the repression of telomerase 
activity. 
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understanding telomerase regulation. Epigenetic regulatory mechanisms of telomerase 
gene expression/repression may be different in stem cell populations as compared to the 
normal and tumour cell lines. The studies in the hMSC showed similarities to the studies 
in the normal, telomerase positive cancer and telomerase negative ALT cells, but also 
showed some interesting differences which may entail different regulatory mechanisms. 
hTERT expression in the hMSC upon chromatin remodelling has also allowed a link to be 
made between modulation of the chromatin environment in stem cells to neoplasia, a 
hypothesis backed recently in a recent review (Feinberg et al., 2006). Further, the 
comparisons made between normal and CML CD34+ hHSCs provide an excellent platform 
for further studies into epigenetic regulation of the telomerase genes in this cell type, and 
the role epigenetics has in disease evolution. 
Overall, the conclusions can be summarised; 
" Covalent modifications of histones are linked to the control of telomerase gene 
expression in normal, ALT and tumour cell lines 
o The chromatin environment of the telomerase gene promoters may 
mediate which telomere maintenance mechanism is utilised in telomerase 
positive tumour cells and telomerase negative ALT tumour cells 
o Methylation of Lysine 20 H4 may be a novel marker for the ALT 
phenotype and may represent a new therapeutic target 
" Modulation of the chromatin environment can affect basal transcription 
machinery dynamics at the telomerase genes 
" Epigenetic regulation is a common regulatory feature mediating hTR and hTERT 
expression/repression 
" Covalent modifications of histones are linked to the control of telomerase gene 
expression in stem cells and cancer stem cells 
o Epigenetic dysregulation of normal stem cells may lead to the emergence 
of cancer stem cells 
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o Chromatin mediated telomerase gene regulation may be a common 
regulatory mechanism in multiple different cell types 
Overall, this study has provided an excellent platform towards understanding the global 
effect that the chromatin environment has on gene expression in the bypass of senescence 
and tumourigenesis. This study also raises several questions; 
" What enzymes catalyse the addition/removal of histone modifications important in 
the epigenetic regulation of telomerase gene regulation? 
" What pathways are utilised in order to control these enzymes? 
" Are these enzymes and pathways conserved between cell types? 
" Are other genes important for senescence and tumourigenesis also similarly 
regulated by the chromatin environment of their promoters? 
" If so, what are these genes and what cellular roles do they play? 
These are interesting questions which will need to be answered in the future to fully 
understand telomerase gene regulation and other genes important in tumourigenesis. The 
use of genome wide ChIP techniques such as GMAT (Genome Mapping Technique) or 
ChIP-on-Chip could allow us to answer some of these questions by incorporating the ideals 
of this study into a more wide-ranging mode to allow the study of groups of genes 
regulated in a similar manner upon bypass of senescence and immortalisation. The 
GMAT process allows us to use the ChIP technique to understand the genome wide spread 
of a chromatin modification or patterns of modifications allowing for an unbiased approach 
to understanding how gene regulation is controlled by modulations of the chromatin 
environment. Linking data such as this to gene expression analysis such as SAGE (serial 
analysis of gene expression) would allow an excellent comparison between gene 
expression and gene promoter chromatin landscape on a genome wide scale 
Although regulation of the chromatin environment of the telomerase gene promoters has 
been shown to be important in the control of expression, it is noted that this is but one layer 
of complexity. Further studies will be required in order to identify the proteins involved 
in lysine methylation (Figure 6.3) and histone acetylation/deacetylation (Figure 6.4), which 
impact on the epigenetic control of hTR and hTERT gene regulation. Understanding the 
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enzymes and complexes which orchestrate chromatin modifications, both locally and 
globally, will be the next target in such studies. Such studies may allow identification of 
new regulatory pathways, provide therapeutic drug targets and allow further understanding 
of the processes controlling telomerase gene expression in normal development and 
tumourigenesis. Studies intent on unravelling regulatory pathways have already started to 
uncover some interesting regulatory mechanisms (Bilsland et al., 2006; Ge et al., 2006) 
while specific targeting by chromatin remodelling enzymes to the hTR and hTERT 
promoters to allow a level of transcriptional control is also an exciting prospect. 
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Figure 6.3 Enzymes which Mediate Lysine Methylation and Demethylation 
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A Enzymes which mediate Lysine 20 H4 methylation and possible other interactions. 
Interaction of the yeast protein Crb2 with Lysine 20 H4 methylation is also noted. B 
Enzymes which mediate Lysine 9 H3 methylation and possible other interactions. C 
Enzymes which mediate Lysine 4 H3 methylation and possible other interactions. 
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Figure 6.4 Mammalian Enzymes which Mediate Histone Acetylation and Deacetylation 
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Depictions of the different families and different enzymes contained within these families 
of histone acetyltransferases and HDACS. 
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Lack of Telomerase Gene Expression in Alternative Lengthening 
of Telomere Cells Is Associated with Chromatin Remodeling 
of the hTR and hTERT Gene Promoters 
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Abstract 
The presence of active telomere maintenance mechanisms in 
immortal cells allows the bypass of senescence by maintaining 
telomere length. In most immortal cell lines and tumors, 
telomere maintenance is attributable to telomerase reactiva- 
tion. However, a number of immortal cell lines and tumors 
can achieve telomere maintenance in the absence of detect- 
able telomerase activity by the alternative lengthening of 
telomere (ALT) mechanism. Epigenetic mechanisms have been 
Implicated in the regulation of telomerase expression. We 
show that specific modifications within the chromatin 
environment of the hTR and hTERT promoters correlate with 
expression of hTR and hTERT in ALT. normal and telomerase- 
positive tumor cell lines. Lack of expression of hTR and hTERT 
in ALT cell lines is associated with histone H3 and H4 
hypoacetylation and methylation of Lys9 histone H3. Con- 
versely, hTR and hTERT expression in telomerase-positive cell 
lines is associated with hyperacetylation of H3 and H4 and 
methylation of Lys4 H3. Methylation of Lys" H4 was not linked 
to gene expression but instead was specific to the hTR and 
hTERT promoters of ALT cells. This may provide an insight 
into the differences between ALT and telomerase-positive cells 
as well as a novel marker for the ALT phenotype. Treatment of 
normal and ALT cells with 5-azadeoxycytidine in combination 
with Trichostatin A caused chromatin remodeling of both 
promoters and reactivation of hTR and hTERT expression in 
ALT and normal cell lines. This data establishes a definite link 
between the chromatin environment of the telomerase gene 
promoters and transcriptional activity. (Cancer Res 2005; 
65(17): 7585-90) 
Introduction 
In most cancer cell lines and tumors, telomere maintenance is 
achieved by the reactivation of telomerase (1). However, some 
cancer cell lines and tumors can maintain their telomeres in the 
absence of telomerase by the alternative lengthening of telomere 
(ALT) mechanism (2). but it is unclear why some cells use the 
ALT pathway whereas other cells reactivate telomerase. ALT lines 
represent an interesting model for telomerase gene regulation as 
some express hTR but not hTERT and others lack expression of 
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both components. hTR and hTERT gene expression is regulated 
on many levels during development and tumorigenesis and 
evidence suggests that epigenetic mechanisms may also be 
involved. We have previously shown that CpG methylation at 
the promoter of hTR in ALT cell lines is associated with gene 
repression (3), whereas other groups have linked CpG methylation 
with transcriptional status of the hTERT promoter, although the 
correlation is not clear (4,5). The influence of DNA methylation 
of gene expression suggests that histone modification may also 
regulate telomerase gene expression and previous studies have 
provided links between transcription factor binding and chroma- 
tin remodeling leading to changes in hTERT gene expression (6), 
although these studies have analyzed a limited number of 
modifications in the hTERT promoter alone. The histone code 
hypothesis (7) proposes that it is through the combination of 
several histone modifications that gene expression can be altered. 
Thus, to investigate how the chromatin environment might 
influence telomerase gene expression and how this may influence 
the mechanism of telomere maintenance in different cell types, 
we studied histone acetylation (histones H3 and H4 and Lys9 
histone H3) and histone methylation (Lys4 and Lys) H3 and 
Lys2' H4) at the hTR and hTERT promoters in tumor, normal, and 
ALT cell lines. 
Materials and Methods 
Cell lines. Cell lines used were C33a (cervical carcinoma); A2780 
(ovarian adenocarcinoma); 5637 (bladder carcinoma); WI38 (normal fetal 
lung fibroblast) and SUSM-1, SKLU, GM847, KMST-6, and W138-SV40 
(all ALT). 
Chromatin immunoprecipitatlon assays. Cells were used when at 70% 
to 80% confluence and chromatin immunoprecipitation (ChIP) assays were 
done following the instructions recommended by the kit supplier (Upstate 
Biotechnology. Dundee, United Kingdom). Sonication was optimized to give 
chromatin fragments of around 500 bp to 1 kb in length (8 x 10-second 
pulses at 5 pm with 20-second rest between each pulse on ice using an MSE 
Soniprep150 sonifier). Resultant DNA from each immunoprecipitate was 
purified using the QlAquick PCR Purification Kit (Qiagen. West Sussex. 
United Kingdom). Also included in each experiment was a no antibody 
control immunoprecipitate to detect any background, which if present was 
subtracted from each immunoprecipitate within that experiment. 
Antibodies. Antibodies used are the following: TriMeK4 H3. DiMeK9 H3, 
and TriMeK9 H3 (all Abcam, Cambridge. United Kingdom); DiMeK4 H3, 
DiMeK20 H4, TriMeK20 H4, AcH3, AcH4. and AcK9 H3 (all Upstate 
Biotechnology). 
Quantitative PCR. Products from the ChIP assay were quantified by 
quantitative PCR on an Opticon2 DNA Engine (MJ Research. Inc Waltham. 
MA) using primers to hTR and hTERT core promoter sequences and the 
SYBR Green Q-PCR Buffer (Finnzymes, Espoo. Finland). hTR primers. 29SF 
5'-CCCGCCCGAGAGAGTGAC-3' and 5ALTR 5'-AAGTCAGCGAGAAAAA- 
CAGC and hTERT primers, TERTSF 5'-TCCCCT TCACGTCCGGCATT-3' 
and TERTSR 5'-AGCGGAGAGAGGTCGAATCG-3'. 
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Expressbn aaulyala hTR ezpresaion was analyzed by quantitative 
PCR using the following primers TRC3F. S-CI'AA000TAACTGAGA- 
AGGGCGTA"3' and TRC3R. 5'-GGCGAACGGGCCAGCAGCTGACATT3' 
and adjusted to glyceraldehyde-3-phosphate dehvdrogenase (GAPDH) 
expression (primers GAPDHO. 45F 5-ACCACAGTCCATGCCATCAC-3' and 
GAPDHO. 4SR 5-CCACCACCCTGTFGC7'GTA-3'). hTERT expression was 
analyzed by methods outlined in Keith et aL (8) using primers which 
detect all splice variants (pnmees HT3026F 5-000 FGAGCTGTAC t rCT- 
CAA-3' and HT2482R 5-GCCAAACAGC TGTTCCCCATGTC-3'). hTERT 
expression is displayed ss total amounts of all four main splice variants 
(wild type. ndeletion. l%-deletion, and nj%deletion). 
Tridiostatln A astd S-azadeoxycytidim te- - at. Cells were treated 
twice for 24 hours with S-aaadeoxycytidine (5-azadC. Sigma Dorset. United 
Kingdom) to a final concentrations of 2S Mmoi/l, and treated for 16 hours 
with Trichodatin A (TSA. Update Biotechnology) at a final concentration of 
350 nmol/L 
Results 
Profile of repressive histone lysine methylatlon states at the 
hTR promoter. To understand the relationship between expres- 
sion levels of hTR and chromatin remodeling at the promoter, we 
first examined hTR gene expression levels from each cell line. In 
Fig. IA, we see that hTR is expressed in GM847.5637, A2780. SKLU, 
C33a. and W138, whereas expression levels were negligible in 
SUSM-1. KMST-6, and WI38-SV40. 
To examine the relationship between expression and histone 
modifications. ChIP assays using antibodies against specific histone 
modifications were used to generate a profile of the chromatin 
environment surrounding the hTR promoter in each cell line. 
Methylation of Lys9 histone H3 (MeK9 H3) facilitates the 
formation of heterochromatin (9,10), and elevated levels of 
Figure I. A. hTR expression analysis of 
cell lines used normalized to GAPDH 
expression. ChIP analysis of the hTR 
promoter was completed using antibodies 
against (B) Di-MeK9 and Tn-MeK9 H3, (C) 
Di-MeK20 and Tn-MeK20 H4, (D) AcH3 
and AcH4, (E) AcK9 H3, and (F) Di-MeK4 
and Tn-MeK4 H3. Each immunoprecipitate 
was quantified in triplicate by quantitative 
PCR analysis and related back to an input 
sample in each experiment to normalize 
the data. 
Canoes Res 2006; 66: (17). 8splsmbw 1.2006 7586 www. amcrjoumals. org 
Chromatin and Telomerase Gene Expression 
50 
40 ý 
"Ö 
O 
Flptw. 2. A. hTERT axp. saan rWyw 
of c. a Yn. s u. W norrtrYZ. a b ßAPOº+ 
urpr. snon. ChIP anWytw at wo hTERT 
promolsr was oonpl. Nd usag s*Mibodi. s 
aqanp (B) Dr-M. K9 and Tn-M. K9 H3. (C) 
DNd. K20 and Tn-M. K20 HA, (D) Adi3 
and Adi4, (E) AdC9 H3. and (F) Da-k"4 
and Tn-#A. K4 H3. Each nrnuwprsupRate 
was QuarWfi. O in 1rpYtate by qunmtaCr. 
PCR analyss and nwt. d badt lo an nptA 
aanpto in . ach . xp. m+. rg 10 norma#z. 
"w data 
ý 
10 ý 
hTERT TO E*mmm 
ý 
rh 
i 
N/lb 
B 
2D 
I 
I 
I 0+---T 
nhat a& rri. Neryl k8 H9 
N -rlly(0 
aYK9 H3 
oe 
C 
ý 
E6 
S 
ý 
ATERT DE t T}FYNQO F41 
,., 
I 
ý 
r, n 
Mt-0,44 
wl QY. m 
ýJ 
I 
D 
30- 
n `20ý 
1.0 20 
hTERT AcH3 & H4 
. 
1. 
Im In., 
1. 
In . ]! ý 
ýrý1ý ý1G _`1 ýý ýý, ýpý ýýýaý 
E 
ý40 
030 
w 20 
10 
Io 
rf, 
a ýý-a 
F 
ý 
Co 
030 
0 
hTERT AcKR H3 
 AcH4 
QAc1G 
iýý 'ý iii 't T "' iý 
ý, 
ý1ý1 #0 J 
hTERT DF d Tri-hletlrrl K4 Fq 
15'riNeK4 
aueu4 H3 
all 
0 
120 
s ý10 
ý 
ý, 
$ ýýýý J// 
MeK9 H3 at promoter sequences are associated with repression of 
gene expression (11.12). Figure 1B shows that MeK9 H3 is elevated 
in cells with low hTR expression (W13ß, SUSM-1. KMST46, and 
W138-SV40) when compared with cells expressing relatively high 
levels of hTR (GM847.5637. A2790. SKLU. and C33a. which were 
nearly devoid of McK9 H3, showing that increased levels of MeK9 
H3 at the hTR promoter are associated with repression of hTR gene 
expression. 
MethyWion of Lys" histone H4 (MeK20 H4) is a mark of 
constitutive and facultative heterochromatin (13), but Fig. IC 
stows that there is no clear link between MeK20 H4 and h77? 
expression. In this study. McK20 114 was only elevated in the ALT 
cell lines (GM847, SKLU. SUSM-1. KMST-6. and W138-SV40L which 
may indicate a novel role for this modification 
 
ýý 
Profile of transcriptionally permissive histone lysine mod- 
ifications at the hTR promoter. Acetylated histones H3 and H4 
(AcH3 and AcH4) are associated with euchromatin (14), and 
acetylation of promoter proximal histones is associated with gene 
expression (15,16). Figure 1D shows that high levels of AcH3 and 
AcH4 are linked to elevated levels of hTR gene expression, with 
GM847.5637. A2780, SKLU, C33a, and W138 exhibiting higher levels 
of AcH3 and AcH4 than SUSM-1, KMST-6, and W138-SV40. Higher 
levels of AcK9 H3 (Fig. IE) are also observed in cell lines with 
higher expression. 
Methylation of Lys histone H3 (MeK4 H3) is also associated with 
active gene transcription (17) and elevated levels have been 
observed at active gene promoters (18). Figure IF indicates that 
high levels of MeK4 H3 are associated with elevated hTR gene 
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expression with GM847,5637, A2780, SKLU, C33a, and W138 
exhibiting higher levels of MeK4 H3 than SUSM-1, KMST-6, and 
WI38-SV40. This data shows that increased levels of MeK4 H3, 
AcH3 and H4, and AcK9 H3 at the hTR promoter sequence 
correlate with increased levels of hTR gene expression. 
Overall. the data shows that distinct patterns of modifications 
present at the hTR promoter sequences are associated with gene 
expression (histone hyperacetylation. MeK4 H3, and lack of MeK9 
113) and gene repression (histone hypoacetylation. MeK9 H3, and 
lack of McK4 113). Interestingly, McK20 H4 seems to mark for the 
ALT phenotype rather than being linked to gene repression. 
Profile of repressive histone lysine methylation at the hTERT 
promoter. As for h TR. we first established hTERT gene expression 
levels from each cell line. As Fig. 2A shows, of the cell lines studied. 
only the tumor cell lines (C33a. A2780, and 5637) have appreciable 
levels of hTERT gene expression. Apart from the GM847 cell line, 
which expresses very low amounts of hTERT, the ALT and normal 
cell lines showed no hTERT expression. The profile of the 
chromatin environment surrounding the hTERT promoter was 
then investigated. 
MeK9 H3 is associated with gene repression and consistent with 
this the levels of MeK9 H3 were lowest in the cell lines expressing 
high levels of hTERT (C33a. A27S0, and 5637) compared with the 
normal and ALT cell lines (Fig. 2B). 
As with the hTR promoter. McK20 H4 is observed at higher 
levels at the hTERT promoter in the ALT cell tines in which only 
GM847 has any hTERT expression. In contrast normal fibroblasts 
(WI38) have levels of McK20 IN that are comparable with those 
found in hTERT-expressing tumor lines suggesting that either 
different mechanisms of repression exist in ALT and normal cells 
or that McK20 H4 has a role other than in gene repression 
(Fig. 2C). 
Profile of transcriptionally permissive histone lysine mod- 
ifications at the hTERT promoter. Acetylation of promoter 
histories 113 and 114 are generally considered to allow the gene to 
be permissive for transcription. Figure 2D and E show that the two 
tumor cell lines expressing the highest levels of hTERT (C33a and 
A2780) have the highest levels of AcH3. AcH4, and AcK9 113. 
However. 5637, which express a relatively high level of hTERT. has 
acetylation levels comparable with that of the nonexpressing cell 
lines. The ALT and normal cell lines that do not express hTERT 
(except for very low amounts in GM847) show low acetylation of 
AcH3. AcH4, and AcK9 H3. 
Although MeK4 113 is associated with active gene expression all 
the cell tines exhibited some degree of MeK4 H3 whether they 
express hTERT or not. However, apart from the KMST-6 cell line, 
McK4 H3 is higher in the hTERT-expressing tumor cell lines (C33a. 
A2780, and 5637) than in the hTERT-nonexpressing normal and 
ALT cell lines Fig. 2F. 
Thus, as with hTR, the data shows that distinct patterns of 
modifications present at the hTERT promoter sequences are 
associated with gene expression (histone hyperacetylation. MeK4 
113. and lack of MeK9 113) and gene repression (histone 
hypoacetylation and McK9 1-13). Interestingly, McK20 H4 again 
seems to mark for the ALT phenotype rather than being linked to 
gene repression. 
ßesctivathm of tebroerase gene expression by chromatin 
remodeling. As active hTR and hTERT promoters show similar 
patterns of histone modifications (high levels of AcH3. AcH4. AcK9 
Ill and McK4 113), we asked whether expression of repressed 
telomerase genes in telomerase-negative cells could be induced by 
promoting such modifications. TSA, a histone deacetylase inhibitor 
and 5-aza-dC, a DNA methylation inhibitor were used in 
combination to induce chromatin remodeling. 
Treatment of KMST-6, W138, and WI38-SV40 with TSA and 
5-azadC in combination resulted in increases in hTR gene expression 
(Fig. 3A) associated with increases in acetylation (Fig. 3B and C), apart 
from AcH3 level in KMST-6 which does not change upon treatment. 
Increases in MeK4 H3 were also associated with increases in 
expression in KMST-6 and W138, although they decreased in WI38- 
SV40 (Fig. 3D). 
hTERT expression was reactivated in KMST-6. W138, and W138- 
SV40 following treatment with TSA and 5-azadC in combination 
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Figure 4. A. hTERT oxprssnon andysrs bNors and attar treatment with TSA 
and S-azadC. ChIP analysis d the hTERT promoter was ccn tebd for (B) AcH3 
and AcH4. (C) Ad(9 H3. and (D) Dr-MN(4 and Tn-MsK4 H3. Each 
w nurwprscC ale vm gu nbhed in trpbcom by quvrMaWa PCR analyse and 
related badt to an spot s~ in sadl espermars to nornlaeze the data 
(Fig. 4A ). This increase in expression was also associated with 
increases in AcH3. Acli4 (Fig 4B), AcK9 (Fig. 4C), and MeK4 1-13 
(Fig. 4D). 
This data shows that for hTR and hTERT an increase in the 
levels of historic modification linked to gene expression at the 
promoter can cause recxpression or increases in expression. 
Discussion 
This study emphasizes the importance of the chromatin envi- 
ronment in the regulation of telomerase gene expression. Common 
chromatin patterns at promoter sequences are associated with 
10 
repression and activation of both hTR and hTERT in normal, ALT, 
and cancer cell lines, and forced chromatin remodeling of the hTR 
and hTERT promoter sequences can induce the reexpression of 
hTR and hTERT. Our results are consistent with a recent study by 
Kumakaru et al. (19) on hTERT; furthermore, the proposal that the 
chromatin-mediated regulation of expression is of importance for 
both hTR and hTERT. We have also shown that the normal cell 
line WI38 has a promoter chromatin profile which shows neither 
euchromatic nor heterochromatic hallmarks compared with the 
normal and ALT cell lines. It may be in this cell line that the lack 
of permissive modifications may be enough to repress hTERT 
transcription without needing the added effect of the repressive 
modifications. This may also be the hallmark of a short-term 
repression of hTERT expression, whereas in the ALT high levels of 
repressive methylation marks are present perhaps pointing to a 
more long-term repressive effect. This study has also uncovered 
a novel association of methylated Lys20 histone H4 with the 
ALT phenotype and may represent a new marker for the ALT 
phenotype alongside telomere length analysis and ALT-associated 
PML body presence. The role of Lys20 histone H4 methylation 
is not clear. It is associated with heterochromatin but as in 
this study is not necessarily associated with regulation of gene 
expression and it has recently been implicated in DNA damage 
response pathways (20). Further investigation of its association 
with the ALT phenotype may help to shed new 
light on the role of 
this modification. 
This study also suggests that modulation of the chromatin 
environment of the telomerase gene promoters could influence 
which telomere maintenance mechanism is used. Telomerase 
reactivation may occur by chromatin remodeling allowing a more 
permissive state of transcription to occur at the hTR and hTERT 
promoters. Conversely, the ALT phenotype may arise due to the 
tight repression of the hTR and/or hTERT promoter, caused by 
chromatin remodeling of the promoter sequences. Chromatin 
remodeling events that cause increased levels of repressive 
modifications to concentrate at promoter sequences may "force" 
a cell to use the ALT telomere maintenance mechanism rather than 
that of telomerase activity, due to the inability of the cell to 
reexpress either hTR or hTERT. Alternatively, the promoter may 
accumulate heterochromatic changes because there is no need for 
telomerase in these cells once ALT is activated. 
Further studies identifying the proteins involved in modulating 
the chromatin environment of the hTR and hTERT promoters may 
allow identification of new regulatory pathways, provide therapeu- 
tic drug targets, and allow further understanding of the processes 
controlling telomerase gene expression in normal development and 
tumorigenesis. Specific targeting by chromatin remodeling 
enzymes to the hTR and hTERT promoters to allow a level of 
transcriptional control is also an exciting prospect. 
Overall our results suggest that the modulation of the chromatin 
environment has an important role in regulating telomerase gene 
expression and may be a significant factor in the acquirement of 
the ALT phenotype by some tumor cells. 
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Transcriptional Repression of Telomerase RNA Gene 
Expression by c-Jun-NH2-Kinase and Spl/Sp3 
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Abstract 
Telonierase is essential for Immortalization of most human 
cancer cells. Expression of the core telomerase RNA (hTR) and 
reverse transcriptase (hTERT) subunits is mainly regulated 
by transcription. However. hTR transcriptional regulation 
remains poorly understood. We previously showed that the 
core hTR promoter is activated by Spl and is repressed by 
Spa. Here, we show that the mitogen-activated protein kinase 
klasse kinase I (MEKKI)/c-Jun-NH2-kinase (JNK) pathway 
represses hTR expression by a mechanism that Involves Spi 
and Spa. Promoter activity was induced by the JNK inhibitor 
SP600125 and was repressed by activated MEKKI. Repression 
by MEKKI was blocked by SP600125 or enhanced by coexpres- 
sion of wild-type but not pbospboacoeptor mutated JNK. 
SP600125 treatment also Increased levels of endogenous 
hill Mutations in the hTR promoter Spl/Sp3 binding sites 
attenuated SP600125-mediated promoter induction, whereas 
coexpression of MEKKI with Spa enhanced hTR promoter 
repression. Chromatin immunoprecipitatlon showed that 
levels of Immunoreactive Spl associated with the hTR pro- 
moter were low in comparison with Sp3 in control cells but 
increased after JNK inhibition with a reciprocal decrease in 
Spa levels. No corresponding changes in SpI/Sp3 protein 
levels were detected. Thus. JNK represses hTR promoter 
activity and expression. apparently by enhancing repression 
through Spa. (('ancer Res 2006; 66(3k 1363-70) 
Introduction 
lelomerase is a ribonucleoprotein reverse transcriptase mini- 
mally composed of core RNA (hTR) and catalytic (hTERT) subunits. 
which stabilizes the telomeres of linear chromosomes (1.2). 
Although telomerase activity is present during human embryonic 
development. its expression and activity are repressed in most 
adult tissues. In contrast. it is essential for long-term proliferation 
of most human cancer cell lines and most human tumors express 
high levels of telomerase (3-6). 
Levels of telomerase in cancer cells are primarily determined by 
transcriptional activity of the hTR and hTERT genes. Both 
transcripts are either absent or at very low levels in most normal 
human cell types but are readily detectable in most cancer cell lines 
(7). Interestingly. ectopic delivery of hTR and hTERT promoter 
constructs results in selective activity in cancer cells as shown by 
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recent preclinical models of transcriptionally targeted gene therapy 
(7-9). Because of the potential for exploitation of telomerase as a 
relatively specific therapeutic target in a broad range of tumor 
types. expanded understanding of the regulation of hTR and hTERT 
expression is of immediate interest. 
Recently. key promoter elements contributing to hTR promoter 
regulation have begun to emerge. The core promoter is essential for 
hTR expression in vivo because its methylation in some cell lines is 
sufficient to silence hTR expression (10). In the 5637 bladder cancer 
cell line, basal activity of transfected core promoter constructs 
(nucleotides -107/+69) is dependent on NF-Y binding to a CCAAT 
box sequence. The core promoter also contains four Spl/Sp3 
binding sites, which serve as sites of positive regulation by Spi and 
negative regulation by Sp3 (11-13). 
We have recently identified, in archived DNA from the buccal 
smear of a paroxysmal nocturnal hemoglobinuria patient, a 
mutation in one of these sites that disrupts Spl/Sp3 binding 
and increases the activity of a minimal hTR promoter in trans- 
fection assays in 5637 cells (14). In the same cells, NF-Y, Spi, and 
TFIIB interact directly with hTR promoter chromatin (12). hTR 
promoter activity can also be regulated by overexpression of pRb 
and MDM2, which act, respectively, as positive and negative 
regulators (15). Notably, upstream signaling events that might 
regulate transcription factors at the hTR promoter are not well 
characterized. 
Accumulating evidence indicates that multiple kinases, including 
mitogen-activated protein kinases (MAPK). directly phosphorylate 
Spl and modulate its DNA binding and/or transactivation activity 
(16-25). MAPK pathways are evolutionarily conserved signaling 
cascades with a minimal core structure in which an upstream 
MAPK kinase kinase (MAP3K) activates a MAPK kinase, which in 
turn activates a terminal effector MAPK (26). Because the hTR 
promoter is regulated in vitro by Spl, MAPK pathways might be 
involved in hTR regulation (Fig. 1). This hypothesis was tested in 
this study. 
Indeed, Spl sites are required for stimulation of several 
promoters by the extracellular signal-regulated kinase (ERK) and 
cJun-NH2-kinase (JNK) MAPK pathways, including the urokinase 
plasminogen activator and p2l"n""v' promoters (22,25). Epider- 
mal growth factor stimulation of gastrin promoter activity in 
gastric adenocarcinoma cells also involves Spi and ERK although 
the direct SpI kinase activity in these cells seems to be an 
ERK effector rather than ERK itself (24). Nevertheless, Spi can be 
directly phosphorylated by ERK in vitro, a modification that 
stimulates Spi DNA binding activity in gel shift assays (19). 
Furthermore, endogenous SpI and ERK coimmunoprecipitate in 
fibroblasts and, in these cells, Raf induction leads to direct 
phosphorylation by ERK of SpI residues Thr°5'` and Thr739. These 
modifications are required for efficient stimulation of vascular 
endothelial growth factor expression (20). In this study, we show 
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Figure 1. RatprWI of the study. The hTR promoter is posdnely and negatively 
regulated in vitro by Spt and Spa. respectively. MAPK pathways are known 
to phosphorylate and regulate DNA bndng of Spt. We tested whether the JNK 
pathway regulates nTR promoter activity and expression using overexpression 
of an activated mutant of MEKK1. wild-type JNK1. plospfoacceptor mutated 
JNK2. and the JNK-speahc inhibitor SP600125. 
that JNK signaling represses the hTR promoter and endogenous 
hTR levels and provide evidence for a JNK regulated transcriptional 
switch that enhances binding and/or activity of the transrepressor 
Sp3 at the hTR promoter and may inhibit Spi. 
Materials and Methods 
Cell 11aes, plaaadds. and inbibkom A2780 (ovarian adenocarcinoma) 
cells were used throughout. The other cell fires used were 5637 bladder 
carcinoma cells. C33A cervical carcinoma cells. I"T29 colon carcinoma 
cells. A549 lung adenocarcinoma cells. and HCT116 colon carcinoma cells. 
Construction of both the 176 by hTR core promoter reporter (nuckrotides 
107/. 69) and the derived Spl mutant construct from pGL3-Basic 
(Prornega Ltd- Madison. %1) has previously been reported in detail 
(II-13). The Spl site-mutated reporter was constructed by PCR muta- 
genesis of the wild-type promoter and carries mutations in all SpI sites that 
disrupt binding and regulation by Sp 1 and Spa but not regulation by other 
key transcription factors Plasmid pCMV-Sp3 was provided by Dr. G. Suske 
(Institut fur MolekuhubkAogw and Tumorforschung Marburg. Germany). 
SP600125 was obtained from Merck Biosciences Ltd (Nottingham. United 
Kingdom). SP600125 was either situated as indicated or used at a concen- 
tration of 25 µmol/I. in medium containing 0.1% DMSO per 10 µmol/L 
SP600125. 
Transfectloas and laeiferw way. All transfections were done using 
superfett transtection reagent according to the instructions of the 
manufacturer (Qiagen Ltd. West Sussex. United Kingdom). A 1: 25 ratio of 
DNA/superfett was used and 250 ng hTR reporter plasmid per well was 
transfected in 96-well luminometer plates (Fisher Scientific UK Leicester- 
shire. United Kingdom) together with varying amounts of pCMV empty 
vector or expression vectors encoding constitutively active MEKKI. wild- 
type or dominant-negative JNK. and Spa. 30 ng pSV40-Renilla luciferase 
expression plan nid (Prornegs) was also cotransfected in each well for 
normalization of hTR promoter activity. hTR activity was also normalized 
to protein equivalents using the Bio-Rad assay (Bio-Rad Laboratories Ltd_ 
Hemel Hempstead. United Kingdom). Forty-eight hours poettransfection, 
cells were lysed and luciferase activities were determined using Dual 
I. uciferase Assay reagents (Promegs) according to the instructions of the 
manufacturer. All transfections were done in quadruplicate and all 
experiments were repeated a minimum of thrice. 
Waster. Witting, Protein extracts were prepared in SDS lysis buffer 
(10th SDS. 500 mmoi/L EFTA. and I rnol/L Tris-HCI). Protein concen- 
trations were estimated at A, % using the Bio-Rad protein assay (Boo-Rad 
Labontoriea). Twenty-microgram protein equivalents were separated by 
SDS-PAGE then blotted onto polyvinylidene difluoride filter (Millipore. 
Watford. United Kingdom) and blocked overnight at 4°C in PBS-T 
containing 5% nonfat dried milk. Filters were probed for 2 hours with 
1: 500 to L2,000 dilutions of primary antibodies and then with a 13,000 
dilution of horseradish peroxidase (HRP)-conjugated antirabbit or anti- 
mouse secondary antibody. HRP was detected using enhanced chemilumi- 
nescence HRP detection reagents (Amersham Pharmacia. Buckinghamshire, 
United Kingdom). Antibodies raised against RSK1, c Jun, c-Jun phospho- 
Sern. JNK, phospho-JNK, and phospho-ERK were all obtained from Upstate 
Ltd. (Buckingham, United Kingdom). Antibody against RSK phospho-Ser363 
was obtained from Abeam (Cambridge, United Kingdom) and antibodies 
against ERK, Spl, and Sp3 were obtained from Autogen Bioclear UK Ltd. 
(Wiltshire, United Kingdom). 
Chromatin immunoprecfpiitatioa assays. Formaldehyde cross-Linking 
and chromatin immunoprecipitation were done as described previously 
(12,15). A2780 cell cultures were treated with formaldehyde for 10 minutes 
followed by the addition of glycine to a final concentration of 0.125 mol/L. 
Cells were then washed twice with cold PBS and were resuspended in lysis 
buffer 11% SDS. 10 mmol/L EDTA. and 50 mmol/L Tris-HCI (pH 8.1)] 
containing proteinase inhibitor. DNA was sonicated to an average fragment 
size of 500 by and cross-linked proteins were enriched by immunoprecip- 
itation with Spl and Sp3 antibodies. A "no Ab" sample was included as a 
negative control for the immunoprecipitation step. After reversal of the 
cross-links and DNA purification, the extent of enrichment was monitored 
by PCR amplification of the hTR promoter using the primers detailed below. 
The PCR product was analyzed both by gel electrophoresis and by real-time 
PCR. For real-time PCR analysis, the ratio of specifically precipitated versus 
input chromatin was calculated with the background (no Ab) subtracted. 
The input sample was processed with the rest of the samples from the point 
at which the cross-links were reversed. 
Quantitative real-time reverse transcription-PCR. Quantitative PCR 
was done using GRl Opticon monitor equipment and software (Genetic 
Research Instrumentation. Essex. United Kingdom). Sybr green was used 
as the fluorophore for detection of amplified DNA. Reactions were done 
in triplicate. The primers 5'-CTAACCCTAACTGAGAAGGGCGTA-3' and 
5'-GGCGAACGGGCCAGCAGCTGACATT-3' were used for detection of 
endogenous hTR and the primers 5'-ACCACAGTCCATGCCATCAC-3' and 
5'-TCCACCACCCTGTTGCTGTA-3' were used for detection of glyceralde- 
hyde-3-phosphate dehydrogenase (GAPDH). The primers 5-CCCGCCCGA- 
GAGAGTGAC-3' and 5-AAGTCAGCGAGAAAAACAGC3' were used for 
detection of the hTR promoter following chromatin immunoprecipitation 
experiments Primer dimers were excluded from the quantification by 
performing the optical read step at 81 °C. 
To analyze effects of JNK inhibition on endogenous hTR levels, 
exponentially growing cells were treated for 16 hours with 25 µmol/L 
SP600125 or with DMSO followed by RNA extraction, cDNA synthesis, and 
quantitative PCR. The mean value of the triplicate measurements of hTR 
levels was normalized to the mean value of the GAPDH triplicates. 
To analyze the relative levels of SpI and Sp3 at the hTR promoter in vivo, 
cells were treated for 16 hours with DMSO or 25 pmol/L SP600125 followed 
by chromatin immunoprecipitation and quantitative PCR Background 
(no Ab) was subtracted and immunoprecipitated samples were compared 
with the input sample. Additionally, Spl immunoprecipitate levels were 
compared with those of Sp3. Quantitative PCR was repeated twice for each 
experiment, and the experiments were repeated four times. 
Statistical analysis. Statistical analysis of all experiments was done by 
ANOVA using the Microsoft Excel data analysis tool pack. Mean values from 
each independent experiment were included in the analyses. Differences 
were statistically significant with P<0.05 or highly significant with P<0.01. 
Results 
The JNK pathway represses the hTR promoter in vitro. To 
determine whether the JNK pathway regulates the hTR promoter 
in vitro, we transfected A2780 ovarian adenocarcinoma cells with a 
176 bp hTR promoter-luciferase reporter construct. Our previous 
studies using this cell line have indicated that the basal hTR 
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promoter activity is very strong in these cells by comparison with 
other cell lines and they, therefore, provide a robust model for 
analysis of promoter regulation (A. 9). Thirty-two hours post- 
ransfection, cells were treated for 16 hours with a titration of 
the INK inhibitor SP600125. Concentrations of SP600125 over 
123 pmol/1. increased hTR promoter activity (Fig. 2A). The activity 
of the hTR promoter was induced by 2-fold at 12.5 gmol/L 
(P < 0.05) and by 2.4-fold at 50 pmol/l. (P < 0.01). Therefore, despite 
high-level basal hTR promoter activity in these cells, manipulation 
of signal transduction pathways can still lead to significant 
promoter up-regulation. These data also suggested that INK 
signaling might repress the hTR promoter. 
To verify these results, expression vector encoding the constitu- 
tively active kinase domain of MEKK1, a major MAP3K for the INK 
Figure 2. The JNK pathway represses the hTR promoter in vitro. A. a Iuciierase 
reporter driven by a 176 by tragrrient of the wild-type hTR core promoter 
(nudeobdea - 107/+6$) was trararenty traratended into A2780 ovarian cancer 
ceps. Thirty-two hours aller transtection, the cells were exposed to a titration of 
the JNK i tutor SPS00125 for a further 16 hours before Nxiferase assay. 
B, the hTR core promoter was cotrans acted in the cells indicated at a 1: 1 ratio 
with either empty vector or pCMV-MEKKI. encoding a fusion protein comprising 
the constitutively active tunas domain of MEKKI. t. uci erase activities were 
quantthed 48 hours later. Relative ludhrase activities were normalized using 
both an internal Control vector and by measurement of IuCiferase activity in 
protein egrwaants. AN experiments wen done in quadruplicate and repeated 
thrice. Cc wwis, means derived from three independent experiments and 
represented as told reporter activity relative to Control: bars, SE. Results were 
anayzed by ANOVA (*. P<0.05. ". P<0.01). 
pathway, was used to test whether activation of the JNK pathway 
would repress hTR promoter activity. Figure 2B shows that MEKKI 
led to strong repression of the hTR promoter. Using a 1: 1 ratio of 
hTR/MEKKI vectors, hTR promoter activity was reduced to 1.8% of 
basal levels in A2780 cells. We also did this experiment using five 
other cancer cell lines (5637 bladder carcinoma cells, C33A cervical 
carcinoma cells. HT29 colon carcinoma cells, HCT116 colon 
carcinoma cells, and A549 lung adenocarcinoma cells). MEKK1 
transfection led to strong repression of the hTR promoter in all cells 
tested (P < 0.01). Together, these data suggested that the canonical 
JNK pathway might repress the hTR promoter. 
To confirm that JNK is the effector of MEKKI-mediated hTR 
promoter repression, we examined the effect of blocking or 
augmenting activated MEKK1 signaling in A2780 and 5637 cells. 
As shown in Fig. 3A, a 10: 1 ratio of hTR reporter/MEKKI repressed 
hTR promoter activity to 42% of basal levels in A2780 cells. 
MEKK1-mediated repression was completely blocked by 25 µmol/L 
SP600125 (P < 0.05) and hTR promoter activity was even activated 
relative to basal levels in the presence of both MEKK1 and 
SP600125. In 5637 bladder cancer cells, a 2.5: 1 ratio of hTR 
reporter/MEKKI repressed hTR promoter activity to 55% of basal 
levels. In cells treated with both MEKKI and 25 ttmol/L SP600125, 
this effect was completely blocked (P < 0.05) and hTR promoter 
activity was strongly elevated relative to control. Thus, chemical 
inhibition of JNK blocks MEKKI-mediated repression of the hTR 
promoter. 
We also hypothesized that repression of hTR promoter activity 
by MEKKI could be enhanced by additional overexpression of JNK 
(Fig. 3B). A2780 or 5637 cells were transfected with a 10: 1: 4 ratio of 
hTR reporter/MEKK1/wild-type JNKI or JNK2^PF, which harbors 
mutated phosopho-acceptor residues and, therefore, cannot be 
activated by upstream MAPK kinase. In A2780 cells, MEKKI alone 
reduced hTR promoter activity to 22% of basal levels. As predicted, 
repression of the hTR promoter by MEKKI was further enhanced 
in the presence of wild-type JNK1 (10% of basal levels, P<0.05), 
whereas JNK2APF was not able to enhance MEKK1-mediated 
repression. In 5637 cells, this dilution of MEKK1 only had a mild 
effect on hTR promoter activity, which was not significant (83% of 
basal levels). However, the addition of wild-type JNKI enhanced 
repression to 62% of basal levels (P < 0.05 compared with control). 
Additionally, the phosphoacceptor mutant JNK2APF blocked mild 
repression by MEKK1 in these cells. These results confirm that JNK 
activation can mediate repression of the hTR promoter by MEKK1. 
The JNK pathway represses endogenous hTR expression. To 
determine whether the JNK pathway affects the endogenous 
expression of hTR, exponentially growing A2780 cells, 5637 cells, 
or C33A cervical cancer cells were incubated with 25 µmol/L 
SP600125 or DMSO control. After 16-hour treatment, RNA was 
extracted from the cells and the levels of hTR were analyzed by 
quantitative PCR and compared with those of GAPDH. The results 
from three independent paired treatments were analyzed twice by 
quantitative PCR. The pooled data, shown in Fig. 4A, show that 
Sp600125 treatment led to a 63% increase in endogenous hTR 
levels in A2780 cells and increases of 88% and 94% in 5637 and 
C33A cells, respectively. GAPDH levels were not affected by the 
treatment (data not shown), whereas induction of hTR in the 
presence of SP600125 was statistically significant as determined by 
ANOVA (P < 0.05 in A2780 cells, P<0.01 in C33A and 5637 cells). 
These data indicate that JNK inhibition can substantially increase 
the steady-state hTR level in diverse cell lines even where hTR 
expression levels are already high (10). 
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Fi0ure 3. JNK activation mediates repression of the hTR promoter by MEKK1. 
A. a Wahres rsporMr driven by the wrd-type hTR core promoter (nucleotides 
107469) was traruwnuy cotranslclod into A2780 ovarian Cancer Cells or 
5637 bladder cancer cells with empty vector or with pCMV-MEKK1 at a 10: 1 ratio 
(reporter/MEKKI) in A2780 cells or a 2.5: 1 ratio on 5637 cells. Thirty-two hours 
after trarnbction. MEKK 1 -translacted c eft were treated with 
25 µnaUL 
SP600125 or DMSO for a further 16 hours before luciterase assay. B. a 
lualerase reporter driven by the wed-type hTR core promoter was transiently 
cotranstected into A2780 ovarian cancer Calls or 5637 bladder cancer cells with 
empty vector or with pCMV-MEKK1 alone. or in combination with wild-type 
pCMV-JNKI or pCMV-JNK2A" at a 10: 4: 1 ratio (reporter/JNK/MEKKI). 
JNK2A" encodes an inactive JNK2 mutant in which the activating Thr-Pro-Tyr 
ptaepnoaccepbr residues are mutated to Ala-Pro-Phe. Forty-eight hours 
posttranstecbon. Wcilerase activities were determined. Relative lucderase 
activities were normalized using both an internal control vector and by 
measurement of luciteraas activity in protein equivalents. An experiments were 
done in quadruplicate and repeated thrice. Coilmrs, means derived from three 
independent experiments and represented as told reporter activity relative 
to control: bars. SE. Results were analyzed by ANOVA (', P<0.05). 
To confirm that JNK activity was specifically inhibited by 
Sp600125, exponentially growing A2780 cells were treated for 
16 hours with 25 itmol/L SP600125. After treatment, protein was 
extracted and Western blot analysis was done for total expression 
and phosphorylation of ERK and the ERK-specific substrate 
p90-RSKI. and for JNK and the major JNK substrate c-Jun. As 
shown in Fig. 4B. SP600125 did not significantly affect the levels 
or phosphorylation of ERK, p90-RSK 1. JNK, or the level of c-Jun 
protein: however. c-Jun Ser" phosphorylation was thoroughly 
inhibited. demonstrating that SP600125 does not interfere with 
the activating phosphorylation of JNK but with its downstream 
signaling as expected. In contrast, SP600125 neither inhibited 
the phosphorylation of ERK or its downstream substrate RSK. 
Thus, under conditions of JNK inhibition, hTR expression is 
increased. Taken together, Figs. 2 to 4 suggest that the JNK 
pathway is a genuine repressor of hTR levels and that elements 
in the core promoter are likely to participate in JNK-mediated 
repression. 
Repression of the hTR promoter involves Spl and Sp3. 
Several studies have indicated that MAPK pathways may regulate 
gene expression partly through Spl/Sp3 binding elements (19,20, 
24,25). To determine whether the hTR core promoter Spl/Sp3 
sites are involved in JNK-mediated repression of hTR promoter 
activity, we used an hTR reporter construct carrying functional 
mutations in all Spl/Sp3 sites (construct no Spl). Previous 
Figure 4. JNK inhibition increases endogenous levels of hTR. A, up-regulation 
of endogenous hTR levels. Exponentially growing A2780 cells, 5637 cells, or 
C33A cervical cancer cells were treated for 16 hours with 25 µmoVL SP600125 or 
with DMSO control. After treatment, cDNA was synthesized from RNA extracted 
from treated and untreated cells. Levels of endogenous hTR in control and 
treated samples were analyzed by quantitative PCR using hTR-specific primers 
and normalized to levels of GAPDH. The experiment was repeated thrice and 
quantitative PCR was done twice on each independent experiment. Columns, 
means of pooled data from all independent experiments; bars, SE. Results were 
analyzed by ANOVA (', P<0.05, Pc 0.01). B, inhibition of JNK activity. 
Exponentially growing A2780 cells were treated for 16 hours with 25 pmoVL 
SP600125 or DMSO control. After treatment, protein extracts were made and 
probed for inhibition of the JNK pathway by Western blotting 20 µg extract for 
total and ptosphorylated levels of ERK and its substrate RSK1 and for JNK and 
its substrate c-Jun. Experiments were repeated at least twice. Representative 
blots are shown. 
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characterization determined that binding and regulation by Spl 
and Sp3 but not by NF-Y or MDM2 are specifically ablated in this 
construct (11.12). 
A2780 and 5637 cells were transfected in parallel with the wild- 
type or no-Spl reporters and were treated with DMSO or 25 
pmol/l. 5P600125 (Fig. 5.4). In these experiments. 25 pmol/L 
SP600I25 resulted in 2.2-fold induction of wild-type promoter 
activity in A2780 cells but induction of the reporter lacking 
Sp I , Sp3 sites was attenuated, reaching only 1.5-fold induction 
(P < 0.05). In 5637 cells. SP600125 induced the wild-type hTR 
promoter by 1.61-fold but the mutant promoter was induced by 
only 1.26-fold (P < 0.05). These results suggested that part of 
the mechanism for induction of hTR promoter activity by JNK 
inhibition involves SpI and/or Sp3 proteins, although the 
incomplete attenuation indicates that other factors may also be 
involved. Our previous studies have shown that SpI activates 
the hTR promoter, whereas Spa is a repressor. We, therefore, 
sought to investigate whether Sp3 is involved in repression of hTR 
by JNK. 
A2780 or 563; cells were cotransfected the wild-type hTR 
promoter along with vector or MEKKI and vector or Sp3 in a 5: 1: 2 
ratio (reporter: MEKKI/vectorSp3/vector). For each experiment, 
we also calculated the product of the repression mediated by 
MEKKI and Sp3 individually as a representation of the expected 
promoter activity assuming additive effects between MEKKI and 
Sp3. As shown in Fig. 5B, MEKKI alone repressed the hTR to 30% 
of basal levels in A2780 cells. whereas Sp3 alone repressed the hTR 
to 68% of basal levels. The calculated expected promoter activity 
(exp column), assuming only additive effects between Sp3 and 
MEKKI. was 18% of basal levels. However, cotransfection of both 
MEKKI and Sp3 repressed hTR promoter activity to 9% of basal 
levels (P < 0.05). 
In 5637 cells. MEKKI transfection alone resulted in 50% 
reduction of hTR promoter activity, whereas Sp3 alone decreased 
promoter activity to 55% of basal levels. Across all experiments. 
the expected promoter activity assuming perfect additive effects 
between MEKKI and Sp3 (Fig. 5Q exp column), would have been 
27sf of basal levels. Instead, in the presence of both MEKKI and 
Spa, hTR was reduced to only 11.5% of basal levels (P < 0.05). 
Therefore, in both 5637 and A2780 cells, Sp3 and MEKKI seem to 
act cooperatively to repress the hTR promoter. 
JNK regulates Sp 1 /Sp3 bbadisg at the hTR promoter in vivo. 
Several studies have suggested that regulated Spl/Sp3-dependent 
promoter activation may be mediated by a change in the ratio of 
Spi and Sp3 expression (27-29). To determine whether our 
results reflect altered expression of Spl or Sp3 (e. g, repression of 
SpI expression by JNK), we did Western blots for total cellular 
levels of SpI and Spa in control cells or cells treated for 16 hours 
with SP600125. As shown in Fiig 6A. 16-hour treatment with 
25 pmol/L SP600125 had no significant effect on the levels of Spl 
or Sp3 protein. Therefore, any JNK-dependent regulation of Spi 
or Sp3 is likely to be mediated through a posttranslational 
mechanism. 
To investigate the hypothesis that the JNK pathway enhances 
repression of the hTR promoter by Sp3 and/or constrains Spl- 
mediated activation in these cells, we did chromatin immunopre- 
cipitation experiments. pulling down either SpI or Sp3 from 
control cells or from cells treated for 16 hours with 25 pmol/L 
SP600125. The presence of the hTR promoter in chromatin 
immunoprecipitates was assessed using both conventional and 
quantitative PCR. 
Figure S. Repression of the hTR promoter JNK involves Spl and Sp3. A, 
induction of promoter activity by SP600125 requires Spt binding sites. 
Luciterase reporters driven by either the wild-type hTR core promoter 
(nucleotides -107/+69) or a mutation construct in which all the Spl binding sites 
are ablated (construct no Spl) were transiently transfected into A2780 ovarian 
cancer cells or 5637 bladder cancer cells. Thirty-two hours after transfection, 
cells were treated with 25 µmoVL SP600125 or DMSO for a further 16 hours 
before luciferase assay. 8, MEKK1 enhances Sp3-dependent repression 
of the hTR promoter. Wild-type hTR core promoter reporter was transiently 
cotransfected into A2780 ovarian cancer cells or 5637 bladder cancer cells 
with vector or MEKK1 and vector or Sp3. Forty-eight hours posttransfection, 
luciferase activities were determined. The expected repression by MEKK1 + Sp3 
assuming ideal additive effects was calculated in each experiment from the 
product of the fold repressions by Sp3 and MEKK1 alone. All experiments were 
done in quadruplicate and repeated thrice. Columns, means derived from three 
independent experiments and are represented as fold reporter activity relative 
to control: bars, SE. Results were analyzed by ANOVA (', P<0.05). 
Spl-specific products seemed weak compared with the Sp3- 
specific products in control A2780 cells (Fig. 6B and C). This may 
simply reflect the different affinities of the two antibodies for their 
targets or it may indicate that Sp3 occupancy of the promoter is 
greater than Spl. More importantly, after 16-hour treatment with 
Sp600125, the intensity of the Spl-specific product had increased, 
whereas that of Sp3 was reduced. As shown in Fig. 6D, pooled data 
from all experiments showed that Spl represented 33% of the total 
Spl/Sp3 associated with the hTR promoter in control cells but 
increased to 55% in JNK-inhibited cells (P < 0.05). In contrast, 
Sp3 constituted 67% of the total Spl/Sp3 protein pulled down in 
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control cells but the proportion fell to 45% in JNK-inhibited cells 
(P < 0.05). Thus. JNK inhibition results in a shift in the ratio of 
immunoreactive SpI and Spa at the hTR promoter in vwo, favoring 
an increase in the levels of the Spi epitope. 
control sY6oot2ö 
Sp1 
- 
"sp1 oSp3 
Figure 6. The JNK pathway modulates Spt and Spa binding to the hTR 
promoter in vivo. A. cellular levels of Sp1 and Sp3 are not affected by 
SP600125. 
ExponenWly growing A2780 cells were treated for 16 hours with 25 pmoVL 
SP600125 or DMSO control. After treatment, protein extracts were made and 
probed for total cellular levels of Sp1 and Spa Protein. Sp1 p95 was the main 
product: Sp3 p100 (full-length) and p60 (alternative translation initiation site) 
rsoforms were detected. The experiment was repeated twice and representative 
blots are shown. B and C. SP600125 increases detection of Spi in chromatin 
immunoprepptates. Exponentially growing A2780 cells were treated either 
with DMSO or with 25 mmoVL SP600125 for 16 hours. After the treatment 
periods, proteins were cross finked to DNA using formaldehyde and chromatin 
was nmmunoprecrpitated using antibodies specific 
for Sp1 or Spa. The presence 
of the hTR promoter in precipitated chromatin was monitored by conventional 
PCR (B) and quantitative PCR (C) using primers specific for the hTR 
promoter. One representative experiment. Input 
DNA samples were diluted 1: 10. 
D, increased ratio of wrwmu noreactive Spl relative to Sp3 detected at the hTR 
prompter in vivo after SPS00125 treatment. Aker subtraction of background, 
Sp1 and Spa levels were compared with the total amount of Spi + Sp3 detected 
in chromatin inmu loproapitatan. 
Chromatin Immu nopreapitation experiments 
were repeated low tans and each experiment was analyzed twice by 
quantitative PCR. Pooled data for all experiments. The relative shifts in Spi 
or Sp3 levels were analyzed by ANOVA (', P<0.05). 
p 
0 
control SPS00125 
e 411mon- 
4ý : 
Spa 
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Discussion 
Significant interest in recent years has focused on hTERT gene 
regulation as a mechanism controlling telomerase in cancer 
cells. However, recent findings in mice and humans have indicated 
that control of hTR levels may also contribute to overall regulation 
of telomerase. In the mTR knockout mouse, telomerase activity is 
abrogated resulting in telomere shortening and late-generation 
phenotypic abnormalities in multiple organs (30,31). Interestingly, 
and, more recently, it has been shown that haploinsufficiency of 
mTR in mTR+/- heterozygotes results in defects of telomere 
elongation independent of telomerase activity detected by telomere 
repeat amplification protocol assay (32). In humans, hTR 
haploinsufficiency has been documented in autosomal dominant 
dyskeratosis patients (33). Indeed, several mutations that have 
the effect of reducing the stability of hTR are documented in 
autosomal dominant dyskeratosis (34). 
Together, these data indicate that hTR levels are essential for 
telomerase holoenzyme function in vivo, although sparse data exist 
regarding signal transduction pathways affecting hTR expression. 
In situ hybridization analysis of 800 tumor biopsy samples show 
clearly that hTR levels are up-regulated specifically in cancer cells 
(35-40). It is, therefore, critical to begin to define pathways 
affecting hTR. 
In this report, we provide evidence that JNK represses the hTR 
core promoter in transfection assays and also represses endoge- 
nous hTR levels partly via regulation of Spl and Sp3 at the hTR 
promoter. We found that the JNK inhibitor SP600125 up-regulated 
activity of a transiently transfected hTR core promoter reporter in 
a dose-dependent manner and also increased endogenous levels of 
hTR at 25 µmol/L. At this concentration, SP600125 also abrogated 
phosphorylation of c-Jun but not of RSK1, a major ERK specific 
effector, suggesting that the JNK pathway was indeed specifically 
inhibited at SP600125 concentrations leading to elevation of 
endogenous hTR. 
Conversely, overexpression of active MEKK1, a major MAP3K for 
the JNK pathway, strongly repressed promoter activity. Further, 
repression by MEKKI could be completely blocked by 25 tmol/L 
SP600125 or enhanced by coexpression of wild-type JNKI but 
not the phosphoacceptor mutant JNK2APF. Together, these data 
suggest strongly that JNK is a major effector of MEKKI-mediated 
repression of the hTR promoter and that elements in the core 
promoter may be involved in induction of hTR following JNK 
inhibition. 
We next assessed whether repression by the JNK pathway could 
be attributed to Spl/Sp3-dependent mechanisms. Induction of the 
core promoter by SP600125 was partly dependent on intact, 
functional Spl binding sites, indicating that Spl/Sp3 could indeed 
have a role in integrating JNK signaling at the hTR core promoter. 
Overexpression of MEKK1 enhanced repression by Sp3, suggesting 
that MEKK 1 might selectively favor binding or activity of Sp3 at the 
hTR promoter. 
Finally, we showed by chromatin immunoprecipitation that 
SP600125 treatment increases detection of Sp1 at the hTR 
promoter in vivo with a concomitant relative decrease in 
detectable Sp3. These observations are consistent with a model 
in which the JNK pathway enhances binding and/or trans- 
repression by Sp3 and suppresses Spl-dependent transcription of 
hTR. It is important to note that altered Spl/Sp3 immunoreactivity 
does not necessarily reflect overall levels of Spl/Sp3 binding. It may 
instead reflect other changes within promoter bound complexes 
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that unmask the Spl epitope- However. in light of our other 
findings reported here, there remains a strong possibility that Spl 
epitope unmasking in this context might reflect relief from 
inhibition. In context of our finding that MEKKI cooperates with 
Spa to repress the hTR promoter. and based on our previous 
analyses of positive hTR promoter regulation by Spl. these 
observations provide initial evidence of a transcriptional switching 
mechanism underlying hTR repression by the MEKK1/JNK 
pathway. In totality. our data argue for a model in which the JNK 
pathway cooperates with Spa to repress the hTR promoter in vitro 
and in vivo. 
The mechanism underlying the apparent differential regulation 
of Sp I and Spa at this promoter is unclear at present JNK signaling 
may directly modify Spa. specifically enhancing its DNA binding 
activity and allowing it to compete more effectively with SpI for the 
same binding sites. Alternatively. JNK signaling may directly inhibit 
SpI in this instance, which would also be expected to enhance the 
activity of Spa. It should be noted, however, that JNK signaling has 
generally been reported to result in activation of Spl DNA binding 
and transactivation (25.41). It is also conceivable, however, that the 
overall architecture of individual promoters and/or expression of 
cell-specific factors influence the outcome of JNK activation at 
individual genes with respect to Spl/Sp3. In this cell fine, hTR 
promoter-bound Spl may simply be inaccessible for JNK or its 
effectors. leading to preferential signaling to Spa. 
Because both SpI and Sp3 contain potential docking sequences 
for JNK in the first zinc finger and the distribution of minimal 
consensus MAPK phosphoacceptor residues relative to the 
functional domains of Sp i and Sp3 is also broadly similar, such a 
mechanism seems most likely. However. Sp3 lacks an equivalent 
residue to the Spl ERK phosphoacceptor Thr7" . Given that the 
requisite docking domains for ERK and JNK reside in the zinc 
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fingers and are. therefore, likely to be proximal in the tertiary 
structure of Spl, it is possible that JNK binding to its putative 
domain might mask the ERK docking site, thereby inhibiting 
phosphorylation on Thrr" and, thus, DNA binding. Such a 
mechanism would not be expected to affect Sp3 due to the 
absence of an equivalent residue, although it is uncertain whether a 
JNK active site inhibitor could unmask such an effect. 
In conclusion, this report provides the first evidence that Spl 
and Sp3 may act to integrate stress and/or growth signals at the 
hTR promoter. It will be of particular interest to investigate 
whether JNK also represses hTR in cells with low hTR levels, such 
as normal cell strains, and, if so, what its relative contribution to 
hTR repression is. From a therapeutic perspective, improved 
understanding of the signal transduction pathways that regulate 
the hTR gene promoter should allow for the development of lead 
drug candidates targeting pathways involved in hTR transcription. 
Several clinically relevant cytotoxic drugs in widespread use, 
including cisplatin, are known to activate the JNK pathway as part 
of their mechanism of action (42). Interestingly, some ovarian 
cancer cells acquire drug resistance through down-regulation of 
DNA damage pathways while retaining competent but compro- 
mised JNK activation (43,44). It will also be of interest to determine 
whether long-term subtoxic schedules of such drugs might have a 
beneficial effect resulting from inhibition of telomerase even in 
cells that have acquired resistance to apoptosis. 
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The human adult mesenchymal stem cell (hMSC) does not express telomerase and has been 
shown to be the target for neoplastic transformation after transduction with hTERT. These 
findings lend support to the stem cell hypothesis of cancer development but by supplying 
hTERT, the molecular events required to upregulate hTERT expression in cancer 
development are missed. Therefore, the hMSC is ideal for the identification of molecular 
mechanisms regulating telomerase gene expression in stem cells. This study shows that the 
repression of hTERT expression in hMSC is chromatin based and that modifications of the 
chromatin environment lead to reactivation of telomerase gene expression. It is shown 
that repression of hTERT expression in hMSCs is due to promoter-specific histone 
hypoacetylation coupled with low Pol 11 and TFIIB trafficking. This repression is overcome 
by treatment with Trichostatin A (TSA), an HDAC inhibitor, concomitant with increases in 
promoter-specific histone acetylation and increases in Pol II and TFIIB tracking. hTR 
expression is also increased in TSA-treated hMSCs, concomitant with changes in Pol II and 
TFIIB dynamics. 
Stem cells are unique in their ability to both self 
renew and to give rise to differentiated tissues. 
Mesenchymal stem cells (hMSC) are multipo- 
tential cells. Thus, hMSC have the ability both 
In vivo and in vitm. to differentiate into a vari- 
ety of adult mesenchymal tissues. such as bone, 
cartilage, adipose and muscle 11.21 and therefore 
may be of use in the treatment of a diverse vari- 
ety of clinical conditions. In addition, there are 
now strong links between normal stem cells and 
cancer stem cells 131, suggesting that stem cells 
are targets for neoplastk transformation. Inter- 
estingly, despite having stem cell properties. 
when passaged in culture the hMSC gradually 
reduce their proliferative rate and enter replica- 
live senescence 11.21. hMSCs also lack activity 
for the Immortalizing enzyme telomerase which 
an counteract senescence by maintaining tel- 
omere sequence 11.21. Further, when hTERT is 
ectoplcally expressed in the hMSC. neoplastic 
changes are accumulated suggesting that the 
adult hMSCs can be targets for neoplastic 
transformation 141. 
The expression of telomerase is regulated in 
normal human cells. During development. tel- 
omerase expression Is extinguished after 
embryonic differentiation in most cells. Nota- 
ble exceptions are male germ cells, lym- 
phocytes and some stem cell populations, 
which maintain their proliferative capacity in 
adult life, are telomerase competent and can 
express low levels of telomerase. By contrast. 
telomerase is highly active in the vast majority 
of human tumors 15-7!. Thus, a key issue is how 
this complex pattern of expression is main- 
tained in adult tissues and in particular the 
adult stem cell and how this is deregulated dur- 
ing neoplastic progression 181. 
Telomerase activity is achieved through the 
expression of two genes, the hTR gene, which 
codes for the essential RNA component of tel- 
omerase, and the hTERT gene, which codes for 
the telomerase protein component that has 
reverse transcriptase activity. A major mechanism 
to differentially regulate telomerase is transcrip- 
tional control of the hTERT and hTR genes. 
Although much remains to be clarified, the clon- 
ing of the hTR and hTERT promoter region has 
enabled the identification of several positive and 
negative regulators of transcription 191. 
However, gene expression is not only deter- 
mined by the availability of combinations of 
transcription factors but also by chromatin con- 
text and in particular by covalent modifications 
of the core histones including acetylation, 
phosphorylation and methylation 1101. Distinct 
modification patterns at promoter sequences 
have been linked to expression and repression, 
and the dynamics of histone modification in 
transcriptional control is ideally suited to the 
task of organizing complex programs of gene 
activity necessary for many cellular processes 
including cell lineage commitment, cellular 
senescence and tumorigenesis 111-131. Formation 
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of the basal transcriptional machinery into 
transcriptional complexes on promoter 
sequences is also a major step in gene tran- 
scription. It is known that telomerase has a 
critical role in tumor progression and cancer 
cell survival: therefore it is crucial that the 
mechanisms regulating telomerase gene 
expression are well understood. Studies have 
shown that distinct patterns of histone modifi- 
cations are linked to hTR and hTERT gene 
regulation 1141 and alterations in expression 
levels are concomitant with dynamic changes 
in basal transcription machinery binding 1151. 
Thus, the lack of hTERT expression in the 
hMSC provides an ideal model to study telom- 
erase gene regulation in the normal adult stem 
cell. This allows us to study all stages of pro- 
moter function including the key steps of tran- 
scription preinitiatlon complex formation, 
promoter clearance and elongation in the con- 
text of chromatin remodeling. The histone 
deacetylase inhibitor Trichostaun A (TSA) has 
been shownprevlously to cause an increase in 
histone acetylation at the hTERT promoter and 
cause re-expression of the hTERT gene 116-181. 
To this end, we have studied hTERT and hTR 
expression, the acetylation status of the hTR 
and hTERT promoters and RNA Pol II and 
TFIIB dynamics in the hMSC by chromatin 
immunopreclpitation (ChIP), before and after 
treatment with TSA. 
Material & methods 
isoration of hMSC & Cell Witt. " 
Primary hMSC Isolated from bone marrow aspi- 
rates by centrifugation (700 g for 15 min at 4'C) 
over a Fkofl-Hypaque gradient (Sigma) as previ- 
ously described by Pittenger and colleagues 1191. 
The resulting cells were cultivated in high-glu- 
coae (4.5 g/l) Dulbecco's modified Eagles 
medium (DMEM. Gibco. Life Technology, 
USA) supplemented with 10% fetal bovine 
serum (Gibco. Life technology). 100 U/ml of 
penicillin and streptomycin (Gibco, Life tech- 
nology) and 2 mM of L-glutamine. Cells were 
plated out with a confluence of 75% and the 
next day TSA was added at a final concentration 
of 350 pM for 17 h. This was followed by fixing 
in neutral buffered formdin (at a final concen- 
tration of 3.7%) for ChIP assay. 
Chronut*i MY. xx*ve ipNstion assays 
ChIP assays for histone acetylation were per- 
formed following the instructions recom- 
mended by the kit supplier (Upstate 
Biotechnology, UK). Antibodies used were 
anti-acetylated histone H3 (AcH3), which rec- 
ognizes acetylated lysines 9 and 14 and anti- 
acetylated histone H4 (AcH4), which recog- 
nizes acetylated lysines 5,8,12 and 16 
(Upstate Biotechnology, Cat. No. 06-599 and 
06-866). Sonication was optimized to give 
chromatin fragments of around 500 bp in 
length (8 x 10 second pulses at 5t with 20 s 
rest between each pulse on ice using an MSE 
Soniprepl50 sonifier) and the resultant DNA 
from each immunoprecipitation (IP) was puri- 
fied using the QlAquick PCR Purification 
KitTM' (Qiagen, UK). ChIP assays using anti- 
Pol II and anti-TFIIB (both Autogen Bloclear, 
UK) were undertaken as in Gomez-Ramon 
and colleagues 1201. In both ChIP techniques 
and in each individual experiment, a no-anti- 
body control is used to detect any back- 
ground, which if present is subtracted from 
the IN to normalize. 
Quantitative polynwase chain reaction 
Products from the ChIP assay were quantified by 
quantitative polymerase chain reaction (Q-PCR) 
Opticon2 DNA Engine (Mvj Research, Massa- 
chusetts) using primers to hTR and hTERT core 
promoter sequences and exon 12 of hTERT 
using SYBR Green Q-PCR Buffer (Finnzymes, 
Espoo, Finland) 114,151. hTR Primers, 29SF 
5'000 GCC CGA GAG AGT GAC 3' and 
5ALTR 5' AAG TCA GCG AGA AAA ACA GC 
3', hTERT primers, TERTSF 5' TCC CCT 
TCA CGT CCG GCA TT 3' and TERTSR 5' 
AGC GGA GAG AGG TCG AAT CG 3' and 
Exon 12 primers, Exl2Fa 5'CAG GAC AAG 
GAA GCG GGA GGA 3' Ex 12Rab 5'CAG 
CCG CAA GAC CCC AAA GA 3' were used. 
Expression analysis 
hTR expression was analyzed by Q-PCR using 
the following primers (TRC3F - 5' CTAAC- 
CCTAACTGAGAAGGGCGTA Tand TROR 
- 5' GGCGAACGGGCCAGCAGCTGACAT 
T Tand adjusted to GAPDH expression (primers 
- GAPDHO. 45F - 5' ACCACAGTCCAT- 
GCCATCAC 3' and GAPDHO. 45R - 5' CCA 
CCA CCC TGT TGC TGT A 3') (14, IS(. hTERT 
expression was analyzed by methods outlined in 
Keith and colleagues [21[ using primers which 
detect all splice variants (primers HT2026F 5' 
GCCTGAGCTGTACTTTGTCAA 3' AND 
HT2482R 5' GCCAAACAGCTTGTTCTC- 
CATGTC 3'). hTERT expression is displayed as 
total amounts of all four main splice variants. 
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Results 
hTERT gene expression in hMSC & chromatin 
remodeling at the hTERT promoter 
hTERT expression was studied before and after 
treatment with TSA and levels of histone acetyla- 
tion at the promoter were also studied by ChIP 
assays in order to link changes in the chromatin 
environment with any changes in gene expres- 
sion. In control (untreated) hMSCs, there was a 
lack of expression, of any hTERT transcripts 
(F%pm IA). Acetylatlon of histone H3 was not 
detected and acetylatlon of histone H4 was low 
(Fyne III), linking the lack of expression of 
h=with low levels of promoter proximal 
histone acetylatlon. Upon treatment with TSA, 
hMSCs showed re-expression of full-length 
hTERT transcripts (Ilse IA) and this was associ- 
ated with increased levels of AcH3 and AcH4, 
(Fiume IB) linking remodeling of the chromatin 
environment of the hTERT promoter with re- 
expression of hTERTW. 
Basal transcription machinery dynamics at 
the hTERT gene in hMSCs. 
As wet as monitoring acetylation. Pol II and TFIIB 
occupancy at the hTERT promoter and exon 12 of 
hTERT were also studied. to understand the traf- 
ficking of the basal trarnaiptlon machinery along 
the hTERT gene. Eton 12 is located some 31 kb 
downstream from the promoter and therefore can 
give excellent data on the extent of basal transaip- 
tion machinery cranking along the gene-coding 
sequence. Pol II levels were low at the hTERT pro- 
moter before treatment with TSA and decreased 
slightly after nutrnent ft- IC) perhaps signify' 
ing that any Pol II that was present at the promoter 
but was not engaged in transcription. Levels of 
Pol II at croon 12 were increased after treatment 
with TSA (Ftpre IC). Indicating that increasing 
amounts of Pal II was involved in the process of 
trannoription of the h7ERTge ne. 
TFIIB levels in hMSCs were increased at the 
promoter upon TSA treatment. perhaps due to 
the relaxing of the chromatin environment 
allowing the stabilization of the prelnltiatlon 
complex and increased transcription of hTERT 
by Pol II. Low levels of TFIIB at exon 12 before 
and after TSA treatment suggests that the role of 
TFIIB Is primarily at the promoter in stabilizing 
the preinitiatlon complex (Flare ID). 
hTR gene e4nession in hA4SC & chromatin 
remodeling at the hTR promoter 
hTR gene expression and promoter chromatin 
environment was also studied in hMSC before 
and after treatment with TSA. Figure 2A shows 
that hMSCs express hTR and levels increase 
upon treatment with TSA. However, ChIP anal- 
ysis did not detect any change in acetylation of 
histories H3 and H4 before and after treatment 
with TSA (Figure 2B). 
Basal transcription machinery dynamics at 
the hTR gene in hMSCs 
Although there did not seem to be an increase in 
histone acetylatlon, hMSCs treated with TSA 
showed an increase in Pol II and TFIIB levels at 
the promoter sequence (Figure 2C). An increase in 
Pol II and TFIIB at the promoter could indicate 
an increase in stability of the transcriptional 
complex and therefore an increase in transcrip- 
tion levels of hTR that would account for the 
increase in expression. As the hTR gene is rela- 
tively short, extended analysis of PoIII and 
TFIIB trafficking was not possible. 
Discussion 
A common set of features distinguish cancer cells 
from their normal counterparts including loss of 
cell cycle regulation, loss of control over invasion 
and metastasis, failure of apoptotic mechanisms 
and bypass of senescence 17.221. Cellular models 
designed to recapitulate these features of multi- 
stage neoplastic progression have recently been 
developed by a number of groups and epito- 
mized by the work from the Weinberg lab 1211. A 
common element of these models is to use 
ectopic expression of the hTERT gene to over- 
come senescence and thus provide the immortal- 
ization step of cancer progression. However, 
whilst this model for neoplastic transformation 
may be of considerable use in defining a number 
of the key events in progression, by supplying 
telomerase, the molecular events required to 
upregulate hTERT in cancer development are 
inevitably missed. Given the critical role that tel- 
omerase has in tumor progression and with the 
cancer cell reliant on telomerase for its survival, 
it is essential that the mechanisms regulating tel- 
omerase gene expression are Investigated 181. Our 
findings give essential information about the reg- 
ulation of endogenous telomerase gene expres- 
sion in normal hMSCs. Understanding 
telomerase gene regulation in the hMSC, and 
similar cell types, is of importance. Any differ- 
ences in regulation may reflect distinct regula- 
tory pathways for telomerase gene expression In 
these cell types, which need not be the same as in 
normal and cancer cell lines, which has been 
published previously 114.151. 
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(A) hTERT spice variant expression analysis of hMSC before and after treatment with TSA, corrected to 
GAPDH expression and visualized 
using the Agilent Bioanalyser (Agilent Technologies). Lane 1 shows size markers, Lane 2, the negative control for the PCR reaction, Lane 3, 
hTERT expression for the hMSC, Lane 4, hTERT expression for the hMSC treated with TSA, and Lane 5. hTERT expression in the MCF-7 cell 
line as comparison. ChIP assays were performed for (B) histone acetylation (histones H3 and H4) status of the hTERT promoter (C) Pol II 
and (D) TFIIB occupancy of the promoter and exon 12 before and after treatment of hMSCs with TSA. Each IP is expressed as a 
percentage of an input sample to normalize and detected by Q-PCR in triplicate to generate error bars. No antibody controls were 
analyzed within each experiment and Q-PCR allowed the subtraction of any background from each P. 
hMSC: Human mesenchymal stem cell; IP: Immunoprecipitation; Q-PCR: Quantitative polymerase chain reaction; TSA: Trichostatin A. 
The data presented shows that hTERT 
expression is repressed in the hMSC and that 
the mode of repression is chromatin based. 
Upon TSA treatment of hMSCs, hTERT 
becomes re-expressed concomitant with an 
increase in promoter histone acetylation. 
Beside hTERT expression, hTR expression is 
also increased upon TSA treatment although 
large changes in histone acetylation are not 
apparent. This suggests that chromatin and 
epigenetic mechanisms are involved in telomer- 
ase gene regulation in the hMSC. The chroma- 
tin-based repression of hTERT transcription 
and hence repression of telomerase activity may 
act as a tumor suppressor mechanism, whereby 
hMSCs would have a limited lifespan and can- 
not divide long enough to accumulate neoplas- 
tic changes and become tumorigenic. Basal 
transcription machinery dynamics were also 
changed upon TSA treatment. Association of 
Pol II with gene-coding regions has been previ- 
ously shown to coincide with active gene tran- 
scription 123.241, and this agrees well with the 
data for hTERT for which we see an increased 
level of Pol II at exon 12 after treatment with 
TSA. Also apparent is a significant level of 
Pol II at the promoter sequence before treat- 
ment with TSA when hTERT is repressed. This 
may be due to a paused Pol II molecule being 
present at the promoter, perhaps indicating 
that the hTERT gene may be permissive for 
transcription, only needing changes in the 
128 Regenerative Med. (2006) 1(1) 
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Apparent differences in Pol II dynamics between 
hTRand hTERTmay reflect the different regula- 
tion of each of these genes. Changes in the chro- 
matin environment of promoter sequences may 
therefore drive changes in the dynamics of the 
basal transcription machinery and complex 
interactions between transcriptional complexes 
and chromatin may therefore be important in 
mediating transcriptional activity. 
While TSA treatment does lead to an 
increase in hTERT and hTR expression when 
compared with the telomerase-positive MCF7 
breast carcinoma cell line (Figure lA) hTERT 
expression in the hMSC treated with TSA is 
very low. It has also been observed that these 
cells display no detectable telomerase activity as 
measured by telomerase repeat amplification 
protocol (TRAP) [DATA NOT INCLUDED!. This 
observation indicates that while modulation of 
the chromatin environment by TSA is impor- 
tant in the control of hTERT and hTRexpres- 
sion, this action alone is not enough to increase 
levels of h TERT and h TR expression to a level 
high enough to reconstitute telomerase activity. 
This may be due to the lack of other factors that 
can influence gene expression. 
It is known that hyperacetylation of pro- 
moter-specific histones at promoter sequences 
will cause relaxation of chromatin environment 
relative to a compacted state when histones are 
hypoacetylated. This relaxation of the chromatin 
environment will allow the binding of transcrip- 
tion factors, basal transcription machinery and 
other chromatin modifying enzymes to the pro- 
moter DNA. However, if such factors are not 
freely available within the cell, the relaxation of 
the chromatin environment alone will not be 
sufficient to mediate high levels of transcription. 
Analysis of the binding of regulatory factors 
influencing hTERT and hTR expression in the 
hMSC will therefore be an important next step. 
Further analysis of histone modifications 
involved in telomerase gene repression in the 
hMSC may allow the identification of enzymes 
and co-regulators involved, which can then be 
targeted to allow a more specific method of 
modulating telomerase gene expression other 
than TSA. 
Although TSA treatment has been shown to 
(A) hTR expression analysis for hMSCs before and after treatment with TSA, 
detected by Q-PCR and corrected to GAPDH expression- ChIP assays were 
performed for (B) histone acetylation status (histories H3 and H4) of the hTR 
promoter and (C) Pol II and TFIIB occupancy of the hTR promoter. 
Q-PCR: Quantitative polymerase chain reaction; TSA: Trichostatin A. 
chromatin environment of the promoter to cause chromatin changes at the hTERTand 
hTR 
allow transcription (Figure3). The apparent promoter, it is not known if this is a direct 
decrease in Pol II binding at the promoter and action. 
However, the use of TSA does allow us to 
the large increase at exon 12 can be accounted see that changes in the chromatin environment, 
for by increased Pol II tracking along the gene, be they direct or indirect, can lead to changes in 
being no longer paused at the promoter. telomerase gene expression. These data provide 
www. fi1 semedrcine corn 
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Changes in the chromatin environment of promoter sequences may lead to changes in gene transcription, 
through the relaxation of the chromatin environment. 
an impetus for further, more detailed, analysis of 
the interplay between the chromatin environ- 
ment. general transcription nrachinerv and other 
, tern cells (hMSC) have limited repücative capacity 
dnc] iacr< expression of the immortalizing enzyme telomerase. 
" Lack of telomerase may act as a tumour suppressor mechanism as ectopic 
expression of telomerase in hMSC results in neoplastic transformation and 
reveals a cancer stem cell potential. 
" Lack of telomerase gene expression is due to the repressive chromatin 
environment surrounding the telomerase gene promoters. 
" Activation of tekxnerase gene expression is accompanied by chromatin 
remodelling and dynamic shifts in the basal transcriptional complex. 
" hMSC represent an excellent model for studying tekxnerase gene 
expression with direct implications for cell replacement therapies and tissue 
engineering. 
important regulatory factors which may affect 
telomerase gene expression. 
Overall, this study shows that the lack of 
hTERTexpression in hMSCs is due to a repres- 
sive chromatin environment surrounding the 
i1TERT gene promoter and that modulation of 
the chromatin environment has an important 
role in the re-expression of hTERT in these 
cells. This provides an excellent platform for 
the further investigation of the control of tel- 
omerase gene expression in the hMSC and its 
implications for tissue regeneration and cancer 
stem cells. 
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